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In considering the role of a new compound in the treatment of
depressive states, it seems mandatory to examine (1) the epidemiology of
depression - to assess how significant a problem this illness constitutes
today (11) the results of physical treatment, especially electroconvulsive
therapy - to discern the advantages and drawbacks of these procedures and
(111) the results of treatment with other drugs - for purposes of
comparison in respect of therapeutic efficacy. This chapter , a5 an.
introduction to a study of efficacy of amitriptyline in depressive states,
deals consecutively with these three aspects of depressive illness.
THE EPIDEMIOLOGY OF DEPRESSION.
"Depression" is an ambiguous term which, as Lehmann (1959)
has pointed out, can connote a symptom, a syndrome or a nosological entity.
"Depressive state" in the present context is more specific. It is used
to denote the syndrome of a continuing state of pathological depression -
ranging in depth from the profound gloom of a manic-depressive psychosis
to the relatively trivial severity of a neurotic depressive reaction.
Mayer Gross, Slater and Roth (1960) remark that some three or
four per thousand people suffer from affective disorders demanding
psychiatric treatment. They point out that, although diagnostic criteria
vary, true regional and racial differences exist in regard to these
illnessesj thus, affective disorders are rarer in Northern Germany, Norway
and Finland than in Southern Germany and Britain. Similarly, the 16.4
per cent of patients with affective psychoses admitted to mental hospitals
in Victoria, Australia, in 1951, is a higher figure than the 10.1 per cent
admitted to similar institutions in the United States in 1950, though lower
than the 32.1 per cent of admissions to mental hospitals in England and
Wales in 1953-1962 (Krupinsld and Stoller 1962), In Scandinavian countries,
excellent parish records and geographically discrete, relatively homogeneous
populations provide especially favourable conditions for ascertaining the
incidence and prevalence of depressive states. Thus Odegaard (1946) found
a disease expectancy in regard to manic depressive psychoses of 0,7 per cent
in horwayj Larsson and Sjogren (1954) arrived at a figure of .9 per cent for
men and 1.2 per cent for women in Sweden, rates corresponding to Stendstodt's
(1952) overall morbidity risk of 1 per centj and Freezing (1947) found a
higher incidence still in Denmark - 1.64 per cent, 1.03 per cent for men and
2.24. per cent for worsen. According to Helgaaon (1960) the expectancy of
developing manic depressive psychoses in Iceland is 2.09 per cent for both
sexes combined, but is 1.32 per cent for endogenous depressions. It should
be born in mind, however, that most authors exclude depressive neuroses, and
since the cyclothymic temperament is frequently classified under neurosis,
psychopathy or some physical diagnosis, the true incidence is probably higher
as much as 4-3 per cent according to Both (1959). Supporting this higher
estimate of risk, Sorensen and Straagren (1960), who made an intensive study
of the population of the island of Saaso (some 7,OCX) individuals), Pound that
3.9 per cent of the population over the age of 20 years were suffering frora
depressive disease j the prevalence was much higher in females than males,
and neuroses constituted 77 per cent of the cases. In Scania, Essen-r oller
and Hagnell (i960) found that the cumulated life-risk of developing a
depression increased up to 13 par cent for females and 9 per cent for malesj
the risk for psychotic depression alone was 1 per cent for both sexes taken
together.
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Apart twm mental hospital adsalasios flearns, and epid-
esiiiolagical studies, soother index of the jusosJtonoe of affoctiv© psychoses
la provided by mm Mflyiaall in psychiatry In Great IMtain* ta rocsnt
years Item has boon a trend towards the development of psychiatric treat¬
ment ia the wards of English general hospitals or ia psychiatric units
attached to such hospitals (National Association for Ksutal Health, 19615*
the namgoability and rapid response to treatment of most depress ivos,
together with the adfest of neuroleptics, has accelerated this tendency)
thus Brooke and Stafford Clark® (1961) treated 325 psyehiatrleally ill
patients in the yards of a goneml hospital la tendon* nearly three-quarters
mm suffering Ores an affective disorder and " CT was used ia 102 cases*
Capoore and f iron (1961) now adtedt approximately 600 patient* annually to a
56 ted unit is a general hospital of which son© 53 per cent suffer f*w»
affective psychoses.
i-tay depressive states, however, as earlier pointed out, are
inconspicuous or sashed* Accordingly, to gain a clearer perspoctiv© of
the problea, it say be helpful to consider the condition (1) as seen by the
general practitioacrj (2) as aoea by the psychiatrists (3) as reflected
in the phenomenon of suicides (A) as orMountoredt in general hospitals aid
(5) as ©merging, disguised, in alcoholisn and aopteteaine addiction.
BBFIESSI08 AS 3 M 3X TEE CFJRSAL PRACTTTTCSER
Apart from the treatment of infections and acute omoreencies,
rsuch of general practice consists of the aaimgwsegt of chronic illness,
©specially in elderly persons* la long-continued, painful dlssoiso such
as the srthritldoa, depression is a coooon eoncosaitentj son© degree of
depression is eeanQBly present in. association with aaUgnsncios, and also
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in such organic diseases of the central nervous system as cerebral arterio¬
sclerosis and parkinsonism (Roth 1960a)# Loneliness and poverty are
additional burdens compounding depression that many patients, especially the
elderly, have to bear. Where it is clear that depression is secondary,
the general practitioner must direct his efforts to eradicating or
ameliorating the cause through specific treatment; more general socio-
psychological measures and even symptomatic antidepressant therapy may some¬
times however be required.
In the ordinary course of practice, depressive states are
often missed by general practitioners for a variety of reasons. In the
first place, their undergraduate education has frequently lacked an
adequate psychiatric teaching component (Hordern 1962 ). Secondly, some
depressives present gay or smiling exteriors, attempting to minimi.se their
symptoms, so that a subtle change in behaviour - an insidious loss of
interest and vivacity, for example - may be the only clue to the true
diagnosis. Again, as Ayd (1961a) and others have pointed out, some
depressives complain of one or other symptom - insomnia, gastro-intestinal
discomfort, headaches or fatigue - which leads the practitioner to make an
erroneous diagnosis of physical illness; others are hypochondriacal and
are mistakenly labelled neurotic, their underlying depressive state, which
is of much more serious import, being missed. Some depressives go
fruitlessly from physician to physician; over two decades ago Ziegler
(1939) collected 111 patients who had first attended a physician or a
surgeon because of depressive symptoms. Only recently has it been
realized that the depressive colouring of the phobic anxiety-depersonal¬
ization syndrome, a not uncommon condition according to Roth (1960b), can
also lead to diagnostic difficulty.
Despite these diagnostic problems, a number of valuable
surveys of depression have been carried out by general practitioners.
Two may be singled out for brief consideration. Watts (1956), who saw
529 depressives in a 10-year period in an English semi-rural practice of
8,000 patients, concluded that 36 per cent of all new psychiatric cases
were depressives and that two-thirds of these patients were suffering
from the endogenous category of this illness. Fifty-nine per cent of his
cases were mild and could be managed personally, but 24 per cent arequired
electroconvulsive therapy and the illnesses of 17 per cent were so severe
they had to be admitted to hospital. The condition was commoner in women
than in men, with a peak for both sexes between the ages of 45 and 50$
not more than a quarter were seen by a psychiatrist. Though the majority
recovered, Watts discovered that 14 per cent of hi3 depressed patients
ended in a chronic state, died in depression or committed suicide. The
prognosis was worst in severe depressives, and was also poor among the
aged, especially among men. Ryle (1961) investigated depressive illness
in general practice in the course of a survey of the incidence of psychoses.
Between 1956 and 1960 he studied 2,000 patients bom before 1950 and
calculated a disease expectancy rate for endogenous depression of 6.6 per
cent for women and 1.5 per cent for men. Ryle concluded that his figures
probably represented an under-estimates whilst lower than those of Watts
who had employed less stringent diagnostic criteria, they were higher than
rates reported in mental hospital studies. In comparison with the
figures computed by Norria (1959), for first admissions to three
psychiatric hospitals in London, the inception rates in Ryle's practice
were four times greater for men and eight times greater for women.
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DEPRESSION AS SEEN BY THE PSYCHIATRIST.
Another approach to the problem of the epidemiology of
depression is to examine the views of psychiatrists whose practice does
not exclusively centre on mental hospital work. Mayer Gross (1954) and
Partridge (1954) have emphasized the commonness of the disorder; Leigh
(1955) analysing 1,000 domiciliary consultations, found that 34 per cent
of them were for depressive reactions. Twenty-three per cent of the
8 per cent of specialist referrals made by Hopkins in 1956 were patients
with depressive states. Within the last few years Roth (1959, 1960a) and
Ayd (1961a), amongst many others, have emphasized the frequency with which
depressive reactions occur and are seen by the psychiatrist. The recent
resurgence of interest in the epidemiology of depression is presumably
related to the advent of antidepressant compounds which currently provide
an acceptable, widely applicable form of therapy for this condition.
SUICIDE.
The most dangerous complication of depressive illness is
suicide, though suicide, especially in young adults, is not always
associated with depression. The risk of suicide, pari passu with the
incidence of endogenous depression, increases with age. Thus, in children
under 12, suicidal attempts are rare; they are four to six times as
common in adolescence, and become commoner still in adult life. Below
the age of 30, nine times as many females make attempts as males, but over
30 the ratio reversest three times as many men as womep attempt suicide.
Remarking that the young seldom communicate their suicidal intentions,
whilst older individuals frequently do, Ayd (1961 ) puts forward the
accepted view that, below the age of 30, it is usually the tense, deluded
schizophrenic who commits suicide, whilst, above that age, suicides suffer
from the depressed phase of an affective psychosis (including involutional
melancholia) or alcoholism. Before discussing suicide in adult life and
old age, however, some general data on suicide will be scrutinized in
order to underline the magnitude of the social problem it constitutes in
almost every country today.
According to Hirsch (1959)» in the United States between
16- and 20, OCX) people kill themselves each year - a rate of 11.2 per
100,000 population, making it the eleventh commonest North American cause
of death. Even so, since many suicides are hushed up, the actual number
of deaths from suicide is probably nearer 50 - 60,000 per year. In
England and Wales, some 5»000 people kill themselves each year (Capstick
1960), and, according to a recent Annotation (1962) in the British Medical
Journal, the last decade has seen a notable increase in the number of
suicides. In Scotland the total was 50 per cent higher in i960 than in
1950, the increase affecting both sexes, males rather more than females.
In 1957, Australia had 1,170 suicides, a rate of 12.1 per 100,000, putting
it in the top quarter of 60 countries listed in the Demographic Tables of
the United Nations. Dax (1961) has suggested dividing countries with a
high suicide rate into two groups - those which have a high rate of
alcoholism (Switzerland, Sweden, Finland, Denmark and France) and those in
which a high rate is associated with cultural factors (Japan, Germany and
Austria). The rate for Victoria, Australia, in 1956-53 at S per cent per
100,000 was, Dax remarks, substantially below the figure for Australia as
a whole.
The incidence of attempted suicide is variously estimated as
five to ten times the incidence of the successfully completed act.
According to Stengel (1952), attempted suicides and suicides comprise two
different but overlapping populations, A recent Leading Article (1961)
in the British Medical Journal 3tates that the number of suicidal attempts
occurring annually in England and Wales may currently be as high as 40*000,
though of these only a small proportion - perhaps about 1 per cent per year
of follow-up - eventually commit suicide. Both suicide and attempted
suicide is commoner in people who are socially isolated * the rate falls
from a high point in cities over 100,000 to a low point in rural areas.
According to Carstairs (1960), in Britain, in any one year, there are
12 suicides and 30 attempted suicides per 100,000 population, giving an
average of one attempted suicide per year and one successful suicide every
three years per general practice of 2,500, Watts (1960) lost 12 patients
from suicide in 15 years in a practice of 8,000,
Research into suicide has mainly involved a retrospective
correlation xrf.th social factors in the time-honoured pattern established
by Durkheim (Stengel 1960a). Regarding modes and fashions of suicide,
men habitually terminate their lives in more violent ways than do women}
the method adopted is closely related to the availability of suitable agents
Analysing 32,000 suicides in the State of New York between 1925 and 1954*
Hirsch (1960a) found the commonest methods were gassing (30$), hanging (20$)
jumping from heights (16$), taking poison (13$)* and using firearms (3$).
Since 1943* the use of barbiturates for suicide has increased fourfold,
and in 1954 they were fifteen or sixteen times as commonly used as other
agents; they are now being displaced for this purpose by the
tranquillisers. The dynamics of suicide, according to Hirsch (1960b)
centre round the constellation of loss (real or fantasied), aggression
(the chief dynamic force producing the act) and depression (which ia
commonest later in life). Nevertheless suicidal attempts have very complex
motivations and, as Stengel (1960b) observes, no ready formula exists to
encompass them. One fact has become increasingly apparent in recent years -
suicide in older people is usually a deliberate, carefully contemplated act
and, in as many as 70 per cent of cases, a prior communication of intent to
suicide is made to the family or to friends (Capstick 1960). The
communication may be posthumous, by means of a suicide note, as described in
an Annotation (1961) in the British Medical Journal, reviewing a number of
studies of this aspect of suicidal communication.
According to Stengel (1960s) "no reliable criteria for the
prediction of suicide have been established beyond the high incidence in
depressive illness". Thus, a depressive illness is the condition most
strikingly associated with successful suicidej and according to a Leading
Article (1961) in the British Medical Journal, some 14 per cent of patierts
with psychotic depression end their lives in this way. Dorpat and
Ripley (1960), studying 114 consecutive suicides in the Seattle area of the
United States through interviews with relatives and friends, found that
psychotic depression had preceded suicide in 17.6 per cent of cases,
and psychoneurotic depression in 12 per cent. Capstick (1960), who studied
831 suicides in five years in Wales, found that 39 per cent of suicides had
been depressed prior to their demisej and Nomura (1960) found that 29.7 per
cent of 1,457 suicides investigated in two Japanese institutions were
suffering from endogenous depressions. Nevertheless, the relationship of
depressive illness to suicide is somewhat obscure in chat, although the risk
of suicide is undoubted in severe cases, it is uncertain which patients will
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attempt suicide and which will not. Walton (1953) carried out an
interesting investigation of this problem by exaning the case notes of
223 depressives admitted to the Maudsley Hospital, London in 1955, in regard
to attempts and threats of suicide. Dividing his cases into those vhich
appeared definitely suicidal (attempts with or without definite threats)
and those which did not, Walton found that there was no correlation between
suicidal behaviour and social isolation or social degeneration, but that
3uch behaviour was highly significantly correlated with parental
deprivation (loss of a parent before the age of 14, repeated parental strife
or a feeling of prolonged estrangement). Age was not correlated with
suicidal behaviour but women showed such behaviour considerably more often
than men} no association was found between suicidal behaviour and type of
depression i.e. endogenous or reactive categories.
Suicidal attempts, in general, peak between the ages of 55 and
64, the highest incidence for women being between the ages of 45 and 54,
and that for men occurring a decade later, continuing at four to five times
the female level throughout the remainder of life (Roth and Morrissey
1952). Nevertheless, in recent years suicide rates in females have been
rising and are still on the increase, especially in the elderly (Mayer
Gross, Slater and Roth 19-0). This increase, as Sainsbury (1960) has
pointed out, is probably due to factors other than the economic hardships
of old ago, and there is general agreement that three groups of causes are
broadly responsible: mental illness, physical disease and social problems.
Regarding the former, Batchelor and Napier (1953), O'Neal, Robins and
Schmidt (1956), Capstick (1960) and others agree that pathological
depression precedes suicide in about half of all cases. Affective
psychoses are common conditions which increase in frequency up to a certain
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age in both sexes j and since the peak incidence of suicide is a decade
higher in men than in women, it may very well be that the higher incidence
of suicide in older men is due to the gene which is instrumental in causing
the condition being pushed to the end of reproductive life by genetic
modifiers (Roth and Morrissey 1952). In regard to the part played by
physical disease, Sainsbury (1960) concurs with earlier investigators that
it can contribute significantly to suicidal behaviour, both directly
through restricting activities and indirectly in many other ways. Thus
physical illness, by threatening earning capacity, may produce anxiety
in a breadwinner by arousing in him fears for the economic future of his
family} such illness may also be a factor in alcoholism, liiich is
commoner amongst males, and is frequently associated with suicide. Finally,
with regard to social factors, Sainabury's findings show that ante¬
cedent loneliness and bereavement are significantly more common in elderly
suicides than in younger individuals attempting (and achieving) a similar
goal. The true significance of these factors, however, probably lies in
their effect in precipitating rather than causing the depressive psychoses
which at one time in the elderly, were so frequently missed (Roth and
Morrissey 1952).
DEPRESSION IN GENERAL HOSPITALS.
As pointed out earlier, the symptoms of depressive illnesses
can readily suggest physical disease, especially if a depressive affect
is not prominent and the disorder be manifested solely in hypochondriacal
complaints. Since, -unless the depression reraits or appropriate therapy
is given, such symptoms persist, a not inconsiderable proportion of
depressed patients present in general hospitals, where the true nature of
their condition may or may not be recognized. In a five-month survey of
the consultations seen by staff of the Department of Psychological Medicine
at an English teaching hospital, of 77 patients referred, 27 had melancholias
and 16 were given EOT. There were also 21 patients with neuroses, of whom
7 had psychoneurotic (reactive) depressions (Hordem 1955)# In Scandinavia,
Helsberg (1958) examined 500 adult patients attending Aarhus County Hospital
between December 1947 and December 1948. Only 288 had "pure" somatic
illnesses and in 134 (2255), psychiatric disorder was present. Depression,
suicidal attempts and manic-depressive psychoses together constituted
22 per cent of these cases, i.e., they made up some 4 per cent of all
admissions, but the incidence of depression would have been higher had some
neurotics been included.
A further study of psychiatric illness at a medical and a
surgical out-patient clinic in London has recently appeared in print.
Culpan and Davies (1960), as a preface to their investigation, summarize
eleven previous studies which together include 6,842 patients; the mean
incidence of npureM psychiatric illness was 27.3 per cent. In their own
investigation Culpan and Davies found that, of 100 consecutive newly referred
medical outpatients, 51 had a psychiatric illness and in 38 no relevant
organic disease was present; in 100 new surgical outpatients 21 had
psychiatric illnesses, but in only 5 was no organic component present.
ALCOHOLISM AND AMPHETAMINE ADDICTION.
Many years ago alcoholism was regarded as a cause of mental
illness in general, apart from those specific psychiatric disorders -
delirium tremens, Korsakov's psychosis, alcoholic pseudoparanoia - which are
directly related to its excessive use. Kraepelin (1921), however, though
an abstainer himself, regarded alcoholism as a symptom rather than a cause
of mental illness, an opinion echoed by Henderson and Batchelor (1962).
Dipsomania, in particular, is probably symptomatic of a manic depressive
psychosis, and the alarming results that a combination of alcohol and a
disturbed mood state can some-times produce have been remarked by Mayer Gross,
Slater and Roth (1960). Because of its end result, alcoholism has been
described by Karl Kenninger (1933) as "chronic suicide". Whether this is
so or not, the incidence of actual suicide is very much higher in
alcoholics than it is in the general population. Lemere (1953) found a
rate of 11 per cent in 500 followed-up alcoholic patients; in a more recent
study of 131 voluntary patients discharged from Maudsley Hospital after
treatment for alcoholic addiction, which was analysed in combination with
data from a second series of 37 patients admitted to a London Observation
Ward, Kessel and Grossman (1961) found an incidence of suicide of 8 per cent
and 7 per cent respectively. In regard to overt depression, of a series of
161 alcoholics treated in the Payne Whitney Clinic, New York, since 1932,
6.8 per cent were found to be suffering from depression in middle or later
life (Sherfey 1955). The evidence, therefore, would seem to suggest that
a definite, if subtle, relationship exists between alcoholism and depression,
and that the latter condition may, on occasion, present as the former.
Cade and Krupinski (1962) recently tested the hypothesis that alcoholism in
the male might substitute for depression in the female. They examined the
incidence of depression in alcoholic and non-alcoholic migrants to Victoria,
Australia; however, in the Southern European (non-alcoholic) group, the
magnitude of Hie differential sex incidence of depression was maintained, a
finding tending to refute their hypothesis. Finally, aside from these and
other published figures, the author's experience suggests that sopm-e people,
drink to alleviate a state of depression or despair. It would seem logical
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therefore, to suppose that la a proportion of alcoholics, depressive con¬
ditions underlie their alcoholic behaviour. The difference between such
an individual and the overt depressive is probably to be aought in the
genetic inheritance and the personality of the patient.
A less common, but still prevalent, way in which depression
roay present is an addiction to amphetamines. Besides prodicing a aehiso-
phrenio-Hke psychosis (Connell 1953), excessive amphetamine consumption can
aggravate pre-existing psychiatric abnormalities and lead to adverse social
consequences. Klloh and Brandon (1962) have drawn attention to the huge
quantities of amphetamine currently being prescribed and have described the
lengths to which addicts may go to obtain these drugs. Habituation, which
occurs mainly in chronically neurotic women, is not uncommon? according to
Kiloh and Brandon those who become habituated often lack confidence, suffer
from neurasthenia or react to adverse social consequences with depression.
Two of the six illustrative canes described by ? cCormick (1962) to portray
the side effects of amphetamine addiction used the drug because of depressive
episodes, and two others may also have become addicted for this reason.
Thirteen of fourteen amphetamine addicts described by Bell and Trethowan (1961)
experienced clear mental stimulation after taking the compound? in many cases
a mood change approaching elation was produced together with increased con¬
fidence and libldftnal stimulation? depression was tee commonest symptom
following withdrawal and tendencies to suicide were noted. In some amphet¬
amine addicts, electroconvulsive therapy has been reported to reduce the
craving (Kennedy and Fish 1953). All this suggests that a proportion of
deprescivea may be found amongst amphetamine users and that the practice of
taking this drug may be, in some individuals, a symptom of an underlying
depression.
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PHYSICAL TREATMENTS FOR DEPRESSIVE STATES
CONVULSIVE THERAPY
Tha successful treatment of the vast majority of savors depressive
states depended, until the advent of antidepressant drugs, on the artificial
induction of epileptio-like convulsions. Indeed, convulsive treatment
originated in a supposed antagonism between schizophrenia and epilopsyj
Modura, who first reported the technique and results of pharmacological con¬
vulsive treatment in 1935, originally used intramuscular injections of caropbor
to produce fits. Clinical trials soon began em the Continent of Europe but
were more slowly undertaken in English-speaking countries, partly, Kennedy
(1940) observes, because of traditional caution and partly because, at the
time, attention was focused on treatment with prolonged narcosis and insulin.
Meanwhile, in 1934, the uncertainty and delay with which camphor produced
convulsions led Moduna to substitute pentamethyleno tetrazol ("Cardiaaol0
"ffetrazol") which produced a more predictable response and could be given
intravenously. Though many did not agree with Meduna's basic hypothesis, his
treatment proved to be of definite, if limited, value in schizophrenia (Harris
1933). Nevertheless, it soon became evident that it was potentially of ouch
greater value in the treatment of patients with affective psyshosea. Thus
Low, Sonenthal, KLaurock, Kaplan and Sherman (1933) reported recoveries in
13 out of 16 manic-depressives given Metraaol, and the results of pharma¬
cological convulsent therapy in patients with depressive states remained con¬
stantly good, for it was both more effective and leas dangerous than prolonged
narcosis, Fitzgerald (1943), reviewing the results of pharmacological con-
vulsant treatment in eight reports covering 377 depressed patients, arrived
at an overall improvement rate of 84 per cent (59£ recovered or
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greatly improved and 2% improved), an order of betterment paralleled, but
never convincingly surpassed, by electro-convulsive therapy.
Cerletti, the originator of electroconvulsive therapy, like
Meduna, was also interested in epilepsy. Seeking originally to devise a
method of inducing epilepsy in dogs, he bagan to study the problem of the
maximum amount of electricity that could safely be given without producing
death or disastrous sequelae. The result was the discovery that, given in
suitable amounts, electric current, applied through cephalic electrodes,
could rapidly and safely induce convulsions indistinguishable from epilepsy.
He gave the first electric convulsive treatment to a 39 year-old male
schizophrenic in Home in 1933.
The efficacy of electroconvulsive treatment, combined with its
convenience, cheapness, rapidity of application and safety, soon led to its
adoption on an extensive scale. Since the treatment was not accompanied
by the terrifying sensations that had attended the administration of
pentamethylone tetrazol, patients preferred EOT to pharmacological shock
therapy, as also did hospital staff. Thus, in 1942, Kolb and Vogel,
reporting the answers to a questionnaire sent to 305 North American hospitals,
stated that a third of these hospitals said that they used all three shock
treatments - electrical, cardiazol and insulin - and that 60 per cent
preferred EOT , whilst only 8 per cent showed a preference for pharmacological
convulsant therapy. The latter treatment was gradually discarded as, in
the course of time, a number of new techniques were developed which, whilst
rendering EOT less disturbing to patients, cut down the incidence of
fractures, dislocations and other unwelcome complications.
To begin with, sedatives, together with parenteral atropine,
were given prior to therapy which, though generally administered to in¬
patients, also came into outpatient use. Curare was the first of a number
of muscle relaxants which, given intravenously, was found to modify the
muscular component of the convulsions; however, by 1953, curare had been
generally replaced by succinylcholine, a safer and more convenient drug
(Wilcox and Wilcox 1954) • These compounds did not diminish the central
side effects of EOT - cumulative memory disturbance and confusion - but by
obviating the Valsalva phenomenon (the sudden increase of blood flow into
the heart at the end of the convulsion), they safeguarded the heart as well
as the skeletal system. This was a most desirable development, for sudden
cardiac failure was (and is) the commonest cause of the infrequent deaths
that follow ECT (Tewfik and Wells 1957). In addition, thiopentone
anaesthesia, with or without the inhalation of oxygen, was employed by many
to induce sleep prior to treatment (Impastato and Berg 1956). Subsequently,
a few therapists began to omit the anaesthetic, devising special techniques,
such as the so-called P.M. - GJM. method, to lessen the pre-shock anxiety
that relaxants given alone, as a result of paralysis of respiratory muscles,
were prone to evoke (Impastato and Gabriel 1958).
A second approach to the problem was to alter the electric
impulse through modification of the electroconvulsant apparatus. These
developments have recently been reviewed by Goldman (1962). The use of
glissando and other techniques, however, whilst leading in general to fewer-
skeletal complications, has not resulted, Mayer Gross, Slater and Roth
(1960) observe, in any appreciable lessening of post convulsive confusion
and disturbance of memory. Indeed, although the mode of action of ECT
remains unknown - Ulett (1962) recently stated that the literature lists
more than three score theories purporting to explain the action of ECT -
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experience has shown that the results of modified and unmodified EOT are
virtually identical (Seager 1959 j-mi ^ &«• treatment, in general, is extremely
safe. In 1959 Barker and Baker sent a questionnaire to 13 London teaching
hospitals and 42 other hospitals$ they found that thiopentone and succinyl-
choline were used at 60 per cent of institutions, while thiopentone alone
vaB used in 84 per cent} in less than 50 per cent of hospitals was an
anaesthetist present during treatment. The death rate was one in 28,000
treatments - a fatality rate of .0036 per cent. This figure is somewhat
lower than that arrived at by Perrln (1961) who, summarizing eleven large
series, arrived at an estimated rate of 1 death per 1,000 cases.
EOT, like pharmacological shock therapy, initially was widely
used in schizophrenia but, like the earlier treatment, soon found its most
fruitful application in affective psychoses, particularly of the depressive
type. Thus Sargant and Slater (1944), discussing the status of EOT in the
first edition of their well-known work on physical treatment, observed that
in the treatment of involutional depression, successes of the order of
70-80 per cent had been reported} this was, they felt, a great step forward,
for previously these states were very refractory to treatment. The two
authors went on to state that the swings of mood of patients with affective
psychoses were more resistant to EOT than involutional depressions, and
that, in manic-depressive depressives under 40 years of age, EOT could
produce a troublesome temporary mania, or perhaps only a transient allev¬
iation of their symptomatology. The best results were obtained, Sargant
and Slater thought, when the depressive phase had lasted an unduly long time.
In certain reactive depressions also, there was, they believed, a place for
electroconvulsive therapy.
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Since EOT was, until comparatively recently, one of the very
few treatments in psychiatry that was simple, effective and safe, a tendency
understandably developed to administer it to patients whose illnesses did
not exactly conform to the patterns in which the best responses were to be
anticipated. This, together with the dissimilar diagnostic criteria
employed by different investigators, probably explains the discrepant rates
of response that have been reported in depressive states. For purposes of
subsequent comparison, it is worth examining the views of some leading
authorities as well as scrutinizing a number of investigations in greater
detail.
In the United Kingdom, Henderson and Batchelor (1962), in the
latest edition of Henderson and Gillespie's textbook, state that of all
depressive illnesses, involutional melancholia responds best to EOT, an
80 per cent rate being usual. Although manic-depressive depressives also
respond, they do so most effectively, the two authors believe, when the
nadir of their depression is passed} given earlier, EOT can, Henderson and
Batchelor believe, produce a temporary improvement followed by a rapid
relapse. In less-typical recurrent depressions which run courses longer
than average - cases characterized by hypochondriasis, and in younger people,
by unreality and anxiety - EOT may make the picture worse. Further, it is
of little value in neurotic depressions. Lewis, (1956), in his section on
mental illness in the ninth edition of Price's Textbook of Medicine, states
that women suffer from depression more than men, and that first attacks of
melancholia in late middle life clear up in two-thirds of cases. He gives
no percentage response rates to EOT, though he considers that it is
effective in older patients, remarking that its value in younger cases is
uncertain. Mayer Gross, Slater and Roth (1960) in the second edition of
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their textbook, whilst: strongly advocating the use of ECT in affective dis¬
orders, particularly in involutional depression, give no figures with which
to assess its efficacy. It is difficult to find, in any of these three
endorsements, data regarding the rate of relapse of ECT - treated patients
after discharge.
The views of authorities in the United States are very similar.
Appel, Myers and Scheflen (1953), summarizing 17 studies in which ECT had
been given to 6,551 patients with affective psychoses, found an improvement
rate of 71-10 per cent with ECT in contrast to a rate of 5&^?9 per cent in
patients treated conservatively. Kalinowsky (1954)# who once worked with
Cerletti in Rome, stated that in his opinion between 80 and almost 100 per
cent of depressives responded to ECT. He noted that opinions had been
expressed that future episodes tended to occur sooner in cases treated with
ECT rather than conservatively; but in view of the rapidity with which ECT
brought relief, together with the way it cut down hospital stay, he regarded
this as an academic question. Writing five years later in the American
Handbook of Psychiatry, Kalinowsky (1959) stated that some statistics for
ECT in typical psychotic depressions came close to 100 per cent recovery
of episodes: such patients responded equally well whether their depressive
states were manic-depressive, involutional or geriatric. Results were
poorer in depressives with neurotic reactions characterized by listlessness,
dejected mood and anhedonia; indeed in these cases iproniazid was sometimes
superior. He again remarked the prevalent clinical impression that
intervals between episodes were shorter after depression had been treated
with ECT instead of having been allowed to recover spontaneously. Bigelow
(1959), describing involutional psychoses in the American Handbook, states
that 90 per cent of involutional melancholies respond to a course of about
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fifteen electroconvulsive treatments® Alexander (1958), another American
authority* give® the following figure® in Ms monograph on objective
approaches to psychiatric treatmentj for Involutional melancholies treated
on a conservative regime and/or intensive psychotherapy, 44 per cent response
in contrast to 82 per cent improvement in those treated with ECTs for manic
depressive depreosives, 53*7 per cent improvement when treated conservatively
versus 67*9 per cent recovering after EOT* In the State of Hew York,
Alexander remarks, 70 per cent of cases of affective psychoses treated with
ECT had spent less than two months in hospital versus 18 per cent of conserv¬
atively-treated controls® According to this author, in 116 cases the rate
of spontaneous recovery of depression (including both complete and social re¬
coveries) was 66,4 per cent, materializing Airing the first year in only 44
per cent of cases | intensive psychotherapy, which achieved 46*4 per cent of
recovery in 203 cases, could not bettor these figures® On the other hand, in
deprossives treated with EOT the rate of complete or social recovery in 2165
cases was 67.9 per cent®
TABLE 1*
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Table 1 summarizes the salient findings in nine investigations
of the immediate response to and relapse rate after electroconvulsive treat¬
ment was given to 2028 patients with depressive disorders. With the
exception of Karagulla (1950), all the other investigators cited in the table
agree that, given in depressive disorders, ECT alleviates suffering, increases
the rate of improvement, shortens hospital stay and lessens the risk of
suicide. Karagulla, by omitting deaths and combining cases that recovered
with those that improved, found that the percentage of recovery did not vary
greatly whether conservative therapy or ECT was used, and further concluded
that ECT did not shorten the duration of hospitalization to any significant
degree. Slater (1951) soon criticized these conclusions, observing that
Karagulla's data revealed (1) a much higher mortality in the untreated than
the treated group (2) a significantly higher percentage of recoveries in the
treated versus the untreated groups and (3) a substantially lower proportion
of unimproved cases in patients admitted during the years 1900-1939.
Accordingly he observed that a more careful examination of the data suggested
that the exact contraries of both Karagulla's propositions were correct.
In regard to readmissions, Karagulla found their frequency was
dependent on two factors (1) the length of the period through which patients
had been traced and (2) the number of previous admissions. Although the
relapse rates in the ECT and control groups differed in the first year
following discharge, after that time no matter which group the patients had
been in, the number of relapses had a direct relationship to the chrono¬
logical period during which they were followed up. In a similar manner the
percentage of relapse was found to increase pari passu with every subsequent
readmission. Seeking to explain the slightly higher percentage of relapse
in the first six months in patients treated with ECT, Karagulla drew
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attention to the higher percentage of EOT cases discharged "recovered" in the
treated group (56.4$) versus toe control group (46.8$), This might be due,
she postulated, to EOT inducing in some cases a false sense of well being.
"In this state of mild euphoria" Karagulla wrote "the patient tends to
assert (her) sense of well being and demands to be discharged. This mood is
short lived, hence the greater tendency to relapse in treated cases in the
first six months after discharge as compared to cases that recovered
spontaneously" .
In 1954- Thomas reported some interesting findings in a group of
307 patients with depressive states treated with EOT. He divided depressive
syndromes in patients who, after the completion of EOT, again became ill into
two groups (1) relapses - a need for further treatment within four weeks of
toe last EOT and (2) recurrences - any worsening of condition calling for
further EOT, readmission, admission to another hospital or leading to suicide
occurring more than four weeks after the patient's last EOT. In 74- per cent
of his cases, recovery was smooth and uneventful, but in 98 per cent of the
remainder a relapse or "interruption of recovery" occurred within 16 days of
the cessation of treatment. Their subsequent rat© of recurrence was 41 per
cent as opposed to 16 per cent in patients who had achieved an uninterrupted
recovery. Thirteen months after the final EOT the overall recurrence rate
was 23 per cent, although the rates for certain types of depression were
somewhat higher (agitated depression 41$, involutional depression 38$ and
depression with hypochondriasis 33$). In a controlled trial of ECT and
iproniaaid in toe treatment of endogenous depressions, Kiloh, Child and
Latner (1960) also found a high relapse rate with ECTj of their 52 cases
treated with ECT, 94- per cent showed a good immediate response but in the
course of six months 48 per cent relapsed, many of them within two or three
weeks following the cessation of treatment.
In table 1, it will be noticed that the majority of the 2023
patients were women with psychotic depressive states, either manic depressive
depressions or involutional melancholias. In general in tho earlier studies
with seven or more convulsions actainistered per patient and a fairly long
period of hospitalisation - three months or more - tho response rate is high
(80$ or more) and the relapse rate is low (8 -17*). Studies in which fewer
treatments have teen given, as that of Thorns (1954)> or in which hospital
stay has been unduly short {Thiston and tocher 1943b), have shown
corus,';(ieruidty higher rates of relapse (73% and 31' respectively). :'iloh,
Child and Latrier'a study probably falls Into the latter category though,
since they do not state either tho average number of FCT's given or tho
period of hospital stay, it is difficult to be certain of this. Tn general
the finding is consistent both with tho author's personal exporience and
with some E.'i.G. findings reported by Roth, Given eight or nine treatments,
fewer of the author's depressed cases relapsed thin others given five or
six (Rordarn 1956). Roth (1952) was able to correlate response to ECT
with the release of paroxysmal bilaterally synchronous two to three per
second slow waves appearing in the thiopentone E.E.G., after the third
treatment* he found that the duration of such activity steadily increased
to a maximum of 150-200 seconds after seven to nine convulsions. This
duration of delta discharge must, in general, bo reached (by giving seven
to nine convulsions) if subsequent relapses are to be kept to a minimum
(Roth 1956).
LEUCOTOMY
Prefrontal leucotomy, which was introduced by Moniz in 1935,
was originally regarded with some distaste by many, for the early "classical"
forms of the operation, by permanently damaging large areas of the brain,
not infrequently led to deterioration of the personality and troublesome
post-operative epilepsy. Nevertheless, with the advent of more anatomically
restricted techniques which have almost completely obviated the undesirable
sequelae of the classical procedure, the operation has come to be viewed
with more favour. The published results leave little doubt that, amongst
other disorders, depressive states, especially of the endogenous variety,
respond well to this treatment. Chronic intractable depressions have
generally been the cases subjected to leucotomy, as well as patients with
recurrent depressive episodes whose recovery with EOT has been too transient
for appreciable benefit.
In an early investigation Partridge (1949) studied 82 patients
with affective disorders out of a total of 300 subjected to prefrontal
leucotomy. In general, the results were good; of 61 endogenous cases,
20 showed post-operative persistence of symptoms and relapse occurred in 4?
of 21 reactive cases, none showed post-operative persistence of symptoms but
relapse also occurred in 4* Partridge's conclusion from these findings was
that reactivity carried a more favourable prognosis with regard to the
operation, but that it also implied a greater chance of subsequent relapse.
A few years later Freeman (1957) in the United States, reported a study of
3,000 lobotomized patients followed up for one to twenty years j for
involutional depressives his response rates (as measured by the patient being
out of hospital and at home) were 80 per cent for classical prefrontal
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lobotomy and 90 per cent for the transorbital operation. With the latter
technique there was. Freeman found, a much lower incidence both of post¬
operative personality change and convulsive disorder. Meanwhile, in England
a year earlier, Elithorn and Slater (1956) had conducted a follow-up
questionnaire enquiry into the views of 103 patients who had undergone pre¬
frontal leucotomyj 66 said that they were glad they had had the operation,
and 72 of 93 relatives thought the patients were better off.
Elithorn (1953) subsequently concluded that leucotomy was most
beneficial when the depression was autonomous or secondary to a genuine dis¬
ability. A year later, an investigation carried out by Thorpe (1959) into
the 5-9 year follow-up results of limited leucotomy in patients over 65, 46
of whom had had depressive illnesses, also showed how beneficial leucotomy
could be. Thorpe concluded, on the basis of his findings, that lower
quadrant leucotomy was an effective treatment for intractable or recurrent,
severe melancholic statesj at least two thirds of patients with such
conditions could, he believed, recover completely as a result of the
operation and could survive for at least five years without relapse.
According to Mayer Gross, Slater and Roth (1960), however, the
part that leucotomy or similar operative procedures can play in the treatment
of affective psychoses, is still not yet fully explored, though they believe
that there can be no doubt that leucotomy can often rapidly terminate a
depressive episode. They state that leucotomy should only be employed when
convulsive therapy has failed and the outlook appears hopeless without it.
In this connection some figures furnished by Tooth and Newton (1961) on
leucotomy in England and Wales between 1942 and 1954 are of particular
interest.
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Tooth and Newton undertook their survey in early 1956}
between May of that year and December of the following year they sent out
questionnaires which eventually yielded data on 10,365 patients who had
undergone leucotomy between 1942 and 1954* 2637 of these patients, 794 »©n
and 1834 women, had had the operation performed for amelioration of affective
psychoses, illnesses in which the operation achieved its best results.
Seven per cent of these patients were under 35J 80 per cent were aged
between 35 and 65 and the remainder were older still. In 79 per cent, the
standard operation had been performed} 11 per cent had had a modified
standard operation} and 10 per cent had undergone some other surgical
manoeuvre. Twenty per cent of the men and 21 per cent of the women had had
a depressive illness of less than 2 years duration} 43 per cent of both
sexes had had their psychoses for 2 to 6 years? 16 per cent of men and 14
per cent of women had been ill for 7 to 11 years? and the remainder had
been disabled for an even longer period. Despite this, 63 par cent of the
men and 69 per cent of the women had been discharged - indeed, in all, 4-9 per
cent left hospital within one year of the operation? 20 per cent of men and
22 per cent of -women had remained in hospital? and 17 per cent and 9 per
cent respectively had died in hospital. Total recovery was achieved by
24- per cent of the men and 29 per cent of the women? social recovery (with
residence at home) had occurred in 23 per cent of both sexes? and great
improvement had taken place in 13 per cent of men and 12 per cent of women.
These figures were obtained at the price of serious post operative side
effects (mainly personality change from damage to the frontal lobes) in
2.1 per cent of patients and persistent post-operative epilepsy in 1.3 per
cent. The overall relapse rate was 18 per cent? relapses, in general,
were higher in patients in the younger age groups. In passing, the report
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observes that though the level of leucotomy in England and Wales between
194-8 and 1955 was running at approximately 1000 cases per annum, by 1959
the number had dwindled to 400 patients annually.
In regard to the way in which leucotomy exerts its effect,
Roth and Garside (1962) have pointed out that, like electroconvulsive
therapy, the operation interferes with the thalamo-frental association path¬
way^ the interference is, they think, temporary with electroconvulsive
treatment, but permanent with leucotomy. Roth and Garside remark how great
would be the advance registered by the Introduction of a form of treatment
less transient in its effects than electroconvulsive therapy, yet less
irrevocable than operations on the frontal lobes. Today, antidepressant
and tranquillizing drugs should be given a full trial before leucotomy is
considered. Despite the advances these new measures represent, however,
Sargant (1962), in a discussion of the present indications for leucotomy,
still finds room, in certain depressive states, for the modified operation
providing the previous personality has been adequate. Pippard (1962),
after pointing out that the decline in the number of leucotomies has been
confined to the use of the standard operation, also indicates that he feels
that leucotomy can be of value amongst other disorders , in persistent
depressive states in the elderly and that, at the present time leucotomy is
probably under'JUsed.
THE TREATMENT OF DEPRESSION WITH DRUGS
The use of drugs in psychiatry, as Mariey (1959) has pointed
out, can be traced back to the dawn of Western Civilisation. "The Greeks"
Marley states, "made good use of the pharmacopoeia, prescribing borage,
bugloss, marigold, polypodie and epithyme for melancholy, more specifically
recommending wormwood, centaury and pennyroyal for the hypochondriac malady".
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Burton, in his "Anatomy of Melancholy", first published in 1621, described
the use of black hellebore and other purges, whilst other writers living in
Burton's era, such as Culpeper, recommended plant and herbal remedies for
depressive states. Such remedies were of a non-specific nature, and the
modern era of pharmacotherapy for depression began in 1936 when Peoples and
Guttman in the United Kingdom, and Myerson in the United States, began to
use amphetamines in depressive illnesses. The antidepressant compounds
currently in use (or in use at some time since 1936) are shown in Table 2,
which is adapted from a table contained in a review by Cole, Jones and
Klerman (1961).
TABLE 2 - ANTIDEPRESSANT DRUGS
GENERAL CLASSIFICATION GENERIC NAME TRADE NAME
(1) PSYCHOMOTOR
STIMULANTS
A. Amphetamines amphetamine Benzedrine
dextroamphetamine Dexedrine
methamphetamine Methedrine
B. Amphetamine-like phenmetrazine Preludin
C. Non-amphetamines methylphenidate Ritalin
pipradrol Meratran
deanol Deaner
(2) MAO INHIBITORS iproniazid Marsilld












Amphetamine compounds haw little eiiecfc in severs states of
depression. Accordingly, these drugs have, in the tain, been used in the
treatment of milder "neurotic" or "reactive" cases on an outpatient basis.
Unfortunately, though in general they engender euphoria, increase alertness
and lessen fatigue, in a proportion of patients they produce increasing
anxiety, agitation and despair. Their side effects include dryness of the
mouth, palpitations, anorexia and inaomniaj but sine©,Roes (1960) points
out, their mood-elevating effect is often short-lived and succeeded by an
intensified state of irritability, fatigue and dejection, and since
toleration quickly develops, the physician prescribing amphetamines not in¬
frequently finds he has to administer them in steadily increasing quantities
in order to continue to obtain good results. Combinations of aaphctaminee
with barbiturates (such as "Brinamyl", which is dextroamphetamine 5 rag. with
amylobarbibone grs. £) have mitigated amphetamine side effects to some
degree, but have not minimized the chief hazard of their use - addiction.
This problem, a serious and not very infrequent complication of amphetamine
treatment, has received an Increasing amount of attention of late (Oormell
1958, Bell and Trethow&n 1961, HcCormick 1962). Phenraetraaine ("Preludin"),
a related compound, through its use as an anorsxoganic agent and euphoriant,
has also led to addiction and toadc psychoses (Bartholomew and larley 1959).
Amongst other non-smphataiisine stimulants which have proved of
limited usefulness are mothylphenidat© ("Ritalin"), plpradrol ("Koratrsn")
and deanol ("Daaner"). Though methylphenidate antagonizes neserpine and
promotes alertness, a blind controlled trial has shown that it is no bettor
than placebo (Robin and Wlseberg 1958). Pipradrol did not live up to the
expectations of Fabwigr, Hawkins and Moult?*. (1955), and deanol, the third compound
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mentioned, has also, in a double blind self-controlled clinical trial, been
shown to be ineffective (Dominion 1960). On the other hand, a proprietary
combination tablet of benactyzina (1 mg.) and meprobamata (400 mg.),
"Deprol", has been shown to be of value in mild neurotic depressions, though
whether this relief is due to one or other constituent, or both together,
remains uncertain (Cole, Jones and KLerman 1961).
(2) MAO INHIBITORS
IPRONIAZID
The first major breakthrough in the drug treatment of
depression was the introduction of iproniazid ("Marsilid") in the mid 1950's.
Two papers by Kline and his associates (1957) and Crane (1957) given at an
American Psychiatric Association Conference at Syracuse "set off", Cole et
al. (1961) remark, "the current frenzy of clinical, pharmacological and bio¬
chemical research." "The significance of these reports", they percipiently
go on to state, "was not so much their claims for therapeutic effects, but
the linkage of clinical action to enzymatic inhibition." The same year
saw a second major breakthrough in the treatment of depression - the intro¬
duction of the iminodibenzyl derivative imipramine ("Tofranil") by Kuhn
(1957). Parenthetically it is interesting to note that the development of
the two major groups of antidepressants, the amine oxidase inhibitors and
the iminodibenzyl derivatives, of which iproniazid and imipramine were the
forerunners, was foreshadowed by the successful treatment of schizophrenia
with reserpine and chlorpromazine in 1954 and 1952 respectively. As with
convulsion therapy, history would seem to have repeated itself.
Kline (1956) has described how his success with reserpine in
schizophrenia led him to attempt the treatment of withdrawn and depressed
patients vith iproniazid. Iproniazid's parent compound isoniazid had earlier
been shown to be of value in the treatment of tuberculous patients, in whom
it produced euphoria and gain in weight, an action at first mistakenly
attributed to improvement in the pulmonary circulation, Iaoniazid actually
underwent preliminary trials as an antidepressant (Delay and Buisson 1952),
but together with its daughter compound iproniazid was abandoned as too toxic
for clinical use, Nevertheless Kline, visiting his laboratory one day, was
struck by the observation, made by one his associates, that animals pre-
treated with iproniazid did not become sedated when given reserpine. It
was this antagonism between reserpine, which he knew tranquillized schizo¬
phrenics, and iproniazid, that encouraged Kline to try the latter drug in
depress!ves. Later, parallels between clinical efficacy and the property
of monoamine oxidase inhibition encouraged theoretical explanations of
iproniazid's antidepressant action as being due to the latter property.
Despite the fact that iproniazid has been in use longer than
any other effective antidepressant, the papers describing the clinical
actions of the drug are, by and large, Cole et al, (1961) point out, inferior
to those on imipramine. Early reports suggested that response to this
compound, when it occurred, was dramatic and striking. Some authors felt
that iproniazid was better in psychotic than neurotic depressions while
others, notably West and Dally (1959) found that atypical, primarily neurotic,
depreselves responded best. More recently, several controlled trials have
been carried out in which iproniazid has been compared with psychotherapy,
placebo or EOT (Cole, Patterson, Craig, Thomas, Ristine, Stahly and
Passamanick 1959 J West and Dally 1959} Pees and Benaim 1960$ Filoh, Child
and Latner 1960 a,bj and Wittenborn, Plante, Burgess and Livermore 1961),
The available evidence seems to suggest that while iproniazid is not, in
general, as effective as EOT, it is of value in alleviating the acute
symptoms of a proportion of severe depress!ves and of a larger proportion
of mild cases. It is also effective in maintenance therapy, as shown in
table 3 which, amongst other trials, summarizes the only followed-up blind
controlled iproniazid study to appear in print. Unfortunately, the drug
has several dangerous side effects, of which the commonest is hepatitis}
thus Cares and Buckman (1961) list 17 deaths from hepatic necrosis following
iproniazid therapy, and other complications include mania, orthostatic hypo¬
tension, peripheral neuropathy, oedema, hyperreflexia, impotence, dizziness,
blurred vision, insomnia, dry mouth and constipation. Because of these
side effects, iproniazid has lost ground to the newer MAO inhibitors and
iroipramine, and now is seldom used in clinical practice (Hordorn and
Somerville 1962).
THE NEWER MAO INHIBITORS.
The newer MAO inhibitors however, whilst somewhat safer, have
not so far shown themselves to be convincingly more efficacious than
iproniazid, their parent compound. In this connection Cole et al. (1961),
who base their opinion on the evidence provided by a large number of
clinical reports, summarize the position as follows:- "It seems reasonably
certain that the MAO inhibitors are potent and effective drugs, whose actions
cannot be explained solely on the basis of placebo effect, suggestion, added
care or social effects. Pharmacologically they are different from, and
clinically they are superior to, the traditional psychomotor stimulants such
as amphetamine, methylphenidate or pipradrol. Most observers seem agreed
that their slow onset of action precludes their use in severely depressed
patients, especially where suicidal tendencies are strong. Practically no
clinicians feel that the results of treatment with MAO inhibitors surpass
- 34-
those with EOT. Iproniazid remains the standard of comparison. Although
the newer compounds are more active pharmacologically in animal studies than
iproniazid, there is little evidence that a larger proportion of patients
are improved, or that the quality of improvement is superior to, or even
very different from that obtained with iproniazid. The new compounds do
offer fewer adverse effects and less danger of serious complications;
whether they offer added clinical efficacy remains to be proved."
Increasing experience with MAO inhibitors has shown that these
drugs can have adverse effects if indiscriminately combined with other
medications. They potentiate opiates, atropine derivatives, barbiturates,
ganglionic blocking agents, corticosteroids and anti-rheumatic compounds;
they enhance the hypotensive effects of chlorothiazide and hydrochloro¬
thiazide; and they sensitize patients to the release of histamine, to novo¬
cains and anaesthetic agents. Phenelzine can cause hypotension (Davies
1960); excruciating headaches, combined with constricting sensations in the
chest, tachycardia and palpitations, have occurred when methylamphetamine
has been given intravenously to patients who have been on MAO inhibitors
(Dally 1962). A combination of amphetamine and tranylcypromine 1ms caused
death on more than one occasion (Zeck 1961, Mason 1962), the usual pre-mortem
diagnosis being subarachnoid haemorrhage or phaeochromocytoma. Ayd (1961 b)
has pointed out that the effects of MAO inhibitors persist after cessation
of the drug, so that it is wise to wait at least a week after discontinuance
of a MAO inhibitor before giving imipramine or amitriptyline; for this
reason the treatment of a severe depression should probably always commence
with an ixaino-dibenzyl derivative.
mmmsam and erhryptamije.
Phenipraalne ("Catron") ma found to be of the some order of
effectiveness as iproni&sid in a blind trial carried out by Crisp, Hays
and Carter (1961), Unfortunately the compound was toxic and following
Beer and Schaffner' e (1959) report of red-green colour blindness and severe
hepatitis, pheniprasine was generally withdrawn fro® world markets.
Erytryptamine ("Moaaase"), another recently-developed MAO inhibitor, has
also been withdrawn because of toxicity and iproniaaid itself was omitted
from a selective list of psychiatric medications issued in Washington B.C.
in 1962 by the Psychopharraacology Service Center,
XSOCARBOXAZID.
Isocarboxasid ("harplan"), an analogue of iproniasid, is safer
than the older drug, arid has been shown to be more effective than placebo in
the treatment of depressive syndromes (Rothman, Grayson and For.uson 1961a),
According to a second study carried out by the same authors, it my alleviate
depression in a way that differs from imipramine, which they also find to be
an effective antidepressant (Eothran, Grayson and Ferguson 1961b),
Unfortunately, the value of these two carefully performed blind studios is
limited by the small numbers of patients completing them, and also by the
inclusion of cases belonging to such varied diagnostic categories as
achiaophrenia, achiso-affactive state, depression and personality disorder,
a similar shortcoming - that of including a large, heterogeneous group of
"secondary" depreosivca - is evident in a third controlled trial in which
isocarboxasid was compared with placebos 50 per cent of 26 patients on
isocarboxasid were improved or markedly improved after 30 tag, of isocsr-
boxasid daily for three months in contrast to 10 per cent improving on
placebo (JoaM 1961), In this trial, depress!ves in general responded well
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to isocarboxazid, particularly secondary depressions accompanied by
agitation in elderly patients, but psychoneurotic deprassives did not do so
well, and severe and recurrent endogenous depressives were not helped at all.
Forte of the three studies, therefore, suggests that isocarboxasid is un¬
usually effective in the treatment of depressive syndromes. In connection
with the clinical value of isocarboxazid Cole et al. (1961) pertinently
remarks, "Although most clinicians are agreed that it is safer than ipron-
iazid, almost none feel that its clinical effectiveness is greater than the
original MAO inhibitor or EOT. However, in the hands of clinicians
experienced in the use of more than one MAO inhibitor, the compound appears
to be more potent than nialamide and safer than phenylisopropylhydrazine
and iproniazid. At this point, however, it is impossible to ascertain
whether it is clinically more effective than phenelzine or EOT."
NIALAMIDE.
Nialamide ("Niamid"), also more potent pharmacologically than
iproniazid, seemed promising at first because it did not produce the hypo¬
tensive side effects of the older compound. It has, in general, turned out
to be less effective than other MAO inhibitors, though in one recent con¬
trolled trial in chronic depressives, nialamide was more effective than
iproniazid and pheniprazine, ranking second only to phenelzine} patients
under 40 responded best to the drug (Bates and Douglas 1961). On the other
hand, a blind trial carried out in 50 hospitalized depressives, in which
nialamide was compared to chlorpromazine, showed no significant difference
between the improvement rates of patients treated with either compound.
Though, after two weeks the improvement rate was 77 per cent for nialamide
and 67 per cent for chlorpromazine, at the completion of the trial four weeks
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later, the respective improvement rates had dwindled to 50 per cent and
42 per cent (Affleck, Forrest and Martin 1961). In summary therefore, Cole
et al's. (1961) statement appears to provide an accurate estimate of the
value of nialamides "It is probably less toxic, and also less effective, in
the treatment of severe depressions than most of the other MO inhibitors."
PHENELZINE.
Phenelzine ("Nardil") is a further MAO inhibitor Which,
chemically, is closer to pheniprazine than iproniazid. Although the com¬
pound has the advantage of being relatively safe, an early controlled trial
carried out by King (1959)* in which 25 severely depressed patients were
randomly assigned to phenelzine or SCT, revealed that the drug was far
inferior to electroconvulsive treatment. A brief blind controlled trial of
phenelzine in hospitalized female depressives, carried out by Harris and
Robin (1960), showed no advantage for the drug over placebo, but other
trials have given more promising results. Thus, Hutchinson and Smedberg
(1960) found phenelzine significantly better than placebo in a double blind
cross-over trial on 34 hospitalized female depressives> the trial lasted
six weeks, of which four were occupied in giving the active drug. As
mentioned earlier, Bates and Douglas (1961) found phenelzine superior to
pheniprazine, iproniazid and nialamide in the treatment of 54 depressives.
Rees and Davies (1961), in a triple-blind, self-controlled trial carried
out on 20 hospitalized depressives, gave phenelzine and placebo randomly
for two three-week intervals} they found that 50 per cent of phenelzine-
treated patients recovered completely, or improved markedly, in contrast to
15 per cent responding similarly to placebo (p^.05). However, 13 of the
20 patients still required EOT to effect a complete recovery, and Rees and
Davies state: "there can be no doubt that the drug is not as effective as
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EOT for severe depressive illness." A more recent trial carried out by
Hare, Dominion and Sharps (1962), compared phenelzine with dextroamphetamine
sulphate and placebo in 43 moderately depressed patients, 4 of which were in¬
patients, while the others were attending a day hospital. Drugs were given
for two weeks and the assessments were subjected to sequential analysis.
On the clinical manifestations of depression, neither phenelzine nor dextro¬
amphetamine were better than lactose, but phenelzine was significantly
better than both other compounds in alleviating agitation and anxiety. In
summary, therefore, it seems that, while phenelzine is not as effective in
severe depressives as EOT, it is at least as potent, if not more so than
iproniazid, and is more effective than nialamide (Cole et ai. 1961).
TRAHILCIPRjCMNE.
Tranylcypromine ("Parnate") is a non-hydrazine MAO inhibitor
which chemically resembles amphetamine. The MAO inhibitor activity of this
compound, unlike its predecessors, appears rapidly and lasts only a brief
time (Tsdeschi etaL,This property, together with absence of the hydrazine
moiety, has been claimed to make the compound safer than other MAO inhibitors
in clinical use. Enthusiastic early reports describing the rapid clinical
improvement effected by tranylcypromine have been substantiated by a con¬
trolled trial in which it was compared to placebo in out-patient depressives.
Bartholomew (1962) gave 30 mg. of tranylcypromine daily for two weeks,
followed by 60 mg. of the compound for four more weeks} overall, the results
indicated that tranylcypromine was superior to placebo at the 5 per cent
level, though no significant superiority could be demonstrated in the treat¬
ment of either endogenous or involutional depressions. Bartholomew
concluded that tranylcypromine was of most value in the treatment of the
milder or reactive depressive states. The effect of the drug may, Cole et al.
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believe, be related to an amphetamine-like stimulating action which can lead
to troublesome and dangerous side effects. As mentioned earlier, spasmodic
hypertension has occurred, causing severe occipital headaches leading to a
diagnosis of subarachnoid hypertension or phaeochromocytoma. At least two
deaths have occurred from giving a combination of tranylcypromine and
amphetamine, either orally (Zeck 1961) or intravenously, as an abreagent
(Mason 1962). Because of the disadvantage of tranylcypromine * s side effects,
a combination of 10 mg. of this compound with 1 mg. trifluoperazine has now
been prepared, which is available for use under the trade name "Parstelin".
(3) IllINCDIBEKZYL DERIVATIVES.
IMIPRAKIHE.
Imipramine ("Tofranil") was synthesized in 19-48 in the Geigy
Laboratories in Switzerland in the course of work on the development of
sedatives, antihistaminic and antiparkinsonian agents. Imipramine is not
a monoamine oxidase inhibitor} indeed, chemically it resembles chlor-
pronazine ("Largactil"). Kuhn carried out preliminary trials with imipramine
as long ago as 1950, but the drug was shelved until 1954, when interest was
rekindled by the realization that its action in potentiating narcosis and
producing artificial hibernation paralleled that of chlorpromazlne; the
latter compound, because of its effectiveness in schizophrenia, was at that
time very much in the psychiatric eye. In the next three years Kuhn (1957,
1958) treated 500 psychiatric patients with imipramine, thinking that it,
too, might be of benefit in schizophrenic patients} nevertheless he dis¬
covered that depressives rather than schizophrenics showed a beneficial
response. Indeed, 75 - 80 per cent of endogenous depressives improved as a
result of administration of the drug} moreover, he obtained good results in
reactive depressives as well. In 1958, imipramine became generally available
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in Europe | a year latsr, through the medium of a Conference on Depression
and Allied States held at I cGill University, Montreal, it was introduced to
North America* A great nany impressionistic studies soon appeared but, as
usual, adequately controlled trials were not vory numerous® An increasing
amount of clinical experience, however, began to show that in&pranJuae uas
suporior to the MAO inhibitors in the treatment of severe depressive states®
Thus, in 1960, a reviewer wrote, "Xproniazld ("MarBllid*) seemed at first to
give ECT sane competition but its side effects proved too hazardous for its
general use. Indpramine ("Tofranil") ha3 edged iproniazid out of the
running as a substitute for EOT »..•••" (Wilcox 1960)®
TABLE 3.
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Table 3 summarizes the salient features of a number of blind
controlled trials of iproniazid and imipramino, prior to amitriptyline the
most effective antidepressant medications. Ball and Kiloh's imipramine
trial has the merit of having been carried out on an adequate number of
patients who vere all ttpurett depress!ves} their study was well followed up
and has provided the basis for many subsequent comparisons. Two aspects of
Ball and Kiloh's investigation should, perhaps, be especially emphasized,
both arising from the fact that it was carried out on out-patientst-
(1) Very severely agitated, and/or depressed patients who required EOT were
excludedj thus few patients with overt depressive delusions were admitted
to the trial (2) Side-effects were found to constitute a considerable
problem. The commonest were dry mouth, sweating, constipation, faintness,
dizziness, nausea, vomiting, shakiness and tremor. Insomnia, malaise,
blurred vision and an unpleasant taste in the mouth also occurred. One
patient developed grand mal epilepsy and one became hypomanic. Overall,
side effects of some degree were present in $3 per cent of cases.
The trial carried out by Kenning, Richardson and Tucker is
significant, for it was the earliest blind adequately-controlled study in
which an attempt was made to establish whether or not iraiprocaine possessed
a specific effect over and above hospitalization and other non-specific
agents. Sixty per cent of the isainramine treated patients responded and
side effects vere noted to be unusually mild, A similar order of response
was found in a second trial conducted on in-patients by Friedman, Mowbray
and Hamilton (1961), Though deluded patients in particular did not respond
to inipramine, the overall response rate to the drug was 65 per contj side
effects did not constitute a problem. Finally, in table 3, the
investigation carried out by Bees, Brown and Benaim merits scrutiny, for it
•was conducted on 20 unusually severe hospitalized depressivesj their
response to imipramine was 35 per cent, in contrast to a response rate of
10 per cent to placebo. Again, side effects did not constitute a real
problem.
The trials summarized in table 3 have been specially selected,
since it is considered that each has particular relevance to an investigation
of the efficacy of amitrlptyline in hospitalized depressives. The ipron-
iazld trial conducted by Kiloh, Child and Latner demonstrates that the
results obtained with this, rather toxic, compound are not as good as those
obtained with imipramine. Ball and Kiloh's trial of imipramine shows that
good results, both immediate and after six months, can be obtained with
imipramine, though side effects can be a troublesome complication of treat¬
ment. Kenning et al's. trial shows that the results produced by imipramine
in in-patients are not quite as good as those obtained in out-patients
(60% vs. 6(yi)t though side effects in in-patients are much less troublesome.
These findings are supported by the investigation conducted by Friedman et
al.j and finally, the last trial on table 3 shows that if the administration
of imipramine is confined to severe depressives, the response rate is lower
still - of the order of 35 per cent.
In all these trials, the methods by which patients were
evaluated are of interest, for evidence will later be presented that
valuable information may be missed if imprecise instruments are used.
Kiloh, Child and Latner, and Kiloh and Ball employed five-point clinical
assessments. Kenning et al. relied on clinical appraisals, the Wittenbom
scale and a number of psychological testa. Friedman et al. used a 25 item
questionnaire, a five-point scale based on an instrument constructed by
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Shapiro, and the depression aub^cale of the ulttenhorn ating scale,
teas ©t &1. graded clinical feature# cm a tve-padnt seal®, also using
nurses' observations and weekly overall physician#* grading# of thoir
patients' state.
Oofora leaving inipraaino, a raster of otter trial# loss
I
relevant in the present correction, mdt brief mention. Cm of the first
trials roportod was that of Lehman, Gohn and de crteuil (1953), who found
that ix&pra itat woe significantly superior to placebo In averting and re¬
lieving tho relapse# that could b© produced by deliberate oatssior* of ti»
drug during the period of trcatecnt with it. Leyberg and Beraaarit (1959)
obtained good results with itiprarine In a controlled blind stu.iy en 20
clinically depressed in-patients. k further trial was carried out in 24
chronic deprossivea by Pouot, Levis, ? iilor, Hprott and Wright (1959).
Patients entered this trial In replications of groups of four to receive no
drug, placebo, dextrocmptetardm. iproniosid and iedpm ainoj although
inipsmoino was administered for only one w?*ak, several patients improved.
In 1960, f1oit, Wright and flecker reported a stud;/ in which
thoy had given irdpramine, Isocarboaasid, ten©lain© and teniprasdno to
100 hospitalised patients. All four drugs were found to bo affective anti¬
depressants, inipracdne producing results conparabls with plioraolaine, the
beet drug of the four. Since no indication la given a# to whether ratings
were blind, and since patients in several iagnostlc categoric® war®
included, the result of this trial oust bo interpreted with caution. Brno©,
Crcme, Pltspatriek, Frowin, Cillic, Laacellas and Mtrskey (1961), who com¬
pared iMpramlne with 101 in 50 consecutive admissions (49 of whom were
endogenous deprosslvea), found that a hitter percentage of patients had
responded to EOT after a month, but that 60 per cent of imipramine-treated
cases also recovered. Ashby and Collins (1961) carried out a double-blind
comparison of imipramine and placebo in 15 chronically depressed in-patients,
each patient randomly receiving nine weeks on the drug and nine weeks on
placebo. Some patients became more settled but no significant change could
be detected on the rating scale that was employed. Oakley (1961), comparing
imipramine with pheniprazine in a blind trial on 49 hospitalized endogenous
depressives, could find no difference between the two compounds.
SUMMARY.
In summary, the data presented in the first section indicates
that depressive disorders are extremely common in the majority of countries
for which reliable figures are available. The incidence and prevalence of
these disorders in the community is appreciably high; secondary and primary
forms of the illness are frequently encountered in general practice;
psychiatrists see a great many depressives; such patients form a sizeable
proportion of individuals committing suicide; many depressives are admitted
to general hospitals with the symptoms of physical illnesses, and depression
can also present in the guise of alcohol or amphetamine addiction.
Accordingly, there can be no doubt that depression is a widely prevalent
disorder at every level of medical experience.
The second section reviewed the results of treating severer
depressive states with convulsant techniques and surgical procedures.
Electroconvulsive therapy, -though safe and highly affective in most cases,
has the drawback of being distasteful to patient and physician, of producing
transient confusion and memory impairment and, worst of all, of being
followed by an appreciable proportion of relapses - overall, these occur in
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some 20-30 per cent of cases. Leucotomy, whilst very effective in severe
v-1
depressive states, still seems an unduly serious and irrevocable step to
take, to be avoided, if possible, in the majority of cases.
The third section, which considered the drug treatment of
depressive states, presents evidence suggesting that, prior to the advent
of amitriptyline, imipramine was the most effective antidepressant available
for the treatment of severe depression. The trials that have been conducted
indicate that, whilst improvement with imipramine does not occur as rapidly
as is the case with EOT, the drug can produce results comparable with EOT
some months after treatment, providing patients are kept on adequate
maintenance doses. In general, the severer the depression the lower the
percentage of success with imipramine} Indeed, grossly depressed, overtly
deluded patients have been noted to respond poorly, if at all. Side effects,
it lias been found, can be troublesome} in general, they have been more of a
hazard in out-patients than in in-patients treated with this compound.
CHAPTER 11.
Af'ITRIPTYLINE IK DEP'ESSIVE STATUS* A COKTROUED TRIAL
In 1960 the first clinical reports began to appear on
amitriptyline ("Elavil11 "Tryptizol" "Tryptanol"), a now antidepressant
developed by Merck Sharp and Dohiae of Philadelphia* Amltriptyline is
(5 - amino - propylidino) ~ dibenso (a, d) (1, A) cycloheptadiene hydro¬
chloride, a compound structurally similar to both iniprari.no and chlon-
promaaine. The resemblance is clearly evident in the fomilae of the three
compounds#
FIGOHS 1.
ch3 ch3 ch3 ch3 ch3 ch3
CHLORPROMAZINE IMIPRAMINE AM ITRI PTYLINE
Since amitriptyline has rally recently been developed, mid
since no blind controlled trials have yot been reported, the pharmacological
and clinical studies so far reported will be briefly reviewed.
Vernier (1961) has provided a description of the pharmacology
of antidepressant agents in general, with special reference to the pharraa-
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codynamic actions of amitriptyline. Extensive experimentation in animals
has shown that amitriptyline weakly tranquillisea both the EEG and operant
behaviour} the drug is a fairly powerful anticonvulsant, and possesses
weak peripheral atropine - like actions; it has strong antihistaminic
properties and weak antiserotonin effects. Amitriptyline produces a degree
of adrenergic blockade and has a gastric antisecretory effect} it is rapidly
metabolised in the body in manner similar to imipramine. According to
Sabelli, Levin, Siegler and Toman (1961), in animal studies amitriptyline
behaves like imipramine} the pharmacological effects of these two compounds,
together with chlorpromazine and chlorprothixizine, differed quantitatively
rather than qualitatively (Herr, Stewart and Charest 1961). In squirrel
monkeys and rats trained on a Sidman avoidance schedule, Hanson (1961) re¬
ports that amitriptyline, like chlorpromazine and imipraraine, caused loss of
avoidance responding at moderate doses and produced decreased escape
responses at higher doses; both amitriptyline and imipramine produced
erratic responses at high doses and, like chlorpromazine, depressed behaviour.
Weissman (1961) stabilized rata on a non-discriminating avoidance task;
they showed a stimulant effect with d- amphetamine, which was potentiated by
premedication with imipramine. The effect of pre-treatment with amitrip¬
tyline was similar, Weissman found, though its onset was more rapid and its
duration shorter; on the other hand, chlorpromazine (given in a lower dose)
antagonized the effect of amphetamine. According to Pletscher arnd. Gej (i960
amitriptyline, like imipramine, does not alter monoamine oxidase metabolism
in vivo in the rat brain in the way that it is altered by MAO inhibitors,
reserpine and benzoquinolozine derivatives. Calrncrose Gessho-n. and Gu>fc(l9fci)
state that in experiments on cat blood pressures on an animal sedated with
"Nembutal M} low doses of amitriptyline produced a slight pressor effect;
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higher doses (1 rag. per kilogram given intravenously) produced a brief
depressor response. 1 ag. of amitriptyline per kilogram given intra¬
venously potentiated the pressor response of adrenaline and noradrenaline,
but blocked these responses when given in higher doses.
Alexander (1961a,b) has reported investigations of the effect
of aiaitriptyline and other drugs on the human psychogalvanic reflex} he
found that, in this regard, aaltriptyline occupied an intensediate position
between imipranine and chlorpronsaine. Perception as well as mood was
beneficially affected when aaltriptyline was given to male neurotic
depressives (Ostefeld 1961). In regard to the metabolism and excretion of
aiaitriptyline, Backer and Porter (1961) state that very little appears un¬
changed in the urine, the compound being found there as deoethylated
derivatives tMch are excreted as glucuronides.
From a clinical standpoint amitriptyline, however administered,
appears to bo well tolerated and to act in manner reminiscent of both
iraipraraine and ehlorpromazine. In oarly trials, depressions accompanied
by high levels of anxiety responded well to oral doses of 75-225 rag. of
aaitriptyllne daily} 50 rag. thrice daily ma the usual dose (Dorfraan 1960).
Freed. (1960) found that severe tension and anxiety, even in elderly patients
with cerebral damage, responded well to parenteral administration of this
compound} 10-15 ag. could safely be given intravenously two or three times
daily. A year later Dunlop (1961a) also reported good results with
parenteral araitrlptyline. In 1960 Ayd went so far as to state that he
believed airdtriptylin© to be the treatment of choice in involutional
melancholia, though other types of depression also responded, an opinion
with which Dunlop (1961b) concurred. Von Arnold and Foltl (1961) state
that amitriptylin© is the most useful pharmacological agent currently
available for the treatment of endogenous depressionsj Bennet (1961a,b)
also endorses its value in these conditions, though the results reported
by Settel (1961) are rather less striking, Ayd (1960,1961c) is of the
opinion that, following recovery, protracted maintenance therapy with
asitriptyline • 3 ©ontha or more - is necessary to prevent relapse, Kost
reports stress the freedom from toxity and low incidence of aide effects
with amitriptyline, though somnolence, blurred vision, dry mouth, dyspepsia,
constipation, sweating, tremor, weakness, fatigue and hypoiaania have all
followed administration of the compound. In studies comparing amitriptyline
with inipramine Ayd (i960) obtained rates of response of 79 per cent and 73
per cent respectively} O^taaan and Frietean (1961), in a blind trial,
obtained rates of 72 and 71 per cent} and Weiss and Pressman (1961) found
that both drugs produced remission in 75 - 79 per cent of cases. In an
Australian investigation of aiaitriptyline Roaenbaura and Gershon (1962) ob¬
tained satisfactory improvement in 75 per cent of endogenous depressivee and
in 50 per cent of reactive cases} they concluded that amitriptyline, whilst
at least as effeotive as imipramine in endogenous depressives, was less
e fective in reactive cases. Side effects with amitriptyline were fewer,
improvement was sore rapid and relapses were less frequent than with imipra ine,
Aside from its effectiveness in primary depressive conditions,
amitriptyline has been used to good effect in the depression, anxiety and
anergia that can acccrapany non depressive psychoses, physical illnossos and
dermatoses (Barsa and Saunders 1961, Dorfnan 1961, Fclcfcor. 1961, Pressman
1961, Pressman and Weiss 1961, Vaisberg and Saunders 1961, Zelcer 1961).
Schuff (1961) found that amitriptyline was effective in the treatment of
gastro-intestinal disorders, particularly duodenal ulcer, when anxiety was
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prominent in the illness.
The findings that have been published thus suggest that
amitriptyline possesses several significant advantages over earlier anti¬
depressants. Although it has been reported to be effective in the treat¬
ment of depression, amitriptyline has not produced palpitations, restlessness,
tachycardia and anorexia, the typical side effects of the amphetamine anti¬
depressants! moreover addiction to aiaitriptyline does not seem likely to
become a problem. As a true antidepressant resembling imipramine, amitrip-
tyline has been found to be effective in the treatment of depression
accompanied by agitation, a syndrome only partly ameliorated by chlorprom-
azine, the other compound to -which amitriptyline is similar. Most clinical
reports suggest that amitriptyline is a more effective antidepressant than
the MAO inhibitors! moreover since amitriptyline does not belong to the
latter group of compounds, it appears likely that its continued use will be
free from the liver and bone marrow complications that have bedevilled the
MO drugs. Further, the available evidence implies that amitriptyline is
at least as effective as imipramine in depression, with the added advantage
of a rapidly-evident tranquillizing effect and more innocuous side effects.
Finally, patients unresponsive to imipramine have been noted to respond to
amitriptyline. If these conclusions are correct, amitriptyline would
appear to be the most useful antidepressant thus far discovered, and one
that well deserves detailed clinical investigation.
A CONTROLLED TRIAL OF AMITPIPTYLINE.
Clearly on the basis of the work presented in Chapter 1,
amitriptyline' s principal rival in the treatment of depressive states is
imipramine. In such conditions, blind trials have demonstrated that
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imipramine is significantly more effective than placebo; moreover though
imipramine is not as rapid in action or as universally successful as EOT,
the results of one blind well-controlled investigation suggest that after
six months there is little to choose between the two methods of treatment
(Kiloh and Ball 1961). Imipramine therefore is the most appropriate
specific referrent agent against which to compare amitriptyline; and the
findings that have been outlined render the inclusion of placebo or ECT
groups unnecessary in a study of amitriptyline1s effectiveness.
Accordingly the investigation to be described was carried out in three
phases:
(1) A double-blind comparison of the effects of
amitriptyline and imipramine was made in
73 hospitalized female depressives.
(2) To confirm these findings, 64. additional patients
were given the two compounds; the total sample
of 137 patients was used to explore both the
phenomenology of depressive states and the prognostic
significance of relevant variables.
(3) A factor analysis of the initial depressive symptom
scores of the 137 patients was carried out in an
attempt to delineate specific depressive syndromes;
in addition, relapse rates were studied during a six-
month period of follow-up period.
SETTING OF THE STUDY.
The investigation was carried out at Royal Park Psychiatric
Hospital, Melbourne, a 240-bed early treatment centre for psychiatric
illnesses, which serves a metropolitan and rural area of approximately one
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million people. The hospital is situated in parkland three miles from the
centre of Melbourne. Its 140 female and 100 male patients are housed in
villa type wards of 35 or fewer beds, only two of which - the admission
wards for the two sexes - are locked. The staff numbers 14 physicians and
90 nurses, and the hospital is a major psychiatric teaching faculty of the
University of Melbourne.
In 1961, at the time of the investigation, approximately
1,700 women were being admitted annually, 70 per cent of them as voluntary
patients. Two-thirds received a full course of in-patient treatment,
staying an average period of one raonthj the remainder, with more adverse
prognoses, were transferred to longer-stay hospitals. Admissions, virtually
unselected, covered the whole range of adult psychiatric disordersj in all,
some 25 per cent of female admissions presented with depressive symptomat¬
ology.
FIRST PHASE OF THE STUDY! PRELIMINARY PLANNING.
In planning the study, particular attention was paid to a
number of methodological points which, in the light of earlier investigations,
appeared to be of considerable importance. The main principles on which
the methodology of the first stage of the study was based were as follows!-
(I) Since female depressives outnumber their male counterparts,
a homogenous sample of depressed female in-patients was to
be assembled for investigation.
(II) To allow of valid conclusions, this sample was to be of
sufficient size.
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(111) Since it was recognized that neither amitriptyline nor
imipramine could be expected to act as rapidly as EOT,
both compounds were to be administered in sizeable doses
for a longer period than was customary.
(1V) To ensure that almost identical groups of patients would
be available for investigation of drug effects, patients
were to be allocated to four age/severity groups, in each
of which the two drugs were to be randomly administered.
(V) To discount milieu as a between-drug variable, physical
surroundings, nursing care, occupational and social therapy,
v£tc. to be kept uniform for all patients.
(VI) To obviate bias, blind techniques of evaluation were to be
used.
(VI1) To ensure greater validity, several different criteria of
improvement were to be settled on.
(VI11) To measure speed of change, serial assessments were to be
used.
(1X) For greater accuracy, both discrete and global methods of
evaluation were to be employed. Outcome in terms of
discharge or EOT - a relatively objective criterion - was
to be the ultimate measure of drug efficacy.
(X) To monitor progress in the early stages of the investigation,
sequential techniques were to be used.
(X1) To assess the probable significance of findings, appropriate
parametric and norv-parametric tests were to be employed.
(X11) Provision was made for extension, if this was indicated by
the preliminary findings.
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With these principles in mind, a detailed protocol of the
first stage of the study was formulated. Two null hypotheses were taken
for disproof:-
(I) Amitriptyline is in no way superior to imipramine in the
treatment of patients with depressive states, as judged by the results at
one, four, and in some cases, six weeks after commencement of treatment
with the two compounds.
(II) Amitriptyline produces side effects which are no less severe
and troublesome than those produced by imipramine.
FIRST PHASE OF THE STUDY: METHODOLOGY
SELECTION OF PATIENTS,
Female patients were chosen since depressive states are
commoner in women than in menj when the study was initiated, this was
reflected in the admission of three times as many depressed women as men to
Royal Park Fsychiatric Hospital. Young and very old patients were rejected,
the former to minimize the risk of including women with personality dis¬
orders or schizophrenia, the latter to lessen the chances of including
patients with organic psychoses. Thus patients who were considered for
admission to the trial were aged between 30 and 70} they had to be prepared
to stay in hospital a minimum of four weeks. It was laid down that none
should have had EOT in the three months preceding admission, or major anti¬
depressant drug therapy (amitriptyline, imipramine or MAO inhibitors) within
the preceding two weeks. No epileptic or leucotomized patients were taken
into the trial} further, in all that were selected, their depressive
illnesses had not to be complicated by severe physical disabilities such as
glaucoma or decompensated cardiac, renal or hepatic disease. Finally,
since many non-English-speaking migrants were admitted to Royal Park
Psychiatric Hospital, subjects for the trial were chosen from those with
no severe language barrier.
Providing these initial criteria were met, consecutive
patients were taken in to the trial as long as their illnesses revealed, as
a primary manifestation, a persistent alteration of mood exceeding customary
sadness, apparent to the examiner and constituting a major feature of the
illness. This primary affective alteration had to be supported by one or
more of the following features: self depreciation, hypochondriasis,
retardation and/or agitation. Depressions which were clearly secondary to
other psychiatric illnesses such as schizophrenia, obsessional neurosis,
dementia or severe mental deficiency were excluded. Subsequently, to
facilitate comparison with the work of other investigators, patients were
allocated, either to the "endogenous" "psychotic" or to the "reactive"
"neurotic" categories.
Potential cases for the trial were chosen at daily routine
interviews of new female admissions. As a rule, suitable subjects were
observed for three or four days before being taken into the trial? during
this time it was possible to ensure that the trial criteria were met, and
diagnosis could bo established with more certainty? further, patients who
were exhibiting transient situational reactions could readily be excluded
■without further ado. When taken Into the trial, patients received full
physical and psychiatric examinations ? weight and blood pressure (recumbent
and erect) were recorded, and laboratory tests were performed. These
included haematological examinations (Hb, W.BCs andESR), serum bromide
levels, thejKline reaction, liver function testa (alkaline phosphatase,
cephalin flocculation) and urinalysis. Specific factors of the psychiatric
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history were noted on a form constructed for the investigation (Appendix 1) j
the Hobson scale (Hobson 1953) was completed, and salient features in the
socio-economic background were recorded by a psychiatric social worker
(Appendix 2).
CARE OF PATIENTS.
All patients were routinely assigned to one hospital medical
officer and in the course of the investigation received a good deal of
additional attention. Only two wards were used, to ensure that milieu
influences were as uniform as possible. After as brief a period in the
admission ward as their clinical condition permitted, patients taken into
the trial were transferred to a pleasant, 21-bed, open convalescent villa.
As soon as practicable, patients began occupational therapy; they worked in
a single group in a standardised situation under the direction of the same
two occupational therapists.
ALLOCATION TO GROUPS: DRUG ADMINISTRATION.
Each patient was initially evaluated by two psychiatrists on
Hamilton's (1960) depressive scale, shortly to be described. On the basis
of age and severity of illness (denoted by the totalled rating scale scores) -
the patient was then assigned to one of four groups (1) "young mild" (aged
30-49, scale score 0-39); (11) "young severe" (aged 30-49, scale score
40-100); (111) "old mild" (aged 50-70, scale score 0-39) or (1V) "old
severe" (aged 50-70, scale score 40-100). On entering the appropriate
group, the patient took the first available code number for drug administrat¬
ion, which was carried out according to a numerical code held in the hospital
pharmacy. This method was settled on so as to avoid too great a degree of
dissimilarity in patients receiving the drugs; it also facilitated the study
of drug effects in relation to two leading prognostic criteria - age and
severity of illness. Table 4 shows the distribution of patients completing
the first stag© of the investigation.
TABLE 4.















Tho hospital pharmacist dispersed the two drugs in identical
orange capsules* each containing 25 mg.j the drug code ensured equal dis¬
tribution of amitriptyline and imipramlne to patients in each age/severity
group. Only the pharmacist and the psychologist who evaluated the results
(but was not involved in rating patients) had access to the code. The nursing
staff were informed that a double blind technique was being used in the in¬
vestigation! thoy wore asked to be especially careful to see that medication
was ingested, and they were specifically requested not to open capsules prior
to their administration. The dosage of the two drugs was arbitrarily fixed
at 150 mg. daily (i.e. 6 capsules) for one week, followed by 200 mg0 daily
(8 capsules) for the next three (or four) weeks. This was followed by a
maintenance dose of 100 mg. daily (4 capsules) for six r;oaths. These dosage
levels together with the intervals at which assessments of change were carried



















All patients were evaluated after one month of hospital treat¬
ment. At this time those who had recovered or had markedly improved were
discharged on maintenance dosage; those who were unchanged were given EOT;
and those who were somewhat better, but not sufficiently well to be dis¬
charged, were given a further two weeks on full dosage before a final
decision was made on discharge or Ed. In 7 cases out of the first 73 -
either for socio-economic reasons (5) or where a need for a further increase
in weight was apparent (2) - discharge was delayed beyond these arbitrary
times, and dosage was reduced to maintenance levels. Three patients who
improved rapidly and wished to leave hospital were allowed home after two
weeks on full dosage of the capsules; they returned for assessment as out¬
patients at the end of one month; their dosage was then reduced to
maintenance levels.
Throughout the trial, with the exception of night sedation
(sodium amylobarbitone grs. 3-6), other medication was restricted to the
very occasional use of intramuscular chlorpromazine for severe agitation.
Ed was never administered until patients had completed their full period of
drug administration (i.e. U or 6 weeks), and had thus been classified as
drug failures.
CLINICAL EVALUATION.
The clinical state of the patients included in the trial was
blindly assessed, initially, after one week, after four weeks - and sometimes
after six weeks - of drug administration. The initial evaluation provided
the baseline score, i.e. the patient's condition prior to the administration
of drugs. The first week evaluation was performed to see whether the
tranquillizing effect claimed to be rapidly in evidence with amitriptyline,
could be detected and, if so, whether it was of prognostic significance#
The four-week evaluation - or, where applicable, the six-week evaluation -
was carried out to assess the results of in-patient treatment. Change in
the patient's condition was registered in two "difference scores" - the
difference between the initial and first week score, and the difference
between the initial and final scorej nevertheless, outcome, in teres of
discharge or EOT, constituted the final criterion of drug efficacy.
The following methods of assessment were employed:-
(1) Rating Scale Scorest Two psychiatrists independently rated each
patient on Hamilton's (1960) depressive scale at a Joint interview,
summing their ratings to produce a total score. This scale
quantifies 17 "target symptoms" of depressionj the order of its
items was slightly rearranged for convenience, as shown in Appendix 3.
Since an independent factor analysis was contemplated, a decision was
made not to use the factors described by Hamilton. The maximum score
patients could attain from the two raters was 2 X 50 = 100.
(2) Overall Clinical Assessments: The two psychiatrists who rated
patients on Hamilton's scale also made independent clinical evaluations
of the severity of their depressive illnesses. On these ratings,
depression was registered as 0 = absent, 1 = mild, 2 = moderate,
3 = severe, U ~ very severs. Totalling the ratings of the two
assessors gave a score range of 0 - 8.
(3) Occupational Therapy Ratings: Two independent ratings, later summed
to make a total score, were made by two occupational therapists at
times corresponding as closely as possible to the Hamilton scale
assessments. Patients were rated during their performance, in groups
of not more than six, on a series of tasks selected on the basis of
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five criteria: (1) they needed only simple, clear-cut instructions
and required little continued support from the occupational therapist
(2) they had a definite objective (3) they required little
preparation (4) they were very similar in degree of difficulty,
requiring the same level of skill and (5) they were inexpensive#
The chosen tasks were those involved in making covers and covering
children's books for a local school# The task for rating 1 was
cutting and pasting magazine pictures in montage form} rating 2 was
made on candle wax painting and drawing; rating 3 was made on
potato cutting and printing; and rating 4> when completed, was made
on book covering, with simplified instructions#
To carry out these assessments, an occupational therapy rating
scale constructed for the investigation was used (Appendix 4)» The
scale quantified eleven items of behaviour under task performance,
depressive symptoms and interpersonal relationships# The total scale
score was 33} summing the two raters' scores, gave a possible
maximum score of 66#
(4) Ratings of Side Effects: These were made thrice weekly by a
physician not otherwise employed in rating procedures. A scale
elaborated to include the reported side effects of amitriptyline and
imipramine was employed (Appendix 5)# Each symptom was quantified
on a four-point range of severity, and both patients and nursing staff
were asked to bring side effects to the rater's attention# Since it
was of paramount importance to distinguish true side effects from
"side effects" which were part of the patients' depressive syndromes,
initial pre-drug assessments were always made#
- 61 -
(5) Outcome of Treatment* Finally, amitiiptyline and imipramine were
compared in terms of the numbers of patients who were discharged
relieved (after four to six weeks) and the numbers who had to go on
to receive ECT; for comparison with the findings of other investigators,
outcome according to category of depression was also computed.
PRELIMINARY FINDINGS
SELECTION CF THE FIRST 7A PATIENTS.
Although, as was earlier pointed out, depressive states occur
very frequently, and constitute an appreciable percentage of female
admissions to Royal Park Psychiatric Hospital, six months passed before 7A
patients were collected who conformed to the designated criteria. During
this period (June - December, 1961) 300 female patients were admitted, some
250 of whom presented with depressive symptomatology. Of those who were
rejected, 21 per cent had had recent major antidepressant drug therapy, 19
per cent responded rapidly to the hospital environment, 15 per cent were out¬
side the age range, 15 per cent had depression "secondary" to other illnesses
(principally schizophrenia), 13 per cent had had recent ECT, 11 per cent had
too severe a language hairier to allow of valid ratings, and 6 per cent were
suffering from associated physical disorders.
SOCIO-ECONOMIC BACKGROUND.
In socio-economic background, as was to be expected from the
method of allocation to the drugs, there was no significant difference
between the two groups of patients. Of 73 patients included in the first
phase of the study (one of the first 7A died) 85 per cent had been bom in
Australia; their mean age was 52.0 with a standard deviation of 10.85 years.
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Eighty-six per cent were, or had been, married, and the majority of these
had one, two or three children. Only 8 per cent had progressed beyond the
primary school level and, for most, vocational qualifications were restricted
to semi-skilled industrial and clerical work. Most were housewives; all
15 per cent who worked were employees. Precise figures in regard to income
were not obtained, but it is known that 45 per cent depended on their
husband's earnings, 34 per cent on pensions, and 11 per cent on their own
earnings. Sixty-two per cent lived in dwellings which they owned or were
paying for; the remainder lived in rented houses or flats. The socio¬
economic profile was of a predominantly lower-middle class group with an
assured but usually low income and generally low levels of education,
vocational training and experience.
PSYCHIATRIC BACKGROUND.
In psychiatric background, likewise, there were no significant
differences between the patients in the two drug groups. Of the 73 patients,
46 per cent had never been previously hospitalized for mental illness; 25
per cent had been in hospital only once before and 29 per cent had been
hospitalized two or more times. Sixty-two per cent had first required
medical attention for their condition within the preceding two years; 12 per
cent had needed help between three and five years before their current ill¬
nesses and 24 per cent had had to seek assistance between six and twenty
years previously. Ten per cent had received antidepressant therapy (within
the specified limits) prior to admission; 6 patients had been given drugs,
whilst 1 had had EOT. One patient had developed her depressive state within
a week, but in 76 per cent the illness had taken one to eight weeks to
. ...
develop; in 23 per cent of cases the depression had come on more insidiously.
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In 52 per cent of patients, no precipitants could be found} in 33 per cent,
however, psychological stresses were in evidence and had apparently pre¬
cipitated the illness. These included domestic anxieties, such as grief,
problems with children or -in-laws, or more general stresses such as anxiety
after car accidents or prior to impending surgery. In the remaining 25 per
cent of patients, physical precipitants were in evidence - alcohol, gynae¬
cological conditions, hypertension, influenza, operations, the puerperium
and the ingestion of reserpine.
LABORATORY FINDINGS.
No significant alteration in blood pressure or other somatic
functions were noted during the trial and both drugs, in general, seemed
3afe and non-toxic in the doses that were used. Nevertheless, one 65 year-
old patient died on the 20th. day of imipramine administration} she
developed a confusional state followed by general epileptiform activity and
hyperpyrexia. Autopsy revealed that death was due to pneumonia and though
the level of imipramine in the liver was unusually high, the pathologist
stated that it was not possible to implicate imipramine directly in leading
to death.
NURSING PROBLEMS.
Contrary to expectation, the ease with which the selected
patients, many of them severely depressed, were managed during the trial
was quite striking. Only one patient was rejected on the grounds of
severity (and this because of refusal to take oral medication)} none of
those accepted had to discontinue the trial in the first four weeks to
receive EOT. A few patients required occasional intramuscular injections
of chlorpromazine in the early stages of treatment, but this was given
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sparingly and only for extreme agitation and distress. This was the more
impressive since the great majority of patients spent virtually their entire
hospital period in occupational therapy and an adequately, but not specially?
staffed open ward®
ANALYSIS OF DATA.
Initially? sequential techniques were used to monitor changes
in total scale scores as well as in individual depressive syaptoras. Three
diagrams illustrating this approach are shown in figure 3®
FIGHT® 3.
ONE WEEK TOTAL IMPROVEMENT-ALL PATIENTS ONE WEEK IMPROVEMENT ON SOMATIC ANXIETY-*OLD SEVERE GROUP"
The top left-hand diagram ahows the results of applying a con¬
ventional charting procedure to the changes in the total depressive scale
scores after one week in 3-4 pairs of patients* no differences between the
drugs are evident. On the other hand, as the right-hand diagram shows, when
a more homogenous sample of patients - the "old severea" - was chosen, and a
single symptom "somatic anxiety" was selected, the one-week improvement in
patients treated with amitiiptyline was significantly greater than the
improvement occurring in patients treated with imipramine. Next, for great¬
er sensitivity, a more powerful statistical technique was employed - the
sequential 2 test (Armitage 1960] „ The lower diagram in figure 3 is a chart
of the sequential Z values of the improvement scores in a number of symptoms
after four weeks in the "old severe" patients. In the graph, penetration
of the "ceiling" denotes statistical significance, an accomplishment rapidly
achieved by amitriptyline for "middle insomnia".
Sequential techniques were valuable in pointing up trends and
providing a guide to the number of cases needed to produce a significant
therapeutic result. In the later analysis, the Mann-Whitney U test,
corrected for ties (Siegel 1956), was used to test the significance of
differences found between the drug groups on physician's ratings, overall
clinical assessments and ratings by occupational therapists. The distrib¬
ution of these various ratings were rarely normal in appearance and "t" tests
or other statistics based on the normal distribution would have been of
dubious merit. The probabilities that are quoted in the remainder of the
chapter are based on one-tailed tests since the research hypothesis under¬




Table 5 summarise# the results of the trial In the group of
73 patients in term of the ability of andtriptyline and inipramine to
mitigate the synptoms of depression itemized in Hamilton's scale®
TABLE 5.
MEAN IMPROVEMENT SCORES ON PHYSICIANS' SCALE RATINGS (n = 73)




OF AMITRIP. IMIP. AMITRIP.
IMIP.
SCORES COIIC (n = 36) (n = 37) (n = 36)
Depressed Mood 0 - 8 1 . 4 1 . 2 3 . 2 2 . 4
Retardation 0 - 8 . 7 . 7 2 . o 1 . 7
Work & Interests 0 - 8 1 . 9 1 . 8 3 . 6 2 . 9
Guilt 0 - 8 . 8 . 8 2 . 1 1 . 5
Suicide 0 - 8 2 . 1 2 . 1 2 . 9 2 . 5
Psychic Anxiety 0 - 8 1 . 6 1 . 6 2 . 8 2 4
Somatic Anxiety 0 - 8 1 . 8 1 . 1 1 . 9 2 0
Hypochondriasis 0 - 8 . 7 1 . 0 1 . 4 1 1
Agitation 0 - 4 1 . 2 1 . 2 1 . 7* 1 2
Initial Insomnia 0 - 4 1 o 1 . 8 2 . 2* 1 7
Middle Insomnia 0 - 4 . 7* - o 1 1 . 3 8
Delayed Insomnia 0 - 4 . 9* - . 3 1 . 6* 7
Somatic Symptoms
(Gastro-Int.) 0 - 4 1 . 2 . 9 2 . 4** 1 5
Somatic Symptoms
(General) 0 - 4 . 8 1 . 0 1 . 8 1 5
Genital Symptoms 0 - 4 o 9 . 7 1 . 6* • 9
Loss of Weight 0 - 4 . 0 . o 1 . 9 1 „ 6
Loss of Insight 0 - 4 . 3 . 1 • 7 • 3
Total Improvement
Score
0 - 100 17 . 9 14. 7 35. 2* 26 . 7
( * Significant at 5% level; ** significant at 1% level)
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The table shows that, at the end of one week, amitriptyline
tended to be slightly superior to imipramine in alleviating the symptoms
of depression. In two symptoms - middle insomnia (p = .01) and initial
insomnia (p = .05) - this superiority was statistically significant. The
total Improvement score of the amitriptylino group at the end of one week
was a little higher than that of the imipramine group, but not significantly
so. At the end of one month, however, the superiority of amitriptyline
was more in evidence. It was significantly superior to imipramine in
relieving gastrointestinal somatic symptoms (p = .005), delayed insomnia
(p = .015)* agitation (p = .04), initial insomnia (p = .05) and genital
symptoms (p = .05). The total improvement score with amitriptyline was
clearly and significantly higher than that produced by imipramine (p = .02),
Inspection of the results obtained in the four sub-groups
revealed that the drug differences shown by the total group were accompanied
by a number of differences in the sub-groups. These differences are shown
in table 6, from which the 10 "old mild" and the 4 "young mild" patients
have been omitted, since their numbers were too small to allow of valid
conclusions. In table 6, all differences with any reasonable possibility
of significance are shown. Although the results for the "young severe"
and the "old, severe" groups are somewhat antithetical, it will be noticed
that the picture with regard to insomnia is very consistent - all results
favoured amitriptyline, and out of 18 differences, seven were significant
(p .05), three of them highly so.
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TABUS 6.
SIGNIFICANCE TESTS ON PHYSICIAN'S RATINGS (n = 73)
(All probabilities are associated with the superiority of amitriptyline except
























Dep. Mood .007** (.06) . 05* . 06*
Retardation . 14 . 16
Work & Interests . 06 (.06) . 18 . 11
Guilt . 11
Suicide . 09 (.09) . 12 (.23)
Psychic Anxiety . 14 (.10) . 11 (.26)
Somatic Anxiety .008** (.28) . 13
Hypochondriasis (.02)* (.13)
Agitation . 14 (.25) .008** . 04*
Initial Insomnia . 16 . 05*
Middle Insomnia .008** . 05* . 02* . 08
Delayed Insomnia . 09 . 11 . 01** . 01** . 015*
Somatic Sympt.
- - - —Gastro-Int. . 09 (.08) . 02* .005**
- - - - -General . 40
Genital Symptoms . 12 . 05*
Loss of Weight
Loss of Insight . 40
TOTAL . 02* (.08) . 07 .014*
( * Significant at 5% level. ** Significant at 1% level)
Illustrative diagrams bring out these differences with greater
clarity. Figures A and 5 show the superiority of anitrlptylino in the "old
severe" group after one week and one month of treatment.
At the end of one week, amitriptyline was highly significantly
superior to iniprumine in ameliorating the following symptoms s depressed
mood (p = .007), somatic anxiety (p = .008) and middle insomnia (p = .008).
The total improvement 3core of the amitriptyline treated group of patients
(19.7) was significantly higher than that of the group on imipramine
(9.8, p ~ .02).
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After one month of treatment, amitriptyline was highly
significantly superior to imipramine in improving agitation (p = .003) and
almost as superior A~ ameliorating gastro-intestinal somatic symptoms
(p = .02) and middle insomnia (p = .02). It was also significantly
superior to imipramine in improving depressed mood (p = .05). The total
improvement score of the amitriptyline treated group (36.3) was not quite
significantly higher than that of the imipramine group (26.3, p - .07).
Figures 6 and 7 illustrate the rather different picture
obtained in the "young severe" patients. After a week, as figure 6 shows,
imipramine tended to be better than amitriptyline in relieving symptoms in
this type of patient, its superiority attaining significance in
hypochondriasis (p = .02) and almost reaching it in depressed mood (p = .06)
and reduction of work and interests (p = .06). Gastro-intestinal symptoms
were more effectively relieved by imipramine at the end of one week (p = .03)
and the total improvement score obtained by imipramine at the time (26.3)
was also higher than that produced by amitriptyline (19.2, p = .08). The
various modalities of insomnia were an exception to this general trend.
At the end of one month, however, as shown in figure 7, imipramine has lost
its pattern of superiority and in no symptom did its superiority reach any¬
where near statistical significance. Indeed the total improvement score
with imipramine was slightly lower than that achieved by amitriptyline
(34-«4 versus 37.6). Delayed insomnia in the "young severe" group was
highly significantly more effectively relieved by amitriptyline than
imipramine.
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Too few "old mild" patients were available for an adequate
comparison of the effects of the two drugs in these types of cases to be
made, but suggestive trends could be discerned in the results that were
obtained. After one week the five "old mild" patients on amitriptyline
showed practically the same improvement in their symptoms as did the five
on imipramine. The mean improvement scores of the two groups were very
similar (10.6 versus 8.2). After a month amitriptyline was clearly, though
not significantly, better than imipramine in relieving depressed mood, re¬
duction of work and interests, hypochondriasis and gastro-intestinal somatic
symptoms. By this time the mean total improvement score of the amitrip¬
tyline-treated group was appreciably and significantly higher than the group
that had received imipramine (27.8 versus 11.0, p = .05).
The two "young mild" depressives who received amitriptyline
did better than the two on imipramine both after one week and one month of
treatment, but the small size of these groups precluded definite results
being obtained.
OVERALL CLINICAL ASSESSMENTS.
The difference between the patients on amitriptyline and on
imipramine after one week and one month are shown in the following table.
TABLE 7














DRUG Amit Imip Amit Imip Amit Imip Amit Imip Amit Imip
Number in
drug group








3.2 2.4 3. 6** 2. 3 3. 3 2. 8 1.8 1. 0 3.0 2.0
( ** Significant at the 1 "to level)
- 73 -
The overall ratings for the total group show that, after one
week, amitriptyline was more effective than imipramlne; after a month this
was more evident and almost statistically significant (p = .06). The
findings were in conformity with the results obtained from the Hamilton
scales. In "old severe" patients, the one week improvement on amitrlp-
tyline was highly significantly greater than with imipramine (p = .01)} the
trend was still almost significant after a month (p = .07). With the
exception of the one-week ratings in the two "mild" groups, the direction
and amount of change shown by the overall clinical assessments paralleled
those shown by the Hamilton scale scores,
OCCUPATIONAL THERAPY RATINGS.
Since some patients included in the trial were not sufficiently
well to begin occupational "therapy immediately after being put on medication,
some O.T. ratings could not be completed until they had been on drugs for
several days. Clearly, for these patients, no valid estimate of change on
O.T. ratings could be made. Accordingly an arbitrary decision was made
not to use ratings completed more than five days after patients had started
on chugsj this left 32 sets of ratings suitable for analysis. Nineteen
ratings were of patients in the "old severe" group (10 of whom had received
amitriptyline) end 13 were on "young severe" cases (6 had been given amitrip-
tyline). As the two groups were so small and as the trends they showed,
unlike the physicians* ratings, were similar, these findings were combined
to produce the results depicted in table 8.
Higher improvement scores were obtained by patients on amitrip-




MEAN IMPROVEMENT SCORES ON OCCUPATIONAL THERAPY RATINGS
POSSIBLE AFTER 1 WEEK | I AFTER i WEEKS
BEHAVIOUR IN RANGE
Amitrip. Imip. Amitrip. Imip.
OCCUPATIONAL THERAPY
SCORES (n = 16) (n = 16) (n = 16) (n = 16)
Grasp of instructions 0-6 . 3 -. 2 . 5 -. 4
Attention to task 0 - 6 . 8 . 3 . 2 -. 1
Motivation 0 - 6 . 4 -. 6 . 9 -. 4
Patient's self-grading 0-6 . 7 -. 4 . 8 -.2
TASK PERFORMANCE SUB-TOTA: , 0-24 2.2 -. 9 2. 4 -1. 1
Depression 0-6 1. 0 . 6 1. 3 . 9
Retardation 0 - 6 . 7 . 1 . 9 ' . 7
Agitation 0-6 . 2 . 1 . 4 6
Physical complaints 0 - 6 . 4 . 2 . 5 . 4
SYMPTOM SUB-TOTAL 0 -24 2. 3 1. 0 3. 1 1. 4
Rapport with O. T's 0 - 6 . 2 . 2 . 7 1.0
Socialization 0 - 6 . 4 . 5 1. 1 1.0
Overall attitude to O. T. 0-6 . 1 -. 3 . 6 -. 1
RELATIONSHIPS SUB-TOTAL 0 -18 . 7 . 4 2. 4 1.9
TOTAL 0 -66 5. 2* . 5 7. 9 2.2
* Significant at the 5 per cent level.
The subtotals and the total scores strongly reflected th1«
trends though only one difference score, that for the total one—week Improve¬
ment, «as statistically significant (p = ,05). Nevertheless the one
month scores on task performance and depressive symptoms almost attained
significance (p = ,07 and ,06),
The O.T» scale results wore next exanined by groups® At the
end of one week, the depressive phenomena exhibited in 0.T* by the "old-
severe" patients were more effectively ameliorated by anitriptyline than by
imipramine? the subtotal scores weres task performance 1,8 versus 1,6,
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depressive symptoms 2.3 versus 1.0 and relationships 1.6 versus .2f the
total scores were 5.7 versus -.1. Nevertheless, none of these differences
were statistically significant. After a month, the same trends were
maintained, though they still did not reach statistical significance. At
this time the task performance scores were 2.3 versus -1.4, the scores for
depressive symptoms were 4.3 versus 1.9 and the scores for relationships
were 3.7 versus 2.7j the total scores were 10.4 versus 3.2. The "young
severe" patients also did better with amitriptyline than with iraipraminej
the three subtotal scores were 3.2, 2.5 and -.5 for amitriptyline, with a
total improvement score of 5.2, versus -.4, 1.0 and .7 for imipramine, with
a total improvement score of 1.3. Again the differences did not attain
statistical significance. After a month, amitriptyline did better in
almost all the items on the scalej subtotal scores were 2.3, 1.2 and 0 for
amitriptyline, versus -1.4, 1.0 and 1.0 for imipramine. The total amitrip¬
tyline score was 3.5 in contrast to .06 with imipramine, once more a non¬
significant difference.
RATINGS OF SIDE EFFECTS.
Systematic initial and thrice -weekly ratings of side effects
were made on 70 patients, 35 on each drug. It was readily possible to
classify the twenty groups of side effects on the scale in appendix 3 into
ten sub-groups which covered almost all the side effects that were
encountered. On this basis, in the dosage that wis employed (150 mg. daily
for one week followed by 200 mg. daily for a further three or five weeks)
both amitriptyline and imipramine appeared to be safe and non-toxic. The
side effects of amitriptyline, contrary to expectation, were found to be
indistinguishable in severity from those produced by imipramine j and no
76 *
significant differences, or ereon any euggostire trends, wore found between
the ttfpca of side effects pno&joed by the tw drega0 With both, side
effects were ralld and easily toXcretodf they dlalniabed or disappeared
after three ut»oks> of treataoat and were quite unrelated to ago* Their
incidence before and after dreg treatment is alxnn in figure 8, In ea&»»
Izdng the diagrera however, the reader should note that it depicts only the
incidence of side effects, and is no guide to their severity® The high
da«**j nt aids effects shown is wwapyrfwiertNin la the light of the fact
that each patient was (regained 12 (or reeetlraes 18) tlruos for their
presence? even one point (on a four point reals), registered on only one
occasion would constitute an addition to the horizontal linos of incidence
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With the aid of figure 8, it is possible to divide side
effects into three groups, the division being cade in tens of the incidence
of each side effect before the administration of medication. Group 1 «
"visual difficulties" (mainly blurred vision) end "somnolence" - appear to
be genuine side effects of both amitriptyline and imiprwnine, Group 2 -
"unsteadiness" (faintness, dizziness and ataxia), "dyspepsia" (heartburn,
nausea and vomiting) and "urinary difficulties" (dysuria and oliguria) -
seem just as likely to be symotocas of depression as to be drug-induced side
effects. The reactions included in Group 3 - "tremor", "dry mouth" and
"agitation" - are false side effects - manifestations of depression rather
than true side effects of the two drugs.
OUTCOME OP TREATMENT
The following table shows the results obtained in the 73
patients according to the numbers that were discharged with or without
electroconvulsive therapy after four and six weeks of drug treatment.
TABLE 9.
OUTCOME OF TREATMENT ACCORDING TO DRUG GROUPS
(n = 73)
AMITRIPTYLINE IMI PRAMINE
tPCOIIC (n = 36)
4 week discharge 22 17
E. Co T. 5 12
6 week discharge 7 4
Eo Co To 3 3
TOTAL discharge 29 21
Eo Co To 8 15
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After four weeks, the difference in the number of patients
discharged without electroconvulsive therapy on the two dings very nearly
reached statistical significance in favour of amitrlptyline (p = .06) j
further a higher proportion of the six week discharges had been on amitrip-
tyline, and the total number of patients discharged on this drug was very
nearly significantly higher than the number sent out on imipramine (p = .06),
In patients who failed to respond to the two drugs the courses of electro¬
convulsive treatment that were given were administered by physicians other
than those involved in the trial# Despite reports to the contrary from
other investigators, there was no evidence that fewer treatments than usual
were adequate to ameliorate the depressive states of these patients.
To examine the results of drug treatment according to type of
depressive illness, the 73 patients were allocated to the endogenous or the
reactive categories of depression. The basis for this allocation was
(а) family history of affective psychosis, (b) history of previous attack^)
of mania or depression, (c) the presence or absence of appreciable
precipitants and (d) the clinical features of the illness. In regard to
the latter, no single criterion was regarded as pathognomonic j rajfher, a
constellation of the following features was used in allocating patients to
the endogenous category, while reactive cases tended to be diagnosed by
exclusion* (1) absence of reactivity to the environment (2) presence of
self derogatory trends (3) objectively evident retardation (4) objectively
evident agitation (5) presence of delusions and/or hallucinations
(б) tendency to symptom-minimization (7) diurnal variation of mood and
other functions and (8) terminal inamonia. As might have been anticipated,
though 63 patients were fairly easily allocated to one or other category, in
10 the allocation was more difficult; these 10 patients were finally
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assigned by "foresd choice" into one or other category in terms of pre¬
ponderance of the criteria that have been enumerated.
Table 10 allows the results that were obtained.













* Significant at the 5% level.
The superiority of amitriptyline in endogenous cases was
statistically significant (p = .04) * In reactive cases, both drugs
achieved good results, amitriptyline again being slightly more effective
than imipramine, though not significantly so.
PRELIMIHAHX CONCLUSIONS BEGIRDING METHODOLOGY
The allocation of patients into groups according to ago and
severity proved very useful for, as has been described, different results
ware obtained in different categories of patients. These differences
•would have been obscured had analysis been confined to the total group of
patients.
In regard to the evaluative techniques that were employed,
valuable information was gained. Freyhan, in 1960, pointed out that the
effects of antidepressant compounds can, with advantage, be studied in terms
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of their ability to ameliorate or abolish specific "target symptoms" of
depression! the experiential continuity preserved when drugs are used
facilitates assessment of the efficacy of antidepressant therapy, la
the present trial Hamilton's scale was found to be very effective in
systematically recording the Incidence and severity of seventeen common
symptoms of depressive states. It took but little time to use and its
reliability was attested by an inter-rater agreement, over the first 74
patients, of 0.35j the mean scores of the two raters were 25*72 and 27.01,
with standard deviations of 6.9 and 6,4, the difference between the two
ratings not reaching statistical significance. The validity of the scale
was clear from the fact that in the great majority of cases a drop in the
soore corresponded with (1) clinical improvement, (2) a drop in the overall
clinical assessment and (3) a fall in the occupational therapy rating. In
95 per oent of patients a final score of 10 or leas corresponded to dis¬
charge, Quits early in the trial Hamilton's scale enabled a number of
significant differences to be detected in the effectiveness of the two drugs
on specific depressive symptoas, a result that could not have been obtained
had reliance been placed entirely on the overall clinical assessments.
The occupational therapy rating scale scores corresponded in
general with the Hamilton scale ratings and the overall clinical assessments,
though the findings with this instrument in "young severe" patients did not
parallel those of the other two. In this connection, there is no evidence
that the three instruments were, in fact, measuring the same types of
behaviour. The times at which the O.T. ratings were made ware not as
accurately tied to the schedule of drug administration as were the other two
ratings! the occupational therapists had less opportunity to practice with
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their scale than the physicians; and the scatter of their scores was very-
wide. In practice, the occupational therapy scale was simple to use and
was rapidly completed; inter-rater agreement was reflected in a correlation
coefficient of 0.90. The close conformity of the results that were yielded
by this instrument and the Hamilton scale afforded further evidence of the
reliability of the general finding in favour of amitriptyline.
SUM4ARY OF PRELIMINARY FINDINGS.
According to the various methods of assessment that were used,
amitriptyline, in the first 73 patients completing the inr-patient phase of
the investigation, showed itself to be superior to imipramine in alleviating
most of the symptoms of depression. In the total group this superiority,
evident though slight after one week, was well marked after one month of
drug treatment. The trend was particularly evident in "old severe" patients
who, after one week end after one month, exhibited significant improvement
both on Hamilton scale scores and on overall, clinical assessments. An
opposite though barely significant trend was shown by these two instruments
in "young severe" patients after one week of treatment; but after a month,
amitriptyline paralleled imipramine in therapeutic efficacy. Results in
"old mild" and "young mild" patients, too few in numbers for valid comparisons
to be made, also tended to suggest that amitriptyline was more effective
than iodpramine. In regard to symptoms, in relieving insomnia in particular,
amitriptyline was more effective than imipramine in every category of patient
studied. On the other hand, in regard to side effects, no superiority for
amitriptyline could be demonstrated and these symptoms, which occurred equally
in both groups of patients, were remarkable only for their paucity and
triciality; many, rather than constituting true side effects were manifest¬
ations of the depressive syndrome. As judged by outcome of treatment in
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terms of discharge or the need for ECT, amitriptyline, which relieved 78
per cent of patients was almost significantly (p = ,06} superior to imipram-
ine, which relieved 53 per cent, Amitriptyline was significantly superior
to imipramine (p = ,0U) in the treatment of endogenously depressed womenj
both drugs were effective in reactive cases. The majority of these findings
have already been reported (Burt, Gordon, Holt and Hordern 1962), Overall
the preliminary findings strongly suggested that amitriptyline was a drug
of great promise in the treatment of patients with depressive states.
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CHAPTER 111.
PHENOMENOLOGY ARC PROGNOSTIC VARIABLES
In the second phase of the investigation a farther 65 vciaen
conforming to the original criteria i.e. female in-patients between 30 and
70 years of age with virtually untreated, relatively "pure" depressive states,
were added to the original ample of 74 patdantej since two died, the total
sample consisted of 137 female patients hospitalised with depressive states.
The sis© of this sample facilitated (1) an investigation of the phenomenology
of depressive states in woman and (2) a study of the significance of a number
of prognostic variables in relation to the drug treatment of depression.
tffiTaODOLOOX OF THE SECOND PHASE
In many ways, the methodology of the second stage of the trial
was identical with that employed in the first. The second phase was carried
out in the same setting by the same staffg patients were nursed in the same
way and, as before, were allocated to groups to receive drugs according to
age and the severity of their illnesses. Ardtriptyline and imipraaine were
given Ui identical capsules in the dose# originally laid down i.e. 150 mg,
daily for cme week, followed by 200 rag. daily for the next three (or five)
weeks. After four or, where necessary, six weeks of treatment, definitive
decisions on discharge or electroconvulsive treatment were made.
In the interests of efficiency and convenience a number of
dnor changes were sad© in the methodology used in the second phase of the
investigation. Two additional ratings were obtained!
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(1) nurses and physicians (C.G.B. and W.F.G.) together listed the type
and content of delusions the patients exhibited.
(2) muses classified patients into three grades of severity - mild,
moderate and severs.
In addition, three procedures employed in the initial phase sera
discontinued!
(3) those laboratory investigations which were considered superfluous,
having shown no change in the first 73 patients, were atoppedj these included
the hematological examinations (hemoglobin, white blood cell count and the
erythrocyte sedimentation rate) and the liver function tests (alkaline phos¬
phatase and eephalin floeculatton)f estimations of serum bromide level, the
Kline reaction and urinalysis were retained.
(4) Occupational therapy ratings were discontinued. As mentioned
earlier, many of these ratings, unavoidably made some days after the patients
had started their medications, had had to be omitted tram the analysis!
further, the arrangements necessary to facilitate the ratings proved difficult
to sustain in the occupational therapy department.
(5) Ratings of side effects were stopped. Those were very time-
consuming and, since side effects for the most part were rare and of trivial
severity, only customary nodical surveillance was maintained.
BBSJLTS IB m> TOTAL SAMPLE.
The findings in the additional 64 patients corresponded closely
with those obtained in the first 73, lending support to tho original con¬
clusions. The overall results in the total sample are shown in table 11.
TABIC 11.
OUTCOME OF TREATMENT IN 137 HOSPITALIZED





4 week discharge 39 (56%) 30 (44%)
E„ Cc T. 8 23
6 week discharge 17 (25%) 7 (10%)
E„ C0 To 5 8
Overall discharge 56** (81%) 37(54%)
E. C. T. 13 31
**p = .002
The distribution of 137 patients completing the in-patient
phase oi the trial in terms of age, severity of illness, menopausal state
and type of depression, is shown in table 12.
Experience during the trial showed that severe depressivea
almost invariably had Hamilton scores in excess of 50 rather than 40, the
original borderline between mild and severe degrees of depression.
Accordingly patients completing the trial were divided into "clinically-
mild* depressivos (with scores below 50) and "clinically severe" depressives
(with scores of 50+).
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TABUS 12®
CATEGORIES OF DEPRESSIVES COMPLETING THE IN-PATIENT PHASE OF THE TRIAL (n = 137)

















0-39 4 4 8 7 6 6




50 - 59 7 10 5 5 5 3
60+ 4 2 8 5 3 8
BY AGE AND TYPE OF DEPRESSION
Amit. Imip. Amit. Imip. Amit. Imip.
ENDOGENOUS (n = 80) 9 7 19 13 14 18
REACTIVE (n = 57) 13 16 9 9 5 5
BY MENOPAUSAL STATE
PR E MENO PAUSAL MENOPAUSAL POSTMENOPAUSAL
AMITRIPTYLINE (n = 69) 16 8 45
IMIPRA MINE (n = 68) 10 8 50
Further, an Inspection oi
' table 12 reveals that sufficient
patients were available to separate the "old" patients (aged 50 - 70) into
"middle aged" (aged 50 - 59) and "elderly" (aged 60 - 70) sub-groups® In
this way the patients in each drug group were divided into six very
comparable sub-groups in place of the four which were originally planned®
Although the patients included in the trial were assigned to
homogeneous sub-groups, the criteria for their selection were rigidly adhered
to5 even so, a number of patients originally included had to be rejected
- a?
sitter during tte in-patient phase or shortly afterwards. Two patients died
In hospital and two developed retention of urine} those cases will be dis¬
cussed under "side effects® • Apart from these four patients, three
schisophrenics, inadvertently admitted to tte trial, were omitted fro© tte
analysis of the in-patient sample f two patients with personality disorders,
one of whom was an alcoholic, were also left out. Finally, two patients,
both on ioipraalne, refused to remain in hospital sufficiently long for their
ratings to be completed. The final sample, which took almost a year to
collect in a psychiatric hospital currently admitting some 1,500 female
patients annually, is thought to be fairly homogeneous. In not more than
tan cases was there any doubt as to the primarily affective basis of tte syn¬
drome, and in the ten case® which night be regarded as dubious, because of an
inadequate personality, alcoholism or a schisophrenic admixture, depression
dominated the clinical picture. These cases, like all others, were randomly
distriteted between tte two drug groups.
SIKi hpFitOT3.
Side effects were more numerous during tte second phase of tte
trial than they had been in the first. One 69 year-old hypertensive patient,
known to be a poor cardiovascular risk, died in her sleep after four days of
imipramine medication} it was not felt that death could bo attributed to the
drug and an autopsy was not performed. Apart from this, medication had to
be discontinued in two patients because of retention of urine} one case
occurred on each drug, and in both patients the complaint disappeared when the
trial capsules were discontinued. Tte patient who had teen receiving
amltrlptyline was Inadvertently put back on this compound by a physician who
was unaware she had boon in tte trial} her retention irsaodiately recurred.
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- One 56 yoar-old patient whose depressive state was relieved by aaitriptyllne
developed an acute glaucoma the day after her discharge from hospital| this
necessitated an immediate operation. She had exhibited no prior evidence
of this disorder, though headache was amongst her depressive complaints.
Other side effects, as in the first 73 patients, were mild and of little
consequence.
CHARACT iKISTICS OP THE TOTAL SAMPLE
SOCTO-CCOKOMIC BACKGROUND.
As was to be expected from the method of allocation to the
drugs, in socio-economic backp?ound there were no significant differences
between the two drug groups, and only in very minor ways did the total aan.pl©
differ from the first 73 patients. Eighty-eight per cent of the patients
had been born in Australia and sever, per cent were British. The mean age
was 52.87 with a standard deviation of 10.02 years. Eighty-eight per cent
were, or had been, married and most had two or three children. The great
majority had finished their schooling at the primary level or just beyond it,
and their vocational qualifications were restricted to seiui-akilled,
industrial and clerical work, lost were housewives; all the fifteen per
cent who worked were employees, Approximately half were dependant on their
husband1 s income, whilst a third subsisted on pensions. Sixty per cent
occupied dwellings they oisied or were purchasing; the remainder lived in
rented houses or flats. The general picture, as in the first 73 patients,
was of a predominantly lower-ciiddlo-class socio economic-group, with an




Here too there was w significant difference between the two
drug group# and the picture very closely resembled that of the firet 73
patients# Forty-eight per cent had never boon previously hospitalised for
psychiatric illness, and twenty-five per cent had boon in hospital only once
before# Sixty-four per cent of the patients had firet required attention
for their mental condition within the last two years. Ton per cent had
received antiebprossive therapy (within the specified limits) prior to
admission* nine patients had boon given drugs, whilst ono had had EOT# In
seventy-seven per cent the illness had developed within ono to ei#t weeks t
in twenty-three per cent it had developed more insidiously# Thirty-four
per cent had illnesses apparently precipitated by psychological stresses,
whilst in seventeen per cent physical precipitant® were recorded, such as tbo
puerpcriua, hypertension and operations. In forty-nine per cent of patients
no precipitant® wore found.
EFFECT UT ACE AM) dbVaiTY OK INITIAL SXMPTOIKOLOCI.
The effect of age and severity of illness on the symptoias of
depression wis studied with the aid of the initial symptom scores of the 13?
patients completing the in-patient phase of the trial, fable 13 shows the
mean, symptom severity scores of four groups of patient® classified according
to age, together with the loean symptom severity scores of four groups
classified according to severity of illness, as denoted by their total scale
scores.
TABLE 13
























Depressed Mood 0-8 4. 00 4. 65 4. 78 5. 05 3. 63 4.46 4. 74 6.27
2 Retardation 0-8 2. 77 3. 30 3.24 3.21 2. 17 3. 11 3. 14 4. 43
3 Work and Interests t 0-8 4.82 5. 30 5.24 5. 31 4. 03 5. 05 5. 46 6. 47
4 Guilt 0-8 2. 77 2, 70 3. 00 2. 76 . 94 2. 03 3. 57 5. 13
5 Suicidal proclivities 0-8 3. 32 3. 43 3.90 2 . 95 1.51 3. 22 4.03 5.27
6 Anxiety, psychic 0-8 5.32 4. 78 4. 60 5. 12 3.26 4.62 5.57 6. 40
7 Anxiety, somatic 0-8 4. 36 3. 69 3. 42 3.55 2. 23 3.24 4. 11 5. 30
8 Hypochondriasis 0-8 2.09 2.17 1. 54 1. 57 . 74 1. 46 2.2 2. 73
9 Agitation 0-4 1.27 1. 74 2. 64 2. 45 1. 14 1. 67 2. 71 3. 43
10 Insomnia, initial 0-4 3. 04 3. 30 2. 88 3. 02 2. 23 3. 03 3. 31 3.60
11 Insomnia, middle 0-4 1. 77 1. 43 1. 56 1.81 . 86 1.59 1. 97 2. 27
12 Insomnia, delayed 0-4 1. 18 2.26 2. 30 2. 19 1. 43 2.00 2. 23 2. 77
13 Somatic symptoms, gastrointestinal 0-4 2.82 2. 74 2. 72 2.88 1. 94 2. 78 3. 06 3.47
14 Somatic symptoms, general 0-4 3.27 3. 35 2.84 3.00 2. 14 2.84 3. 46 3.87
15 Genital symptoms 0-4 3.00 2.17 1. 12 0. 45 . 69 1.51 1.86 1.53
16 Loss of Weight 0-4 1. 77 2. 70 2. 16 2. 48 1.80 1. 73 2.66 3. 17
17 Loss of Insight 0-4 0.82 0. 43 0.52 0.86 . 09 .41 . 71 1.57
TOTALS: 0-100 48. 50 SO. 16 mCOFT 48. 38 30. 57 44. 76 54. 80 67. 83
* HAMILTON, M. (1960) "A Rating Scale for depression " J. Neurol. Neurosurg. and Psychiat. 23:56-62.
AGE,
Five symptoms allowed significant alterations in severity
according to age, despite the fact that no significant differences existod
in the moan total scale scores of any of the four groups (I'olcogorov-
Smirnov test)* Xn the "very young", genital symptoms were significantly
more severe than in the "elderly" (75$ versus 10$, p - .001) but in the
latter group agitation (61$ versus 29$, P~.05), delayed insomnia (55$
versus 29$, p~- .05/, loss of vroight (62$ versus 44$* p -^ .02) and depressed
mood (63$ versus 50$, p-- .06) were significantly more severe.
SEW!EOT OF ILLTESS
Five symptoms showed a disproportionately greater increase in
severity than that registered by the mean total severity score. Whereas the
latter score rose from 30.57 to 67.33, approximately doubling itsolf, the



























































A number of variables mm examined to investigate their
prognostic value in relation to discharge or referral to EOT. The variables
were (1) the Hobson scale score (2) the initial severity of the depressive
symptoms (3) the presence of delusions (4) the effects of age, menopausal
state, type of depression and severity and (5) the response to one week of
treatment. The decision as to discharge or EOT was made, it should perhaps
again be emphasized, entirely on a "blind" basis i.e. the two physicians
making the decision had no idea which .drug the patient in question had been
receiving. This objective criterion of the success of drug therapy -
discharge or BCT - was of great value in assessing the results of the invest¬
igation.
TIE HOBSON SCALE
In 1953 Hobson published a method for scoring a number of
favourable and unfavourable clinical features associated with the outcome of
depressives treated with electroconvulsive therapy. later Roberts (1959),
who studied prognostic features with eleetroshoek treatment in 50 female
depress!ves, found a correlation between Hobson score and outcome of .73
interviewing after one month and .67 two months later. On the other hand,
Hamilton and Whit© (1960), who examined the outcome of depression treated with
EOT in 49 male In-patients, found a correlation with Hobson score of .18, which
was not significant. Hamilton and White attributed their lover figure to the
fact that their patients were more severely ill than those studied by the other
two investigators.
In the present series of patients, scale scores were allocated
according to the method advocated by Ilobson. At the conclusion of the in-
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pationt phase of the investigation the Ilobson scores of 130 patients wore
available for examination0 The results in the total group, the two drug
groups and their twelve sub-groups of patients are shown in table 14.
TABLE 14
HOBSON SCALE SCORES IN 130 HOSPITALIZED FEMALE DEPRESSIVES
CATEGORY OF PATIENT OUTCOME





























































































































Clearly, the variations in the scale scores are insignificant,
whether the total group, the two drug groups or their twelve sub-groups are
examined. The total I'obaon score was of no value in predicting outcome with
either drug, whether the entire group or the six sub-groups wore considered.
!Jor was the situation much better in regard to individual scale items# of
sixteen such items, only two - lack of insight and neurotic traits in adult
life - showed a significant difference between the two drugs. In the total
group, in regard to the presence of both these clinical features, the number
of patients discharged without ECT on amitriptyline was significantly higher
than the corresponding number discharged on imipratnino (p .05 and .02
respectively) j the proportions of respondsrs and non-responders merely
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rafloeted tho proportions responding to the two drugs. Evidently therefore,
with both drugs* absence of insight and the presence of neurotic traits in
adult life did not significantly alter the subsequent outcome,
OIITIAL SEWIRITX OF BBWESSI1E SH'PTCMS
The initial severity of each of the seventeen symptoms in¬
cluded is HaBtlton's scale was examined in relation to the outcome of the
patients in tho two drug groups* In aisdtriptylim-txoatad patients* the
severity of their initJal softens was not of predictive value | tut in
inlpracino~tri3at®d patients* on the other hand, marked severity in any of five
symptoms uo» associated with a aigaifieantly larger proportion receiving EOT*
These synptexss weret reduction of work and intorcsts (pc *001}* depressed
snood (p-=m *01)* agitation <p<=r .02}* psychic anxiety (p-^.Q5) and retard¬
ation (p -^.05, * Turther, whoa in ordsr to assess the effect of tho two
drugs cm severe eyaptoee, the highest scores were cxa'-imd i«e« scores of
five or sore for the first eight sytaptoess and two or aoro for the last nine*
awitriptyliae wm significantly taore effective in twelve of fee seventeen
symptom* These dsprosaed mood (p-c .001), reduction of work and
interests (p<r *001;, agitation (p =^ *01), middle insomnia (p^f ,01), gonoml
somatic syuptoos (p-~ *01), loss of weight (p — .01), psychic anxiety (p^.02),
initial inaoonia (p^1 .02), retardation (p -^.03), terminal insomnia (p -^.OfJ)*
gastrointostinal somatic symptom (p«~- .OS) aad loss of Insight Cp-^.05).
nesssxens
Friodtejan, l owbnay and Masdlton (1961), aaongat other authors,
have pointed cut that patients who are frankly deluded do badly on iniprasdn®.
In the present aeries of 137 patients, 27 (20$) had uimquivoeal deMUnsf 23
of those, 17 on iniprsaine and 6 on ss&trlptylina, were typically and
characteristically depressive, vhilst in 4 "dubious* cases, all cm aedtrip-
tyllao, a schisophrenic admixture was present. Delusions wore cemmmw in
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ictionta over 50 5h?.:. L\ those who were younger (0; versus 7, p ,12s if
the 4 "dubious" cases are omitted, p = .06)j in addition, delusions were
significantly more frequent amongst the clinically-severe cases than asaongsi
the clinically-mild (21 versus 6, p = .02). Twenty-throe of the 27 patients
who were deluded required EOT, six of the ten who were receiving asitriptyllne
and all 17 patients on isiprsusinei two of the four deluded patients who
responded to aiaitrlptyline were those allocated to "dubious" category. In
regard to outcome of treatment, the 59 non-deluded patients on amitriptyline
did highly significantly better than the 10 who were deludodj 56 (38$) were
discharged and 7 required SCT in the non-deluded group versus 4 (40%) dis¬
charged and 6 requiring EOT in the deluded group (p < .01). the same was
true for irriprasiine| of 51 non-deluded patients receiving the drug, 37 (73%)
were discharged without EST in contrast to none discharged without CT of the
17 that were deluded, a difference that is very highly significant (p < .001).
It is clear therefore that depressive delusions, which, as might be expected,
most frequently occur in older patients and in those with severer degrees of
depressive illness, are of bad prognostic import in regard to tee drug treat¬
ment of depression. In the present investigations this was rat-her irore the
case with iraipraraine than with amitriptylim.
AGO, MEWPAUSAL STATE,, THE OF E&FRES&QK AND SBfLHITX
In tee following graphs illustrating the effects of these
variables, tee number of patients in each sub-group is indicated to enable
ready perception of instances where large differences are associated with
small numbers of patients. Exact probabilities, based on ehi-square or
Fisher's Exact Teat (two tail), are shown for all statistically significant
differences. Accordingly, any large differences not indicated to be
significant should be interpreted with caution.
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AGE AND MENOPAUSAL STATE
FlOJiU 10
OUTCOME ACCORDING TO













































Amitriptyllne was superior to imipramiiie in alleviating the
depressive states of the 50 "middle aged" and the 42 "elderly" patients®
In the combined "old" group of 92 patients, thissuperiority exceeded the
1 per cent level of significance® A similar trend was evident in the 95
postmenopausal cases (p ~ .002), though no significant difference could be
demonstrated for premenopausal and menopausal patients.
TYPE CF DEPRESSION
FIGURE 11










































The superiority of amitriptyline over imiprairdne in patients
with both endogenous and reactive types of depression is shown in the two
graphs in figure 11, though only in endogenous cases did this superiority
attain statistical significance (p ~ #001) • Thus the earlier findings in
respect to amitriptyline shown in table 10 (page '5"< ) were confiruad.
SEVERITY OF DEPRESSION
FIGURE 12
OUTCOME ACCORDING TO SEVERITY IN TERMS OF































<40 40-49 50-59 60+ MILD MODERATE SEVERE
SEVERITY
The graph showi In figure 12 (a) demonstrates the effect of
severity of illness on the outcome of treatment with the two drugs according
to assessments made by the two physicians engaged in rating procedures®
Hamilton scale scores ware used since overall clinical assessments corresponded
closely with them, and since the scores could be precisely analysed in torms
of individual symptoms and clusters of symptoms® It is readily evident that
whilst patients on amitriptyline did well at all levels of severity, the
improvement noted in the severest cases ins outstandingly bettor than that
achieved by imipramine (p = o0Q3) • The very severe (score 60+) cases on
imipramine did particularly poorly, oily attaining a 20 per cent level of
recoveryj at this level of severity, imipramine was significantly less
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effective than it was In milder cases (p = .007).
Figure 12 (b) show the effect of severity of illness on the
outcome of fcrealxaent with the two drugs according to the nursing staff's
blind ratings of severity. Thee© were made by three sisters cm the basis
of the patient's behaviour in the ward during the trial. All patients were
assigned to three groups - mild, moderate and severe. The mild group had,
the nurses felt, only minimal symptoms, whereas the illnesses of the severe
group were characterized, they thought, by "depressive delusions, depressive
hallucinations, ideas of hopelessness or guilt, psychomotor retardation or
severs agitation, lack of responsiveness and loss of interest in self,
people and surroundings.11 Only 26 (621) of the 50 patients the nurses re¬
garded as "severe" recovered without >CTj despite this, the graph of their
ratings sliows that the drug success rate was very high in the as&trlptyline
groupi 19 (631) out of 23 recovered with aadtriptyline, versus 7 (26$) of
27 on indprsnine (p = .0008). These figures correspond reasonably closely
with those obtained from the physicians' scales (amitriptyline 30$ success
according to physicians, 83$ according to nursesj inipra";lne 20$ according
to physicians, 26$ according to nurses). Like the physicians* ratings, the
nurses' ratings allowed that, in severely depressed patients, imlpramiae was
much less effective than it was in milder cases (p ~ .001).
The higher effectiveness of aiaitriptyline in vnry severe
depressives may have been related to the group containing a lower proportion
of unequivocally depressively deluded patients than the corresponding group
on inlprcurdne. Of fifteen patients with Hamilton scores of 60 or more
treated with amltriptyline, four had unequivocal depressive delusions j among
fifteen corresponding patients receiving lmipramina, nine were similarly
deluded.
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OCMBOBD EFFECT OF AGE AHD SEVERITY
It was thought possible that there was a relationship between
age and severity as factors in the eventual outeone. To demonstrate this,
the percentage recovering with each drug, according to severity in "young"
and "old" patients, was graphed.
FIGURE 13
OUTCOME ACCORDING TO AGE AND SEVERITY OF ILLNESS
ioo




















<40 40-49 50-59 60+
DEPRESSION SCALE SCORE
The numbers of patients at the mild and severe extremes of
the "young" group were too small to allow of valid conclusions, but it is
interesting to note that the trend they exhibited paralleled that shown by
the corresponding extremes of the "old" group. Age would therefore seem
to have had rather less effect in influencing outcome than severity of
illness. In the "old" group, amitriptyline was significantly superior to
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in&pramine in both clinically-mild (p = .04) and clinically-severe cases
(p * .006). Imiprareine vas significantly less effective in clinically-
severe "old" depressives than it vas in clinically-mild cases in the same
age group (p = .05)®
EFFECT OF AGE AND SEVERITY IN ENDOGENOUS CASES
FIGURE 14










































30-49 50-59 60-70 <40 40-49 50-59 60+
age depression scale score
The graphs demonstrate that amitriptyline was superior to
imipramine in endogenous depression at all ages and at all levels of severity.
As age increased, the effioaey of amitriptyline tended to rise, whereas that
of imipramine fell off; the latter compound was significantly less effective
than amitriptyline in elderly patients (p = .01) and in very severe cases
(p = .04) e With increasing severity, there was some decline in the effective-
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neos of aadtriptyline, though among the 24 clinically-severe patients who
received this drug, the rate of successful response still reached the high
level of 71 per cent, Iraipnaffdne by contrast fell off dramatically in
effectiveness with increasing severity! thus amongst the 20 clinically-
severe patients \&w received iE&praialne, the average response rate was only
27 per cent,
RELATIONSHIP BETVBBH MAJOR VARIABLES
It seamed probable that a relationship existed between age,
menopausal category type of depression and severity of illness. Accordingly,
correlation coefficients were computed for these four variables. Each was
dichotomized as followst (1) age - "young8 (30 - 49) versus "old" (50 — 70)g
(2) menopausal category - premenopausal and menopausal versus postmenopausal*
(3) type of depressive illness - reactive versus endogenous and (4) severity
of illness - clinically-Rilld versus clinically-severe. the intoivcorrelotions
are shown in table 15, the correlations being computed by means of the phi-
coefficient (phi « V chi-aquare / ! )•
As might be expoctod, table 15 reveals that a close relationship
existed between age, menopausal category and type of depression. "Young"
patients were usually pro-mnopauaal or menopausal and tended to suffer from
reactive depressions* "old" patients were usually postmenopausal and
frequently suffered fro© endogenous depressive states. On the other hand a
weaker relationship existed between these variables and severity of illness.
Significant, though low, intorcorrelat.ions were found between type of de¬
pression and menopausal category on the one hand and severity on the other*
but no correlation was found between ago and severity, It appears therefore



















*** : Significant at the 0. 1 per cent level.
** : Significant at the 1 per cent level.
* : Significant at the 5 per cent level.
An analysis of variance of "improvement" scores of 120 patients
was carried out in order to explore further the relationship between drugs,
age and severity as predictors of improvement® With two drugs, three age-
groups and four levels of severity, the patients were grouped into 24 cells
for the analysis of variance® Where a cell contained more than five
patients, one or more were randomly withdrawn, and six cells had to be built
up to the required number by the addition of the most nearly matching
patients from an adjacent cell®
The reduction of the group to 120 left virtually unchanged the
percentage of patients discharged and receiving ECT (new sample: amitrip-
tyline discharged 80$, imipramine discharged 52$ - total group: auitriptyline
*» 104 *■*
discbargad 81$, in&pran&ne discharged 54$).
For the analysis of variance, scores vera computed from
patients percentage improvement in scores on the Hamilton scale by the
final ratings (after four to si* weeks). These percentages vers trans¬
formed to a normalized distribution with moan = 0 and standard deviation = 1®
TABLE 16
ANALYSIS OF VARIANCE
F with combined error
SOURCE d, f S S Mean. Sq. term as denominator
a) Drugs 1 6. 166 6. 166 7. 05 (p*<. 01)
b) Severity 3 3. 744 f-* CO 00
c) Age 2 . 610 . 305
d) Drugs x Severity 3 8. 902 2. 967 3.39 (p-=.05)
e) Drugs x Age 2 . 396 . 198
f) Severity x Age 6 5. 763 . 961
g) D x S x A. 6 6. 170 1. 028
h) Within groups 96 83. 948 . 874
TOTAL 119 115.699
Combined e,f, g,h. 110 96.277 . 875
The results of the analysis are shown in table 16, The
difference between the mean for drugs was highly significant and the drug x
severity interaction was significant at the 5 per cent level of confidence.
Analysis of variance for the two drug-severity columns separately indicated
no significant F for the amitriptyline group and an almost significant F for
the inipraaine group. The differences within the imipraaine group were
tested by means of the t - test and it was found that the mean improvement
score for the "moderate" group was significantly (p - ,05) higher than
those for the mild and the very severe groups.
to examination of the comparability of this new "improvement"
score and fee criterion of "outcome" usually employed in the study showed the
two to be very highly correlated. Phi-correlations for the two criteria wsrei
•8§ for tfe wtolo sample, »?6 for the amitriptylin© group and .88 for the
imiprasine group.
RESPONSE AFTER 0® WfEK OF TBEATKEIJT,
As lias already been mentioned in the patients under investigat¬
ion ajaitriptyline produced an 81 per cant rate of recovery without EOT in
contrast to a rate of 54 per cent achieved by iraipramine. To what extent
was this improvement foreshadowed by fee degree of improvement after one woelc
of treatment? The SjQtroreaont evident at this time was in ease degree
undoubtedly due to %ilieu effect11 for, of the 137 patients included in fee
investigation, 92 (67%) after a maximum period of one day in the (locked)
admission ward, wera moved into an open convalescent ward. Hi® lack of a
group of -patients on placebo made it impossible to assess the degree of
improvement due to this factor, but fee design of the trial enabled "milieu
effect" to be discounted as a between-Arug variable for all patients were
equally exposed to it and no significant difference existed between the periods
fee patients on fee two drugs spent in fee admission ward.
Although only two significant differences between drug® wore
evident when the first-week syciptoo improvement scores of the fetal sample
wore studied, a number of additional differences became apparent when patients
wore examined in their six age-aoverity sub-groups. Those differences are
shown in table 17 which reveals that, in general after one week imipramime
tended to be slightly more effective than amitriptyHite in alleviating the



















niddlo-agod clinically-slid patients; on the other hand, in middle-aged
clinically-severe, elderly clinically-mild and elderly clinically-soverc
cases, amitriptyline was superior.
TABLE 17
































































* Significant at the 5 per cent level.
Since it appeared possible that tho first-week Improvement
registered by tho total one-week difference scores might be related to out-
cone in terns of discharge or ECT, table 18 was constructed, percentage
improvement being used to allow for the effect of differing initial scores.
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TABLE 13
OUTCOME OF TREATMENT IN 137 HOSPITALIZED FEMALE DEPRESSIVES
ACCORDING TO PERCENTAGE IMPROVEMENT IN INITIAL SCORES AFTER 1 WEEK.
% IMPROVEMENT ON AMITRIPTYLINE(n=69)
?
% IMPROVEMENT ON IMIPRAMINE (n«68)
CATEGORY OF PATIENT OUTCOME Below 10- 20- 30- 40- 50- Above Below 10- 20- 30- 40- 50- Above
10 19 29 39 49 59 60 10 19 29 39 49 59 60
YOUNG CLINICALLY-MILD DISCHARGE 2 1 - 1 1 1 4 - 1 2 - 2 1 2
(Aet 30-49, scale score 0-49) E„ C. T. - -
- 1 - - 1 - - 1 1 - "
YOUNG CLINICALLY-SEVERE DISCHARGE - 2 1 1 1 1 1 1 1 - 1 2 _ 2
(Aet 30-49, scale score 50 +) E. C.T. 2 - 1 - " 1 - 1 - 1 " 1 1 1
MIDDLE-AGED CLINICALLY-
MILD
(Aet 50-59, scale score 0-49)
DISCHARGE
E. C. T.


























ELDERLY CLINICALLY-MILD DISCHARGE 1 - 3 - 1 2 2 2 2 - - 1 - 2
(Aet 60-70, scale score 0-49) E. C. Tc 1 - 1 " - - " 2 - 1 1 " " 1
ELDERLY CLINICALLY-SEVERE DISCHARGE - - - 1 2 - 3 2 -
(Aet 60-70, scale score 50 +) E. C. T. " 1 1 - - - - 3 3 2 1 " " -
TOTAL GROUP DISCHARGE 7 5 5 11 7 8 13 4 6 3 4 6 4 10
E. C. T. 3 2 4 2 1 1 0 12 3 6 3 3 1 3
When the bottom row of figures in table 18 are inspected, it
can be seen that, in the case of aciitriptyline, as the percentage of first
week improvement increased, the numbers discharged increased and the
numbers receiving ECT decreased# This trend was not so clearly evident
with imipramine, Moreover when a level of 30 per cent of improvement was
chosen it was evident that at and above this level the depressive stato of
all patients over 60 and all clinically-severe patients over 50 were
relieved by amitriptylime, a development which did not occur in imipramino-
treated patients# nevertheless, the figures in table 13 reveal that the
outcome in terms of discharge i#e# drug success of all patients who
attained a 30 per oont or greater improvement in the first week was
significantly better in both drug groups (amitriptyline p = #02, imipramine
p - #015)# When the number of patients who improved 30 per cent
or more on amitriptyline were compared with those who improved to a
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similar extent on imipramine, the superior drug response rate of the araitrip-
tyllne-treatod group was statistically significant {p » .05) | further, so
uniformly effective was amitriptylino that 26 patients who did not reach the
30 per cent level still fared bettor than 34 corresponding patients on
imipramine, the trend almost attaining statistical significance (p = .07).
For patients treated with ac&triptyline, therefore, a 30 per cent or greater
improvement in Hamilton score after one week of treatment appeared to be a
useful prognostic indicator! at this level the correlation with successful
outcome was .28, a figure significant at the 5 per cent level.
To what extent was the 30 per oent or sore scale score improve¬
ment reflected in changed scores caa the overall clinical assessments? These
five-point assessments were sad© by each of the two physician raters (A.H. and
G.G.B.) after completion of the Hamilton scale % totalling their two assess¬
ments to obtain the score, -the range ran from sero to eight. The correlation
between the overall assessments and the Hamilton score for the 69 amitriptylino-
troated patients, both initially and after one week, was .6. The percentage
improvement in overall assessment during the first weak of treatment was com¬
puted for the amitriptyline patients) a 30 per cent or greater improvement
in overall clinical assessment was correlated with outcome in terms of recovery
without EOT at the level of .23# a figure which just missed statistical
significance (p » .06). It is apparent, therefore, that whilst improvement
in tho overall clinical assessments did not quite predict outcome to a
statistically significant degree, improvement in the Hamilton scale scores did
predict outcome significantly. This finding suggests that tho Hamilton scale
was a more useful instrument for prediction than the overall clinical assess¬
ment.
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to approximate idea of the probability of recovery without
®CT on the two drugs can be gained from an inspection of table 18, Tho
moat important features of this table can be summarised as followsi in the
andtriptyline group, the 30 per cent lovel of first-weak Improvement heralded
recovery without EOT in all patients between 60 and 70, in all those over 50
who were clinically-severely depressed, in 87 per cent of the young clinically-
slid, in SO per cent of the young clinically-severe and in 78 per cent of the
middle aged clinically-nild deprcasivos. In th^iriprasine group, the 30 per
cent level of first week improvement presaged recovery without EOT in only
62 per cent of the elderly patients, in 75 per cent of the clinically-severe
depress!ves over 50, in 71 per cent of the young clinically-mild cases, in
62 per cent of the young clinically-severe patients and in 83 per cent of
those in the middle-aged elinically-raild group.
«!iTHTFrH!!E-TE;5P0R3TC GROUPS OP PATENTS
Although table 18 demonstrates that amitriptyline produced
better results than imlpraiAino in every group of patients included in the
trial, its superiority was particularly striking in patients over 60 and those
over 50 with clinically-severe depressions, Tho mean initial symptom severity
scores (57.07) of these three groups of patients combined (i.e. tho niidle-
aged clinically severe, the elderly clinically-mild and the elderly clinically-
severe) was hig^her than that of the three group® of patients In which the
superiority of an&triptyline was not so well marked (I.e. the young
cllnically-»ild, the young clinically-sevoro and the middle-aged clinlcally-
Hslld, with a mean of 43.37). Further, the one-week improvement score of the
former group (21.78) in which the 30 per cent level was of prognostic value,
was not as high as that of the latter group (14*96) in which this did not to
the same extent apply*
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The 56 amitriptyline respondsrs who were discharged without
ECT were compared with the 13 non-respondera who subsequently required that
physical treatment. In socio-economic and psychiatric background, there
were no significant differences nor were differences in Hobson scale scores
evident. On the other hand, the initial symptom severity scores and the
one-week difference scores in the tiro groups of patients were noticeably
dissimilar.
Initially, the non-respondsrs were more severely ill (though
not significantly so) in respect of guilt, suicidal proclivities, psychic
anxiety, hypochondriasis, agitation, terminal insomnia, general somatic
symptoms and loss of insight. After one week of treatment the groups
differed more markedly still. Whereas the responders had improved signif¬
icantly on all the symptoms enumerated in Hamilton's scale except two (loss
of weight and loss of insight), the non-responders had improved significantly
on only three - depressed mood, psychic anxiety and somatic anxiety. Three
symptoms at this time significantly differentiated responders from non-
responders: non-responders showed significantly less improvement in gastro¬
intestinal somatic symptoms (p-^-.Ol), middle insomnia (p-^ .05) and
reduction in work and interests (p-^.05). In other words, responders could
be differentiated from non-responders after one week of treatment by exhibit¬
ing, unlike the latter, a better appetite, more restful sleep and some return
of interests and the capacity to work. In this connection, it is worth
noting that, as figure 15 shows, whilst the rapidly-evident tranquilliaing
action claimed for amitriptyline was clearly apparent, it was of no value in
forecasting outcome, for both responders and non-responders improved markedly
in psychic and somatic anxiety, and their respective improvements in agitation
were not clinically distinguishable.
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In addition to these differences in severity of symptoms,
as noted earlier, significantly fewer amitrlptyline responders showed
delusions during their period of hospitalization (p<= .01).
mm OF HOSPITAL STAY
In order to assess how the length of hospitalisation of
patients treated with asitriptyline and isipracdne compared with the length
of stay of patients treated with electroconvulsive therapy, a control group
of 60 patients was chosen from depressed patients treated in the hospital a
year before the study. Those patients were matched with the drug groups
in regard to the proportions of endogenous and reactive cases in each age
decade. All 60 had been considered sufficiently 111 to require electro¬
convulsive treatment| 39 had bean given LOT as their sole treatment, whilst
21 had received EOT in conjunction with imipiBinine. Analysis of the time
the various groups of patients spent in hospital revealed that there were no
significant differences between the median number of days for those who re¬
covered on the drugs and the control group (aiaitriptyllna 37 days, imipranlne
31 days, control group 34 days, with 32 days for EOT alone and 36 days for
ECT in conjunction with imipramine). The patients who failed to recover
with drugs stayed longer* the median length of stay for the failures on
ardtriptyline was 60 days and for iaipranlne 62 days.
MUSK
The findings in the second phase of the investigation
corresponded closely with the earlier results, confirming the superiority
of anitriptyline. In the total sample of 137 hospitalised female depreas-
ives $6 (31$) of 69 treated with the drug recovered without CT in contrast
to 37 (54$) of 63 receiving imipiamin® (p^ .002). Side effects did not
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pose a serious problem though one death was probably attributable to
inipmaino.
The socio-economic and psychiatric background of the
patients was unremarkable. When their initial individual depressive
symptom scores were analysed however, it was found that depressed mood,
agitation, delayed insomnia and loss of weight increased significantly with
age and that agitation, guilt, suicidal proclivities, loss of insight and
hypochondriasis showed a disproportionately large increase with increase in
overall severity.
Using the criterion of discharge without CI or recourse to
this treatment, several variables were studied to determine their prognostic
significance. It was found that*
(1) the Hobson scale score - was of no predictive value with
either drug,
(ii) initial severity of depressive symptoms - did not affect the
response to amitriptyline but with several symptoms adversely
affected the response to imiprasdns, feitriptyline was
more effective than irdpraiaine in patients with severe
depressive symptoms.
(iii) delusions - if present lessoned the effectiveness of araitrip-
tyline and nullified the effectiveness of imiprardne.
(lv) age, menopausal state, type of depression and severity -
affected the response to the two drugs, taitriptyline was
significantly more effective than inipramine in patients
over 50 years of age, in those who wore postmenopausal, those
who were endogenous!/ depressed and those who had severe
• 1U-
depressions. Imipratrine was significantly less effective
in severe deproseivea than in milder cases, especially in
patients over the age of 50. Age, menopausal state and
type of depression were highly intorcorrelated i.e. patients
over 50 were usually postmenopausal and tended to suffer
from endogenous depressions, but none of the three variables
correlated appreciably with severity of illness. An
analysis of variance in 120 of the 137 patients revealed a
highly significant difference between drugs in favour of
as&triptylin© and a significant interaction between drugs
and severity of illness.
first-week response to drug treatment - for both drugs was
significantly correlated with outcome. Thirty-nine of 56
patients responding to amitriptyline showed a 30 per cent or
greater iaaprovessent in Hamilton score after one week. This
level of improvement was followed by recovery without EOT in
all patients over 60 and in all those over 50 with sever©
depression. On the Hamilton scale the 56 amitriptyline re~
spondars in comparison with the 13 non-respenders were
initially less severely ill though this was not clinically
distinguishable} after a week, however, non-respondors could
readily bo differentiated by their failure to improve in three
symptoms - gastro-intcatinal somatic symptoms, middle insomnia,
and reduced work and interests. The early tranquiHising
action of amitiiptylino was valueless in predicting outcome.
Patients successfully treated with amitriptylins spent no




FACTOH tmxm OF timm atMro itoaxar
The llaailten sestet ratings of th© initial severity of teo
deproastw aynptooa of the 13? polenta included in the te^oatiatttion yore
factor analysed, fauleyte {nad'asa Lifealihood Method* yhlcfc includes a toat
of the significonco of tee xoalcSaals ms iu»d« The roaulte indicated that
four factors wero suffioiont to account for the variance, tearing a noa»
significant sot of Seaidualeo Th® FaadfiHP Likclllaood 3olutiori yoa rotated,
using a qpaxtteaox procedure., Finally, the rotated factor scores for oach
-1
patient w&ra cooputed according to the raatrix fortsula ZH F ubcra 2 lo a
matrix of standard scores calculated fna tee raw scores, F is tea natrix of
tec rotated factor loading® and ff"' Is tee Inverse of tee o&rrojaiiaa catarix
vite opEraaaalitlce in daagoraX,
TABLE 19
CORRELATION MATRIX OF HAMILTON SCALE SCORES ON 137 DEPRESSED WOMEN


















Depressed Mood 1.00 0.52 0.60 0.46 0.36 0.33 0.16 0.03 0.44 0.17 0.28 0.19 0.29 0.31 -0.09 0.18 0.44
Retardation 1.00 0.41 0.30 0.09 0.10 -0.04 0.07 0.19 0.03 0.24 0.18 0. 15 0.35 0.01 0.07 0.26
Work and Interests* 1.00 0. 34 0.17 0.29 0.08 0. 13 0.33 0.20 0. 16 0.29 0.30 0.45 -0.01 0.15 0.33
Guilt 1.00 0.49 0.49 0.24 0.11 0.44 0. 18 0. 19 0.12 0.14 0.24 0. 11 0.22 0.47
Suicide 1.00 0.31 0.31 0.20 0.26 0.11 0.07 0.09 0.12 0.20 0.09 0.12 0.21
Anxiety, psychic 1.00 0.59 0.28 0.45 0. 32 0.18 0.05 0.20 0.22 0.05 0.18 0. 19
Anxiety, somatic 1.00 0.31 0.29 0.25 0. 12 -0.02 0.21 0.25 0. 15 0.07 0.03
Hypochondriasis 1.00 0.22 0.17 0.06 -0.00 0.16 0.17 0.02 0.10 0. 10
Agitation 1.00 0.29 0.20 0.21 0.20 0. 11 -0. 12 0. 14 0.19
Insomnia, initial 1.00 0.04 0.20 0.24 0.20 0.15 0.10 -0.05
Insomnia, middle 1.00 -0.18 0. 14 0.20 0.01 0.01 0.19
Insomnia, delayed 1. 00 0. 05 0.09 0. 02 0.01 0. 04
Somatic symptoms, gastrointestinal 1.00 0.22 0. 17 0.17 0. 10
Somatic symptoms, general 1.00 0.14 0.10 0.09
Genital symptoms 1.00 -0.00 0. 14
Loss of Weight 1.00 0. 16
Loss of insight 1.00
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Table 19 shows the correlation matrix of the seventeen
factors is the 137 patients* . The saturations of the 'Uirotated factors
are shown in table 20*
TAME 20
SATURATIONS OF UNROTATED FACTORS
Factor 1 Factor 2 Factor 3 Factor 4
(1) Depressed mood 0.75 -0.33 -0.02 0.10
(2) Retardation 0.47 -0.43 0.11 -0.07
(3) Work and interests* 0.65 -0.35 0.25 0.07
(4) Guilt 0.70 0.04 -0. 35 -0.16
(5) Suicide 0.48 0.15 -0.18 -0.15
(8) Anxiety, psychic 0.65 .0.46 -0.02 0.05
(7) Anxiety, somatic 0.44 0.61 0.16 -0.07
(8) Hypochondriasis 0.26 0.27 0.12 -0.01
| (9) Agitation 0.60 0.12 -0.13 0.39
(10) Insomnia, initial 0.33 0.22 0.22 0.14
(11) Insomnia, middle 0.31 -0.06 0.01 -0.07
(12) Insomnia, delayed 0.22 -0.16 0.09 0.20
(13) Somatic symptoms, gastrointestinal 0.36 0.01 0.24 -0.01
(14) Somatic symptoms, general 0.46 -0.08 0.45 -0.27
(15) Genital symptoms 0.06 0.13 0.09 -0.42
(16) Loss of weight 0.25 0.01 -0.06 -0,02
(17) Loss of insight 0.47 -0.24 -0.33 -0.24
The rotated factor saturations are indicated in table 21 g
in this? the items in the scale have been rearranged to enable delineation
of the factors in terms of individual items with saturations of over 0.20#
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TABLE 21
SATURATIONS OF ROTATED FACTORS
r - -
Factor 1 Factor 2 Factor 3 Factor 4
(3) Work and interests t 0. 10 0. 77 -0. 08 0.04
(1) Depressed mood 0. 15 0. 79 COHo -0.12
(2) Retardation -0.09 0.63 0. 07 0.09
(12) Insomnia, delayed 0. 01 0. 30 -0. 11 -0. 13
.(ID Insomnia, middle 0. 12 0.27 0.09 0.05
(17) Loss of insight 0.02 0.43 0.52 0.02
(5) Suicide 0.37 0.25 0. 33 0.02
(4) Guilt 0. 39 0.45 0. 53 -0.06
(9) Agitation 0.44 0.41 0. 05 -0, 42
(13) Somatic symptoms, gastrointestinal 0.23 0. 33 -0. 11 0. 11
(14) Somatic symptoms, general 0.22 0.49 -0. 13 | 0.44
(7) Anxiety, psychic 0. 74 0.25 0. 12 -0.07
(6) Anxiety, somatic 0. 76 0.03 -0.03 0.13
(10) Insomnia, initial 0. 39 0. 19 -0. 19 -0.02
(8) Hypochondriasis 0.38 0.08 -0.05 0.01
(15) Genital symptoms 0. 13 -0.04 0. 14 0.40
(16) Loss of weight 0.14 0.18 0. 12 -0.02
The rotated factor scores of the 137 patients were examined
in relation to age, severity, type of depression, the presence of delusions,
and outcosae with amltriptyline or imlpramlne« Each of the five variables
was dichotomized as follows (1) age - "young" (30-49) versus "old" (50-70),
(2) severity - "clinically-mild" (scale score 0-49) versus "clinically-severe"
(score 50-100), (3) type of depression - endogenous versus reactive,
(4) delusions - deluded versus non-deluded and (5) outcome with amltriptyline
or imipremine - discharged on maintenance doses of the appropriate drug or
referred for E„C„T, The frequency distributions of the factor scores of
every patient on each variable was compared, the significance of the differences
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that yexe found being assessed by means of chi-squa-w, Where differences
vers very nariced, the phl-coaffifldaitt (of correlation) was computed. The
results that ware obtained are shown in table 22,
TWIE 22
RELATIONSHIP BETWEEN FACTOR SCORES AND OUTCOME
1"






























































































For imipramine, a high











































Factor 1# with high saturations of somatic azadaty, psychic
anxiety and agitation, contains a timber of Items that could as well be
found in a severe anxiety state as in an agitated depression. The absence
of depression makes it impossible to label the factor nagitated depress ion" g
further, if the factor had corresponded to the latter entity, a significant
difference in type of depression and, perhaps, on delusions, would have been
evident in table 22 since agitated depressions were invariably diagnosed as
endogenous. Factor 1 must therefore be regarded as an anxiety-agitation
syndrome in which older and more severely 111 patients showed significantly
higher scores and in the treatment of which aoitriptyline wis superior to
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imipramine. On© of the four symptoms that were earlier found to increase
significantly with age - agitation, delayed insomnia, loss of weight and
depressed aood - was present in factor 1, in addition to four of the five
symptoms which increased disproportionately with increasing overall severity -
agitation, guilt, suicidal proclivities, hypochondriasis and loss of insight.
The effect of increase in age and increase in overall severity in the factor
1 score is thus readily comprehensible, as also the fact that high scores
were correlated with age and severity (flf* .16 and .46). Further, the
earlier investigation had demonstrated that patients with severe degrees of
five of individual symptoms in factor 1 - psychic anxiety, agitation,
Initial insomnia, gastrointestinal somatic symptoms and general somatic
symptoms - shoved a significantly better response to amitriptylias than to
iaipraain®. The findings regarding the superiority of amltriptyllne in
patients with positive scores on factor 1 therefore appear consistent with
the results obtained earlier.
Factor 2, with high loadings of depressed mood, reduced work
and interests, retardation, general somatic symptoms and guilt, appears to
correspond to an endogenous depression of the retarded type. It is inter¬
esting, moreover, that in this factor also, agitation had a high saturation.
The scores cm this factor ware unaffected by age but they increased with in¬
creasing severity and were higher in endogenous dspressives and in those who
were deludedj patients with positive scores responded significantly better
to amitriptyllne than imipramine and a high score carried a significantly
poorer prognosis with the latter drug. On inspection it is apparent that
factor 2 contains three of the four symptoms found to increase significantly
with age, but their contribution is evidently not sufficiently great to render
the factor age-susceptible. to clinical grounds this seems quite reasonable,
for endogenous deprosaivea manifesting the symptoms contained in factor 2
would not bo expected to have higher scores when aged between 50 and 70
than those 30 to 49. On the other hand the factor-scores increased
significantly with severity, though only guilt end agitation of the five
symptoms found to increase disproportionately with increase in overall
severity, wore contained within it. As in facto- 1, there was an approc-
iable correlation (£ » .47) botwoon severity and level of score. The higher
score shown by deluded patients on factor 2 and their ph±~cooffleiont of .43
is comprehensible on clinical grounds, for delusions are a not unco raon
symptom in severe endogenous depre«3lves. Again, the superiority of aisitrip-
tyline over ioipramino in patients with positive scorns cm factor 2 is under¬
standable, for amongst patients with severe degrees of all the (symptoms
(except guilt) contained in this factor, araltrtptyline had earlier boon found
to be associated with a significantly bettor prognosis than imipramins.
Finally, the adverse prog ostlc significance, for imipraaine, in patients with
high scores on factor 2, could be linked with the earlier observation that
severity in four symptoms contained in it - depressed mood, reduction of work
and interests, retardation and agitation - carried a significantly worse prog¬
nosis with tills drug.
Factor 3 does not appear to correspond to any known clinical
entity, though for convenience It might be thought of as "delusional guilt",
i'ore severely ill and endogenous depressive* tended to have idgher scores
whereas deluded patients definitely had higher scores, the factor correlating
with delusions at the level of .29. 33mce, in the patients studied, delusions
ted boon rather commoner in those over 50 than in those under 50 years of age,
scores on factor 3 could have been expected to things significantly with age.
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This was not the case, nor did the factor reflect differences between drugs,
though four out of ten deluded patients had responded to axaitriptyline in
contrast to none out of seventeen similar patients receiving imipramine.
Factor 4, again, resists allocation to a clinical category.
The masked affect of age on this factor can be understood in that in the
earlier part of the investigation genital symptoms had been found to decrease
significantly with increasing age whilst the reverse obtained for agitation.
Table 22 shows that endogenous depressivea tended to have a low score on
factor 4, suggesting that its positively loaded symptoms are more commonly
found in reactive depressives who, the earlier port of the investigation had
shown, tended to be younger.
OTHER FACTOR-AFALTTIC STUDIES
Although the results of the (rotated) factor analysis appear
to make clinical sense and to tie together the findings of the earlier part
of the investigation, it is of interest to compare them with those obtained
in three factor analytic studies of depression carried out by Hamilton (1960)
Hamilton and White (1959) and Grinker, Killer, Sabshin, Harm and Runnally
(1961).
Factor 1 in the present study - an anxiety agitation factor
which was reminiscent of agitated depression without depression - broadly
corresponds to Hamilton' a factor 2. Hamilton also remarks on the absence of
depression in this factor. Factor 2 in the present study - which clinically
suggested an endogenous depression with retardation - resembles Hamilton's
factor 1. There was no resemblance between Hamilton's third and fourth
factors and the corresponding factors found in the present study. In general,
however, it seems possible that the symptoms of depression are not identical
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in tho two sexes - depressed woman, for instance, lose their sexual desire
with increasing age to a greater extent than men and may b© more prone to
develop agitated depressions. In view of the fact that whilst Hamilton's
analysis utilised 49 depressed man in England, the present analysis was made
on Yft depressed women iu Australia, the correspondence between the findings
is satisfactory.
Later, Hamilton and White (1959), examining clinical syndromes
in depressive states, classified 64 male patients on aetiologieal grounds
into four groups? Endogenous, Doubtful Endogenous, Doubtful Reactive and
Reactive Depressions. They found that, in addition to differing significantly
in their total scale score, the means of the four groups differed significantly
in their scores on the first factor of the scale (factor 2 in the present
study). This demonstrated, Hamilton and White state, that endogenous de¬
pression was more severe than reactive and that the first factor, which
appeared to be a measure of retarded depression, was also a measure of en¬
dogenous depression. These findings correspond to those obtained in regard
to factor 2 in the present study, Hamilton and White also found that
agitated depressive# had high scores on factor 2 ( actor 1 in the present
study), Factor 3, on which both retarded and agitated patients tad high
scores, had the highest correlation with outcome. High scores on factor 4
wore found in depressed patients who had abnormal personalities ard further
investigation of this group suggested that the factor might correspond to
"psychopathic" depression.
The study carried out by Grlnker ct al. was made on patients
of both seres in the United States and is less easy to compare with the
present investigation since Hamilton's scale was not used. Fifteen factors
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were obtained by analysing the results of a "feelings and concern" check
list (five factors) together with a "current behaviour" check list (ten
factors) in 96 depressed patients. The fifteen factors were combined to
produce four factor-patterns (A) Feelings - dismal, hopeless, loss of
self-esteem, slight guilt feelings$ behaviour - isolated, withdrawn,
apathetic, speech and thinking slowed, with some cognitive disturbances (B).
Feelings - hopeless with low self-esteem, considerable guilt feelings, high
anxiety* behaviour - agitation and clinging demands for attention.
(C) Feelings - abandonment and loss of lovej behaviour - agitated, demand¬
ing, hypochondriacal and (D) Feelings - gloom, hopelessness and a xiotyj
behaviour - demanding, angry, provocative. Grinkor et al's factor pattern
A would seer to correspond broadly to factor 2 of the present study.
Patterns B and C both appear to resemble tho present study's factor 1,
whilst the feelings and behaviour characteristic of pattern D could be
found in either factors 1 or 2.
SIM ART
A factor analysis was carried out of the initial symptomat¬
ology of the 137 patients, using the ratings provided by Hamilton's depressive
scale. Four factors were isolated which accounted for most of the variance
and left a non-significant set of residuals. The rotated factors were
♦
examined since clinically they were the most meaningful! differences in
factor scores in relation to age, severity, type of depression, the presence
of delusions and outcome of treatment with amitriptyline and imipramine were
scrutinised. Factor 1, a syndrome of anxiety and agitation, yielded scores
which rose significantly with age and increasing severity! amitriptyline was
superior to iaipranine in patients with positive scores. Factor 2, which
appeared to correspond to retarded endogenous depression, yielded scores
which were significantly higher in endogenous depressives, those who were
severely ill and those who were cteludedj amitriptyline was superior to
imipramlne in patients with positive scores and, for the latter drug, a
high score carried a poor prognosis# Factor 3» a syndrome of "delusional
guilt", yielded scores which were significantly higher in deluded patients
and tended to be higher in those who were endogonously depressed and those
who were severely ill# Factor 4, which contained positive saturations of
general somatic and genital symptoms and a negative saturation of agitation,
did not correspond to any clinical entityj it yielded scores which were




R.SULTS OF THE FOLLOW-UP
One advantage antidepressant drugs are said to possess over
electroconvulsive therapy is the reduced risk of relapse associated with
continued maintenance dosage. At the conclusion of the in-patient phase of
the investigation, axaitriptyline, to which 56 (81$) of 69 patients had
responded, was significantly more effective than iaipramine, to which 37
(5&&) of 68 patients responded. How did the two drugs compare over the
period of follow-up?
With occasional exceptions, all the 93 patients responding
to the two drugs were discharged on maintenance doses of 100 mg. daily.
Patients were seen two weeks, six weeks, three months and six months after
discharge, or more frequently if their condition warranted it. Three and
six months after leaving hospital, they were rated independently cm Hamilton's
scale by two physicians (A.H, and G.G.B.) at a joint interview. During the
interview information was gathered regarding significant events in their life
since leaving hospital, their level of activity, their persistence in taking
the medication and their need for hypnotics. In addition, patients were
weighed and a note was made of spontaneous comments in regard to their con¬
dition and the side effects, if any, that had troubled thea. As in the in¬
patient part of the trial, a double-blind technique was used.
The 44 patients who, not responding to aisitriptyline or
imipramlne, had had to receive ECT, were also followed up. They were seen
regularly in the out-patient department but only rated on one occasion, six
months after discharge. The ratings were carried out in the same way as
with the drug-respondsrs; the two physicians making thea were not aware to
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which drug the pationt had failed to respond# '.'eights and salient personal
details were tooo. fed#
Tablo 23 ahous the rooultQ in 130 potionta followed up for
a period of six Dontbe (C3,£ of tho sanple)® Sovontocu patient© (12,1) t for
tile following xoaaoLa, had to b© oxcludods (1) ho contact at six soothe -
six potionta (11) Followup iocoDploto wbon steady torainctod - six patients
(111) 1 aintonanoo troatoont ccntra-lndlcated - throe patient© on
mitriprtylin©! two became hypersonic and am developed glaucona the day after
disclmrge (17) Jaixrtomnoe Dedication given to CT cuacs • am patient
gito ecdiriptylixae after <CT in view of her previous history of early re¬
lapse and (?) Philuro to continue taking Dedication - odd pationt on
ixatprw&m also stopped taking her capsules two months after discharge
TIME 23
RESULTS OF FOLLOW UP IN 120 PATIENTS
'















INITIALLY - Well 50 12 34 24
AFTER - Well 45 10 28 21
THREE - Relapsed 3 2 5 3
MONTHS - Manic Episode 2 0 1 0
AFTER - Well 42 (84%) 6 27 (79%) 14
SIX - Relapsed 6* 6 6** 10
MONTHS - Manic Episode 2 0 1 0
* includes one death
** includes two deaths from suicide
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la table 23 "well* mam the patient was living out of
hospital, usually syaptcsa free or with minimi symptoms. The quality of
the remission on discharge and after six swaths will shortly be described
in nore detail# ,,%lapsedH connotes a recrudescence of depressive
symptoms within six rjonths of discbarge, to an extent necessitating further
psychiatric treatment as an iiv-patient# w!'anic episode* do totes readaisaioa
in a state of mania.
Table 2% shows that there was very little difference botwen
the two dru^-respemsive groups at throe and six nwntha, the percentage of
patients remaining well on as&triptyline (84 } being slightly, though not
significantly, higher than those on iaipra-ndw? (79,0#
?m m mmstm w„ll
The majority of patients discharged on drugs, excluding those
who relapsed or beca.-i© ranic, were ayapton €roc throughout the follow up
period. iksmver, there were a few exceptions who, whilst not relapsing, did
not achieve or maintain a completely satisfactory xexissioiu
Of the 42 patients discharged on atdtriptyliae who were well
after six souths, there were eight whose condition at this tdao was not totally
satisfactory! throe of these were unsatisfactory when they left hospital. Two
patients who developed eild symptoms of relapse responded to a few weeks in¬
crease of do9ago to 150 rg daily without the need for readedssion. Of the
42 patients who were wall at six months 35 %4ro were weired showed a aean
gain of 9.6 lb. (range - 8 to +42 lb.). Twelve described their condition
in unusually glowing terms and the sac© number nontitaiod experiencing side
effects - dryness of the mouth, excessive thirst, sweating and an excessive
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appetite* Of the 27 patients discharged on imipreilne who were wall after
six i2oatbs, there were six whos© condition was not optimal at this tin*-)
all 27 had boon quite well on leaving hospital. Again, the isajority (79%)
of the patients who responded were completely well six months after discharge*
Of these 27 patients 25 who were weighed showed a man sain of 5*4 lb. (range -
35 to *24 lb.)* This was less but not significantly lower than the increase
show by the anitriptylino patients* Ton of the patients described their
condition in glowing terras and eleven mentioned experiencing a slid degree of
dryness of the nouth, excessive thirst, sweating and an excessive appetite..
Of 12 a-oitrlptylino-: G? patisnts, all were well on discharge
and one was not altogether satisfactory after six souths j of 24 ivlpranino-
EOT patients discharged, two were unsatisfactory at this time and they were
joined by four more six souths later*
These findings show* thai the majority of drug reaponders
remain in satisfactory reai»sio& for six ;ao»ths if kept on cainbenance
indication* An appreciably lower proportion of 1.0T cases remained well in
tils period.
IELAPSES
tn tabta 23 it can be scan that though relapses in drug ro~
spenders occurred throughout the six months following Eaclarge, FCT relapses,
which were much aoro frequent, occurred mainly between three a d six months
after discharge* In cash drug group a bi^ser proportion of those who
relapsed had had a previous history of dsprssslvs illness* With anitrip-
tylino, five out of six rolapaers had a previous history versus twelve out
of 42 mxv-relapaora (p » *06)j with haipra-' ine four out of six relapses*
had a previous history versus six out of 27 noa-relapses®, (p * .10). Further,
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talcing lidpmialae whoa thoy relapood, tho rate of rcl&pso in tdjoso continuing
to take tfoo drug was 13 per eont (4 of 31 )• The fourth gatiset was not
taking inipmuine9 having becoae hypaoaaicj she required EOT but tho other
thro© pationta responded. to 200 sag# JMpmcifie daily.
Of the 16 SOT pationta who relapsed, on© was in the young
clinically-uild group, four wore la the young clinlcallywsovore group, five
mm in the old cli&ieall^Maild group and six were in the group of old
elinically-eevero patients.
tunc wrmms
Two of the 50 patients discharged on axltriptylino were
road dtied in naaia during tho first throe wraths of the follow-up as wall as
one of the 3<4 discharged mi ixslpmsL.a»« AH tiirm had previously had sanie
episodes so that neither drug could unequivocally be hold responsible,
& ongat tho regaining 81 patients two, both in tho group as had
previously had an attack of aaniaf one relapsed into depression during tho
follow-up and the other reaalno-d well.
mmm& of mmmatmm tmmn
finally it is of interest to compare the results obtained in
the present study with those of other investigations. 3am of the ©ore



















AMITRIPTYLINE 69 56 81% 46 4 9%* Present study 1982
IMIPRAMINE 68 37 54% 31 4 13% Present study 1962
ECT CONTROL 60 60 100% 60 16 27% Present study 1961
IMIPRAMINE 81 49 60% 42 6 14% Kiloh and Ball 1961
IPRONIAZID 30 17 57% 14 2 14% Kiloh et al. 1980
ECT 52 49 94% 49 24 48% Kiloh et al. 1960
ECT 219 " 97% - - 23% Thomas 1954
ECT 923 - 82% - - 18% Karagulla 1950
LEUCOTOMY 2637 - 62% - - 18% Tooth and Newton 1961
♦ Significantly (p< . 05) lower than ECT Control group.
In table 24 amitriptyline emerges as the most effective drug
treatment for depression* Imipramine lags behind, both in the present study
and according to the results of the trial carried out by Eiloh and Ball (1961)C
The findings of a third study show that iproniazid is less effective still
(Kiloh, Child and Latner 1960). With EOT the initial results are usually
excellent. Nevertheless there is an appreciable rate of relapse with this
treatment| so high was this in a group of endogenous dspressives treated by
kiloh, Child and Latrier that Kiloh and Ball concluded that, six months after
treatment, imipramine was as effective as ECT. If this indeed were the case,
the present results imply that, after six months, the results obtained with
amitriptyline are superior to ECTj but examining the figures in table 24, it
is difficult not to conclude that Kiloh, Child and Latner1s post ECT relapse
rates are unusually high. For this reason, the findings in regard to
amitriptyline should also be compared with those obtained in this study's
retrospective matched control group treated with ECT and those reported by
earlier investigators. (Thomas 1954/Karagulla 1950). This comparison
suggests that amitriptyline ia initials t(J ECr> ^ ^
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six months after discharge , there is little to choose between the two forms
of treatment. The results of leucotomy are appended for general interest;
but since patients undergoing this treatment belong to an extremely
recalcitrant group, the figures for leucotomy cannot validly be compared with
the response to other forms of therapy.
SUMAKX
One hundred and twenty (88$) of the original 137 patients were
followed up for six months after leaving hospital. At this time -42 ( 84$)
of the 50 discharged on amitriptyline were well, as were 27 (79$) of the 34.
discharged on imipramine. Most of the patients discharged on drugs remained
■well throughout -Hie period of follow-up. Those on amitriptyline gained an
average of 9.6 lb., whilst those on imipramine gained 5.4 lh., a non¬
significant difference. The quality of the remission produced by the two
drugs was identical and with both, side effects were mild and of little
consequence. Drug relapses occurred throughout the six months following
discharge but EOT relapses, which were considerably more frequent, occurred
mainly between three and six months after leaving hospital. On both drugs
the majority of relapsers had a previous history of depression; most patients
relapsing after EOT had been deluded whilst in hospital. Of six patients re¬
lapsing on amitriptyline, one died at home and five were readmitted. Since
only four of the six patients were taking amitriptyline when relapse occurred
the relapse rate in those who continued to take the drug was 9 per cent
(4 out of 46). Three of the five amitriptyline relapsers admitted to
hospital responded to 200 mg. of the drug daily. Of six patients relapsing
on imipramine two committed suicide and four responded to hospital treatment.
Since only four of the six patients were taking imipramine when relapse
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occurred the relapse rate in those who continued to take the drug waa
13 per cent (4 out of 31 )• Three of the five in&praaine relapsers acteitted
to hospital responded to 200 sag, daily. The thro© patients who boeane manic
had all had previous episodes of mania. The results show that aiaitriptylino,
which Initially had been more effective than imiprardno in the treatment of
uooen hospitalised with depressive states, maintained its superiority
throughout a six-sooth period of follou~ig>. A comparison of the findings
with tS*>3e of otter investigators suggests that aaitriptyline, whilst
initially slightly loco effective than EOT, achieves comparable results six
months after the completion of in-patient treatment.
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CHAPTER VI,
DISCUSSION OF THE FINDINGS
Ilia findings of the Investigation can conveniently be
considered in relation to the phenomenology of depression and the current
treatment of severe depressive states,
THE PffiNOffiROLOGT OF DEPRESSION
The writers of antiquity have provided so many descriptions
of depression that, as Levis (1934a) has observed, in many ways the history
of melancholia is the history of psychiatry. Kraopelin (1921) early
provided a comprehensive description of melancholic conditions in xaontal
hospital patients which has not been added to by later writers. Indeed a
group of American investigators recently went so far as to state that text¬
book descriptions of depression are "stereotyped accounts which have boon
copied from book to book and repeated from generation to generation" (Grinker,
Miller, Sabskin, Stan and Nunnally 1961).
In a very detailed study of sixty-one patients with depressive
states, Lewis (1934b) assembled numerous psychiatric opinions which his
clinical observations tended to support or refute. His study was carried cut
before effective treatment for depression was available and his approach, being
primarily descriptive and interpretive, paid little attention to quantifying
the severity of individual depressive symptoms. Such quantification has only
become possible since suitable rating scales have become available, many of
them constructed to measure the changes produced by effective antidepressant
therapy. Some of the scales currently used in rating depression have been
reviewed by Cutler and airland (1961). Hamilton** scale, In the author's
opinion one of the most suitable instruments for clinical research, pro¬
vided detailed information regarding th® symptoms of depression and the
degree with which they fluctuated with age and severity of illness. This
information, together with the findings yielded by the factor analysis, can
be considered in the light of two investigations carried out by Foulds and
Cain© (1959) and Foulda (1960).
It is interesting to note that on th© Hamilton scale the
severity of five depressive symptoms varied significantly with age, one de¬
creasing and four rising in older patients. The decline in the severity of
genital symptoms with advancing age registered by the scale was reflected in
th© changes talcing place with age in the scores on factor 4, and is compre¬
hensible in the light of everyday experience. Similarly a moment's reflect¬
ion persuades that the common sleep disturbance of the elderly is terminal
insomnia, in contrast to the initial insomnia from which younger individuals
sufferJ the increase in terminal insomnia in the older depress.!ves is there¬
fore not wholly unexpected. Foulds (1960) too found that terminal insomnia
was commoner in psychotic depreaaives over 60 than those under 60, but con¬
cluded that sleep disturbance was associated with age rather than psychotic
depression.. In the present study, agitation also increased significantly
with increasing agej Foulda could distinguish between psychotic and neurotic
depressives by means of this symptom, but found it to be present in psychotic
depressives both over and under 60 years of age. nevertheless clinical ex¬
perience suggests that agitation is commoner in older patients - indeed this
symptom is one of the hallmarks of "involutional melancholia" - so that to
find it increasing in severity with increasing age was not surprising. The
finding was bona out by the factor analysis, an increase in the scores in
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factor 1 "anxiety-agitation" being noted to occur with increasing age as
well as a decrease in scores on factor 4* in regard to the increase that
took place with age in depressed mood and loss of insight, it is conceivable
that older depreasives with less to look forward to than their younger
counterparts, might become gloomier and, being in general in poorer physical
condition, might lose more weight than younger patients. It must be ad¬
mitted, however, that these are makeshift explanations and provide no answer
as to why the overall severity of depression, as registered by the Hamilton
scale, did not rise with age. Decline in severity in genital symptoms would
not be likely to completely counterbalance the increase In the other four
symptoms and again if such explanations are true, why do not other symptoms
also increase in severity with increasing longevity?
In terms of overall increase in severity, the significantly
greater increase shown by the scale in the severity of agitation, guilt,
suicidal proclivities, loss of insight and hypochondriasis was an unexpected
finding. With the exception of lose of insight, all those symptoms were
present in factor 1, the scores of which wore affected by severity as well as
age. Agitation is interesting in that according to the scale it increased
with age as well as severity. Guilt appeared in three of the few factors
obtained, rivalled in its high saturations only by agitation which also
appeared in three factors. Using guilt as a criterion, Foulde and Gains
(1959), by abstracting seven (mainly delusional) items from the MMPX, con¬
structed a Guilt Scale with which they could distinguish between endogenous
and reactive depresaivos. Factor 3, which contained liigh saturations of
guilt, loss of insight and suicidal proclivities also differentiated between
endogenous and reactive ctepieasivBS, those who were ©ndogenoualy depressed
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and/or deluded tending to have the highest scores.
The constellation of symptoms that increased in severity
with increase in overall severity is reminiscent of "involutional melancholia" •
Agitation dominates the symptomatology of this syndrome which is character¬
ized by depression without retardation, anxiety, ideas of unreality, and
hypochondriasis (Henderson and Ratchelor 1962), Does involutional melan¬
cholia exist as a clinical entity? In regard to the fact that this syndrome
is generally regarded as the most serious type of depressive illness, it is
interesting to note that of the three sub-groupa of severely depressed fenalos
studied, the middle-aged clinically-severo patients i.e. worse?1 aged between
50 and 59 with severe depressions, had the highest Hamilton scale scarce.
The group moans wore: middle aged clinically-sevore, 75.26? elderly
clinically-severe, 62,53? and young clinically-scvere, S3.69. Since the
middle-aged clinically severe group appeared likeliest to demonstrate the
existence of involutional melancholia as a clinical entity, the percentage of
patients with no previous history of affective disorder and unequivocal de¬
pressive delusions - two criteria commonly employed in making the diagnosis
of involutional melancholia - were examined. Of 23 middle-aged clinically-
•ever® patients 15 (65$) bad no previous history of psychiatric illness,
practically the same proportion as 12 (65$) of 19 elderly clinically-severe
cases? of 23 young clinically-severe patients 16 (70$) bad had no previous
psychiatric illnesses. Of 23 middle-aged clinically-severe patients 5 (22$)
wore deluded, a lower proportion than 9 (47$) of 19 who were deluded in the
elderly clinically-savcro group? of 23 young clinically-severe patients 5
(22$) were deluded.
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Since the middle-aged clinically-aevore patients could not
be differentiated from the other groups with the aid of two of the principal
criteria used in making the diagnosis of Involutional melancholia, the
present findings agree with those of Tait, Harper and I cClatchcy (1957) who
similarly found little evidence for the existence of the disorder as a
separate entity. From the point of view of the clinical picture, the most
typical "involutional melancholies" included in the present investigation
generally belonged to the elderly clinically-severe group. Within this
group especially, the findings of thej^ardlton scale and the factor analysis
suggest that the narked increase in agitation, somatic anxiety, psychic
anxiety, guilt, hypochondriasis and suicide (factor 1), which occur in con¬
sequence of advanced age and a severe degree of illness, can dominate the
symptomatology by overshadowing the smaller increase in depressed mood, re¬
duction of work and interests, retardation and general somatic symptoms
(factor 2), In old severely depressed patients an increase in guilt (factors
1, 2 and. 3) and loss of insight (factor 3) may be associated with delusions
and suicide (factors 2 and 3), It seems, therefore, that the clinical syn¬
drome of involutional melancholia in women can be understood in terras of the
accentuation of certain symptoms that customarily occurs in older more
severely-ill patients# This formulation reconciles a number of familiar
clinical observations but does not explain why selective increase in symptom
severity with ago and increasing severity takes place#
TIE CURRENT TI&AftBNT OF SEVERS DEPIESSIVi: STATES
Finally, it is necessary to re-examine the place of electroconvulsive
therapy and Iraipramine in severe depressive states. The role of amitriptylino
can then be considered in perspective#
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EI£GTROCOimJLSIVE THERUT
The review of electroconvulsive therapy provided in
chapter 1 demonstrates that tills treatment, whilst rapid, safe and effective,
carries the disadvantage of an appreciable rate of relapse * 20 to 30 per
cent in most studies, manifesting during the six months following cessation
of treatment, nevertheless despite the steadily accruing evidence that
antidepressant drugs are also effective and, in particular, can lessen rates
of relapse, a proportion of physicians continue to hold that ECT is the
treatment of choice for depressive disorders. Such a viewpoint is repres¬
ented by Gammer (1961) who, comparing EOT favourably with drugs, stresses the
effectiveness and speed of action of EOT without mentioning any antidepressant
drug by nan®, Camaer asserts that antidepressants, when unsuccessful, can
increase depression, render it refractary to ECT, sake additional EOT necessary
and convert an acute relatively manageable depression into a chronic state with
a poorer prognosis. Gamer's article stimulated Cahagan (1962) to write of
an unusual development in psychiatric treatment, that is, the
partial replacement of a highly effective and safe node of treatment (EOT)
with an inferior mode (.Antidepressive drugs) ,,,,*•*••«"Gahag&n continues
it is hard •••.,.,,.,to imagine anything more deplorable than the
failure to use early and adequate EST in involutional depression
even the taost optimistic claims for the 'anti-depressive' drugs are short of
the attainments of ECT in the treatment of involutional a d other severe
depressions,,,"
The findings of one investigation appear, at first sight, to
support this view, Harris and Glancy (1961), comparing drugs and electro¬
therapy in a series of hospitalized psychotic in-patients, obtained a 19 per
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cant response to drugs in 21 patients versus a 90 per cent response to EOT
in 22 (p c .001). The former group spent an average of 47 days
versus the latter1 s 33.5 days. In a follow-up averaging nine month# per
patient, relapse occurred in two of the four patients who had responded to
drugs and nine of the 19 patients responding to ECTj but since three and
16 were improved at the time of follow-up, 75 per cent of tie drug-treated
patients and 34 per cent of those treated with EOT were found to be well.
Sorrie and Clancy believe that the objection© usually voiced against EC?
apply more to outpatients than inpatients! and they conclude from their
results that, in hospitalised depressives, electrotherapy is the treatment
of choice. They categorically statei "Electrotherapy has developed into a
treatment whose effectiveness and rapidity of action and safety is yet to be
challenged by any other method. Its careful us© is accompanied by the
lowest incidence of complications of any other treatment. It allows the
patient to return to his community and to his life a# quickly as possible.
The judicious us© of antidepressant drugs routinely in a hospital situation
awaits the development of a drug with much more rapid action and/or one whose
results are much more reliable and predictable.*
How are these views to be reconciled with impressions that
the use of BCF in hospitalised psychotic depressive# has markedly decreased
since 1953 - from 71 per cent to 33 per cent in one short-tera unit in
Chicago (Gulevichj Dardela and S'argolis 1961), that antideprossive# are "the
pith of affective therapy" (Saunders 1961) and that drugs can in the future
be expected to play a more important part in the treatment of depression.
(Mayer Gross, Slater and Ttoth 1960)?
Camrsor ignores the problem of post SCT relapse and his
criticism in regard to antidaproasanta would carry more weight if drugs,
dosages and periods of administration were specified in his article. It
is difficult to accept that antidepressants significantly worsen depression
or necessitate additional SCT without more evidence than Gusaer lias produced,
Gahagan's letter is indicative of a formerly rather widespread attitude which,
in most psychiatrists, is now gradually changing as a result of the mounting
evidence that may antidepressant drugs are very effective, I'orris and
Clancy, like Gammer, do not mention the names or the dosages of the drugs
they used and quote percentages obtained from results in unduly small numbers
of patients, especially in their follow-up. Their contention that white
blood count# and liver function tests are necessary accompaniments of anti¬
depressant therapy is not true for newer thymoleptica such as imipramina and
axaitriptylino. Finally their three week period of drug administration could,
with advantage, have been rather longer. In the circumstances it must be
concluded that the criticisms of drug treatment that have been cited arc not
justified by the available evidence, particularly in regard to newer anti¬
depressant compounds such as imipoeamino and amitriptylino•
mmeam
The effectiveness of imlpramine in the treatment of
depression has been convincingly demonstrated in the investigations described
earlier. The 54 per cent rate of response obtained in the present trial,
together with the 13 per cent rate of relapse during a follow-up period of
six months, is not out of keeping with the results of other studies. Two
studies not previously referred to are of particular interest in conn ctlon
with the present investigation. In the first of these Fleming©r and Groden
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(1962) correlated the clinical features of depression in 56 patients with
their response to imipramine. They found that pronounced individual
features were not useful guides to the outcome of treatment with the drug
and concluded that factors relating reliably to the response to indpraraine
required pursuing beyond merely clinical observation. Kiloh, Ball and
Garsid© (1962) investigated 97 patients treated with imipramine by moans of
a discriminant function analysis, obtaining weighting coefficients which
discriminated between respondent and non-responders. Age over 40, a
qualitative difference in the subjective experience of depression from
"normal depression", weight loss greater than 7 lb., an insidious onset, a
duration of under one year and early waiting were positively correlated with
a good outcome. The presence of precipitants, a more intense depression,
self pity, subjective retardation, a history of a suicidal attempt, irrit¬
ability, failure of concentration, hypochondriasis and restless sleep were
negatively correlated with a good outcome.
The findings of the present investigation agree to some ex¬
tent with those of Kiloh, Ball and Garslde and both studies refute the con¬
tention of Flealnger and Groden. When Kiloh et al's list of favourable
clinical features is examined, it seems that the correlation the author has
shown to exist between age and type of depression would make comprehensible
the different subjective experience afforded by an old patient with an endog¬
enous depression! loss of weight and terminal insomnia have likewise been
demonstrated to be significantly more narked in older depressives. Amongst
Kiloh et al's unfavourable features, severity as denoted by "a more intense
depression", was found in the present study also, to be associated with a
significantly poorer outcome with iiaipramine. In addition severe symptoms
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of depressed mood, reduction of woric and interests, retardation, agitation
and psychic anxiety, as well as the spiptoa complex found in factor 2 were
all associated with a significantly poorer outcome.
A further point worth noting is the extent to which the in¬
clusion of deluded patients alto is the rate of response to imipraxaine.
Evidently the higher the proportion of deluded patients, the lower is the
rato of response to this drug. Thus, administering imipracine, Ball and
Klloh (1959) obtained a rate of response of 74 per cent in out-patients with
endogenous depressions, few of whom were sufficiently depressed to have de¬
lusions of guilt or ideas of self reproach. In the present study, though 73
per cent of non-deluded patients responded, the overall rate of response was
only 54 per cent. Friecfean, Mowbray and Hamilton (1961) had a similar ex¬
perience! amongst their sample of in-patient depress!ves, eight, the most
severe, were deluded and none of thes responded to imipramine, Accordingly
it would appear that the lew rates of response obtained in othor studies
carried out on imipramine in xnary severe depress!vas are attributable in part
to the inclusion of deluded patio its.
Tmipramine has been shown to have a stimulant effect and to
be capable of activating the psychotic process in schisophrenic patients and
non-achiaophrenic psychotics (Gershon, Holmberg, liattson, Eattson and
Marshall 1962). Although the upsurge of anxiety related to the withdrawal
of imipraaine may respond to a resumption of treatment with this drug
(Kramer,Klein and Fink 1961), imipramine has generally been believed to in^
crease agitation and anxiety. Mania following imipramine (Ball and iloh
1959) and imipramine combined with electroconvulsive treatment (Jotkovita
and Gershon 1962) has also been reported. The findings of the present trial
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provide no evidence that inipramine loads to an increase in agitation,
although the presence of narked agitation was associated with a aigrxj-ficantly
poorer prognosis. The "increased" agitation Bhown on occasions by old
severely ill patients is probably related to imipraraino'a relative ineffic¬
iency in such cases and may be a release effect produced by the amelioration
of other symptoms.
As mentioned earlier, side effects were not a problem with
imipran&ne either in the in - or the out-patient phase. The detailed ratings
carried out in the first sixty patients demonstrated that many "side effects"
were actually concomitants of depression rather than products of the two
drugs. Qusfield, Schneller and Capra (1962), who found it possible to dis¬
tinguish between "false" and "true" side effects with antidepressants, reached
the same conclusion. One patient in the group on Imipramino developed re¬
tention of urine which cleared when the drug was discontinued! parenthetically
this "true" side effect can be of value in the treatment of enuresis (MacLean
1960). In general, however, side effects with inipraiuine were trivial! apart
from one case of glaucoma produced by araitriptyline, they were indistinguish¬
able fro® those evoked by the latter drug.
Finally it is noteworthy that four of the five patients who
died during the trial were in the group on iudprsoine. Two patients died
during the In-patient phase of the trial. The mod® of death of the first
patient, who after twenty days of imipraxalne ingestion developed a confusions!
state with anxiety, restlessness, coarse involuntary movements and hyper¬
pyrexia, resembled that described in other cases of iraipraiaine overdosage
(Lancaster and Foster 1959, Lee 1961). The second, a 69 year old hypertensive
who died in her sleep on the fourth day of iu&pnmine administration, was not
attributed to the drug, !Nevertheless the suggestion has been made by
Kristianaen (1961) that imlpraaine can affect the heart adversely in older
patients, especially if heart disease is already present. On the basis
of experimental work in animals, Cairncross and Gershon (1962) have
postulated that the anticholinergic effect of imipramine may increase heart
rate with a resulting decrease in stroke volueno and an unaltered cardiac
output. This could lead, they think, to hypotensive episodes, relative
circulatory stasis and venous pooling i.o, a condition resembling congestive
failure could be produced, which in turn could lead to myocardial infarction
or the precipitation of cardiac failure, Cairncross and Gershon believe
that chronic iraipramlne medication should be carefully controlled in patie ta
with atherosclerosis, essential hypertension or a previous history of cardio¬
vascular diseasej further, although imipramine is well tolerated in patients
with normal cardto-vascular function, any excessive exertion which puts an
undue load on the heart may, they think, induce cardiac impairment. On the
other hand, the demise of the third patient who, during the follow up, was
suspected of having a malabsorption syndrome, was probably due to suicide
during a relapse whilst on isaipramine, A fourth patient who had had no
imipramine for two months, committed suicide soon after absconding from the
mental hospital to which she had been admitted in relapse,
AMlTRIPmifE
According to Denber, Rajotte and Ross (1960), to be regarded
as effective, a new antidepressant compound should (1) produce remission in
a period of time similar to the ono required In known documented treatments
(i.e, EOT) j (2) produce remission in 30 per cent or more patients in a double-
blind study which can be reduplicated by others using similar case material!
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(3) break up the cyclic swings of the depressive disorder and above all,
through maintained medication prevent their reappearanco. Amitriptyline,
In the present study, produced remission when successful in practically the
same period of time as that required by ECT (median stay in hospital for
amitriptylin© 37 days, median stay for EOT 34 days)| remission was produced
in 61 par cent of 69 hospitalised female depressives under double-blind
conditions j and a six-month follow up of 46 re8ponders who continued to take
amitrlptyline revealed a 9 per cent rate of relapse. Accordingly it is
apparent that amitriptyline satisfies Denbsr et al's criteria of effective¬
ness, though the findings require replication and the role of amitriptyline
in male depressives and depressed out-patients requires further investigation.
Three studies comparing anitriptyline and imipramine are of
interest in connection -with the results obtained in the present Investigation.
Oltaan and Friecfoan (19615, in a blind study, found that 72 per cent of 50
female depressive* treated with amitriptyline responded in contrast to 71 per
cent of SO patients given irolpramine. Ayd (1960) obtained a 79 per cent
response to amitriptyline in 130 patients | 73 per cent of 100 patients re¬
sponded to imipramine. Weiss and Pressman (1961), who treated 100 ambulatory
patients with amitriptyline and 100 with imipramine, obtained response rates
of 79 and 75 per cent respectively.
The present findings in regard to amitriptyline correspond
closely with those of Ayd and Weiss and Pressman, and are not markedly
different from these of Oltman and Friedman, In regard to imipraaine, how¬
ever, they differ ratter strikingly. In this connection Foot (1961) has
pertinently observed that apparently contradictory findings resulting from
studies which are not strictly comparable need not be regarded as being die-
crepent tut can be regarded as "the outcome of a constellation of thera¬
peutic effects". In both Ayd's and Weiss and Pressman's sample, a number
of patients not suffering fro© pure depressive syndromes were included, and
/yd mentions combining a dtriptyL' oe with EOT and tranquillisers on some
occasions. In regard to the patients who received iE&praraine in the present
investigation, mention has already been made of the high proportion who were
unequivocally deluded (1? of 68 : 25,1), Since no deluded patient on
imipcrajaine responded, the overall response was rather low (545), In the
amitriptyline group, on the other hand, a smaller proportion were deluded
(10 of 69 * 13/S). However four of tho tea deluded patients in this group
responded, and onitriptyline was also superior to itiipxraainc in noi>-deluded
cases (80$ versus 73%)* It is clear, therefore, that the unequal numbers
of deluded patients on the two drug groups, whilst affecting the results, did
not invalidate the general finding© in favour of anitriptyline.
One patient who responded to oaitriptyline died during the
period of follow up, as has already been described. Although early in the
trial acute retention of urine in one patient caused some inconvenience,
the only serious side effect was a case of glaucoma which occurred tho day
after discharge end necessitated an immediate operation. There was no
evidence, despite the claims that have been made, that the side effects of
cu itriptyline were less troublesorae than those produced by imipramine. With
both drugs, both in the in-patient and th© out-patient phases of the trial,
side effects were trivial and of little consequence. Ayd (1961) and Weiss
and Pressman (1961) mention fairly numerous, though subjectively mild, side
effects with axdtriptylinef it may be that the drug, given in full doses in
out-patients, produces fewer side effects than imipramine. This could not be
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verified in the present study since only in-patisnte received full doses and,
when followed up as out-patients, were placed on lower (maintenance) levels.
On the other hand, from the concomitant use of araitriptyline in patients not
included in the trial, an impression was gained "What in the elderly and frail,
an&triptyline, like imipraraine, should be used in low doses. In some of
these patients weakness, giddiness and tremor observed with both drugs which,
Ilk® the associated confusion, cleared when they were discontinued.
With the exception of the young clinically-aavero group in
which the two drugs were equivalent, amitriptyline was found to be more
effective than imipramino in every group of patients included in the invest-
igation. Reference has already been made to the superiority of amitrlptyline
in deluded patients j It was also more effective than imipremino in relieving
patients with severe degrees of twelve of the seventeen symptoms on Hamilton's
scale and in relieving those with positive scores on factors 1 and 2 (anxiety-
agitation and retarded depression). Again amitriptyline was significantly
superior to iadpoaaine in older patients, those who vera postne repauaal, those
who were severely ill and those suffering from endogenous depressions. In
retrospect, the outcome with anitriptyline could probably have been estimated
from the first-week response to treatment, particularly in patients over 50
yours of age with severe depressions and in those over 60} failure to improve
In the first week in middle insomnia, gastro-intestinal somatic symptoms and
reduction in work and interests was significantly associated with failure to
response. In those who did respond, appreciable improvement usually occurred
within a week in fifteen of the seventeen symptoms on Hamilton's scale. The
decrease in suicidal tendencies, psychic anxiety, somatic anxiety, reduction
of work and interests, agitation, gastre-intestinal somatic symptoms, initial
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insomnia and middle insomnia was appreciable. The tranquillizing effect
of maitriptyllne together with the effect it exerted on appetite and sleep
suggests that, when successful, the drug may rectify the functional hypo¬
thalamic shift which, according to Pollitt (1961), underlies depressive ill¬
ness.
The findings must finally bo evaluated in relationship to
other treatments for depression. Amitriptylins was highly affective in a
high proportion of the depressive worsen to whom it was given. This high
level of effectiveness waa associated with rapid amelioration of moat of the
symptoms of depression and a generally high level of safoty. Within limits,
response was predictable and continued maintenance therapy, as advocated by
Ayd (1960, 1961c), was associated with a low rate of relapse. Against
amitriptyline, inipraraine compared unfavourably and ipronaazid, according to
Sole Jones and Klerman (1961) the standard of evaluation for the monoamine
oxidase inhibitors, on published reports, emerges less favourably still.
Although the present findings are based on a homogeneous sample of hospital¬
ized female depressivos, they appear sufficiently clear-cut to render aiitrip-
tyline the treatment of choice for the majority of patients with depressive
states.
samm
The findings are discussed in regard to the phenomenology
of depression and the current treatment of severe depressive states.
Some reasons why particular depressive symptoms vary with
age and overall severity of illness are advanced. Though the "middle-aged"
clinically-severe group of patients was the most severely ill, and therefore
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might have boon expected to contain a large proportion of involutional
melancholies, it could not he distinguished from the "young" or the
"elderly" groups in respect of either lack of a previous history or the
presence of depressive delusions. This suggests that involutional melan¬
cholia, at least in the form in xhich it is usually described, is not a
clinical entityj the characteristic symptom-profile of this condition is
to be ascribed, it is thought, to the increase in the severity of particular
symptoms which customarily occurs in older patients with severe depressive
illnesses.
The current treatment of severe depressive states comprises
electroconvulsive therapy, imlpras;dne or a *itriptyline. Though electro¬
convulsive therapy is rapid, safe and effective, the high rate of relapse
following treatment is a serious disadvantage. The tendency to relapse
after CT is disregarded by some of Its advocates who, comparing it with
antidepressants sometimes do not provide the names, doses or durations of
treatment of the drugs they have administered. Xiaipramine, prior to amitrip-
tyline the moat effective antidepressant, is not of such value in severe
depression and deluded patients seldom, if ever, respond. Apart from these,
outcome is difficult to predict when ixaiprasaino is given, and cardiac toxicity
is a potential haaard. Amongst patients who, responding to imipraxaine, are
kept on maintenance medication, the rate of relapse is fairly low.
Amitriptyline has usually produced high response rates in earlier studies and
the findings of the present investigation do not differ from these. The
drug is more effective than iraipxamine in severe clepressivos and, unlike the
older compound, produces a remission in a proportion of deluded patients.
Outcome can be predicted, within limits, from the first-week response to
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treatment. Mitriptyline appears to have few serious side effects and
continued administration is associated with a low rate of relapse. The
present findings in regard to as&triptyline - an 31 per cent response in
69 hospitalised female ciepreasives with a 9 per cent rate of relapse amongst
46 reaponders kept on maintenance dosage for six months - reveal that the
compound is more effective than other drugs in the treatment of depression.
Though slightly less effective than EGT initially, amitriptyline produces
results at six months that are equally good, tasking it the treatment of
choice for the majority of patients with depressive states.
APPENDIX 1.
PSYCHIATRIC BACKGROUND
Patient's Name Code Number
(Please print) ~ ~~ " " ~~
Surname Christian Names
Date Rater
1. Previous hospitalizations for mental illness. Do not regard a transfer between two
hospitals as two separate hospitalizations. (Circle one)
1. No previous hospitalization
2. Once before
3. Two or three times before
4. Four or five times before.
5. More than five times before.
2. Number of years since mental condition first required medical attention
3. Was patient treated with antidepressant drugs or ECT before admission.
Yes.
No.
If patient was treated with drugs or ECT prior to admission, fill in the following:
Treatment When How long Effect Side effects, and Remarks
started given
4. Onset of current illness (Circle one)
1. Very sudden - developed overnight or over a period of less than 7 days.
2. Fairly sudden - developed over a period of 1 - 8 weeks
3. Fairly insidious - developed over a period of 2 months to 2 years.
4. Very insidious - developed over a period of 2 yrs to 5 yrs.
5. Unknown.





SOCIAL BACKGROUND OF THE PATIENT
Patient's name: Code No.
(Surname) (Christian names)
Date Rater
1. Patient born: (Circle one)
1. in Australia
2. outside Australia: If "yes", in what country?
2. Age yrs.
3. Marital status: (circle one)
1. Single
3. Separated
4. Number of Children . . .
5. Education: (circle one)
2. Divorced
4. Widowed
5. Married or common law.





6. Professional and/or vocational qualifications of the patient: (circle one)
1. None 5. Commercial and clerical
2. Unskilled and semi-skilled worker. 6. Technical and semi-professional
3. Skilled worker 7. Professional.
4. Trade or similar
7. Patient's occupation: (circle one)
1. home duties only
2. employee, position held ....................
place of work
8. Source of income (circle one)
1. own work
2. husband's work
3. husband's and own work
9. Security of income, as patient sees it.
1. Absolutely reliable
2. Fairly reliable
10. Residence - house, flat, hostel, rooms, other (underline)
1. owned and paid for
2. owned and being paid for in instalments
3. rented.







PHYSICIAN'S RATING SCALE FOR DEPRESSION*
Pt's Name Date Date Code
Unit A
Hosp. No Ward No.
Pt's
Code No.
Key of Grading of Scores
(0-4) 0: Absent 1: Mild 2: Moderate 3: Severe 4: Very Severe
(0-2) 0: Absent 1: Slight or doubtful 2: Clearly Present
Item
No.




^1 Depressed Mood 0-4
2 Retardation 0-4 -
3 Work and Interests 0-4
4 Guilt 0-4
5 Suicide 0-4
6 Anxiety, psychic 0-4
7 Anxiety, somatic 0-4
8 Hypochondriasis 0-4
9 Agitation 0-2
10 Insomnia, initial 0-2
11 Insomnia, middle 0-2
12 Insomnia, delayed 0-2
13 Somatic symptoms, gastrointestinal 0-2
14 Somatic symptoms, general 0-2
15 Genital symptoms 0-2
16 Loss of Weight 0-2
17 Loss of insight 0-2
fotals: 50
0 = Nil
1 = Mild, depress.
2 = Mod. depress.
3 = Sev. depress.
4 = V. Sev. depress.
* Hamilton. M. "A Rating Scale for Depression", J- Neurol. Neuros.
and Psychol. 23:56-62: 1960.
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APPENDIX 3a.
CHECK LIST OF SYMPTOMS OF DEPRESSIVE STATES
Item








essed Mood: Rate on interview behaviour
somy attitude, pessimism about the future
eling of sadness











-dation: Rate on interview behaviour
wness of thought, speech and activity
athy
por
Slight retardation at interview 1
Obvious retardation at interview 2
Interview difficult 3






Listlessness, indecision and vacillation




Stopped working because of present illness - 4
(Absence from work after treatment or




Self-reproach, feels he has let people down
Ideas of guilt
Present illness is a punishment
Delusions of guilt





Feels life is not worth living
Wishes he were dead
Suicidal ideas
/ Attempts at suicide
If on background of no suicidal tendency





















9 Agitation: Rate on interview behaviour
Restlessness associated with anxiety
0-2
10 Insomnia, initial:




CHECK LIST OF SYMPTOMS OF DEPRESSIVE STATES (contd.)
Item
No.
Description of Symptoms Score
Range
11 Insomnia, middle:
Patient restless and disturbed during the night
Waking during the night
0-2
12 Insomnia, delayed:
Waking in early hours of the morning and unable to fall
asleep again
0-2
13 Somatic Symptoms, Gastrointestinal:
Loss of appetite
Heavy feelings in abdomen
Constipation
0-2
14 Somatic Symptoms, General:
Heaviness in limbs, back, or head
Diffuse backache






16 Loss of Weight 0-2
17 Loss of Insight
Loss of insight . . 2
Partial or doubtful loss 1
No loss .. 0
(Insight must be interpreted in terms of





OCCUPATIONAL THERAPY RATING SCALE
SCORE SHEET
Patient's Name Age Code No
Date Admitted Date Started O. T. Date Discharged ,
Ward and Date Diagnosis
Raters Names and Initials /
Evaluate all items of behaviour during O. T. activities
in the light of the patient's background and intelligence.
Scores range for each item from 0, which is normal,
through mild impairment of task performance, mild
symptoms and mild interference with relationships at 1,
and moderate disturbance at 2, to severe difficulties at 3.
Do not omit to fill in any item, and do not mark any item
"Unrateable".
TASK PERFORMANCE
1. Grasp of Instructions
2. Attention to Task
3. Motivation









9. Rapport with occupational therapists
10. Socialization






CHECK LIST OF OCCUPATIONAL THERAPY SCALE ITEMS
*tem
Description of Symptoms •No.
TASK PERFORMANCE
1. Grasp of Instructions: Ability to understand the nature of the task set in O. T.
0. Normal - understands quickly. 2. Poor - constant repetition and corrections.
1. Fair - occasional repetitions 3. Very poor - unable to understand,
and corrections.
2. Attention to task: Degree to which attention is sustained throughout the task.
0. Good - Complete attention. 2. Poor - Attention limited and wandering.
1. Fair - Usually attentive. 3. Very Poor - Complete inattention.
3. Motivation: Drive towards performance of the task as manifested throughout it.
0. Good - no urging needed. 2. Poor - Much urging.
1. Fair - little urging. 3. Very poor - refuses completely.
4. Patients grading of own performance: Degree of consistancy between patients
evaluation of performance and objective performance.
0. Good - Consistent with 2. Poor - Grossly inconsistent with O. P.
objective performance.
1. Fair - Somewhat inconsistent. 3. Very poor - No recognition of quality.
with O. P.
SYMPTOMS.
5. Depression;- Degree of gloom, sadness, pessimism, despair, weeping.
0. No depression. 2. Moderate
1. Mild 3. Severe.
6. Retardation:- Slowness in thought, speech and activities.
0. None 2. Moderate
1. Mild 3. Severe.
7. Agitation: - Motor restlessness associated with anxiety, pacing, wringing hands, etc.
0. None 2. Moderate
1. Mild 3. Severe
8. Physical complaints:- Physical or mental protestations of unease, distress and
disease.
0. None 2. Moderate
1. Mild 3. Severe.
RELATIONSHIPS.
9. Rapport with occupational therapist - degree of empathy with occupational
therapist.
0. Good - Friendly, easy accord. 2. Poor - Strained, infrequent accord.
Reserved.
1. Fair - Reserved. 3. Very poor - No interpersonal contact.
10. Socialization: - How well patient mixes with other patients.
0. Good - Friendly, easy accord. 2. Poor - Strained infrequent accord.






S = Spontaneous. Score Code: 0 = Absent. 1 = Mild. 2 = Mod. 3 = Sev. 4 = Ext Sev.
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